В статьях на сайте использованы следующие сокращения:

• °F — температура по Фаренгейту
• °C — температура по Цельсию
• 5-НТ — 5-гидроксииндолуксусная кислота мочи
• АБ — антибиотик(и)
• АБЛА — аллергический бронхолегочный аспергиллез
• АБТ — антибактериальная терапия
• АВ — атриовентрикулярный
• АГ — артериальная гипертензия
• АГн — антиген
• АД — артериальное давление
• АДГ — антидиуретический гормон
• АДС — анатоксин дифтерийно-столбнячный
• АДС-М — анатоксин дифтерийно-столбнячный (малые дозы)
• АДФ — аденозиндифосфорная кислота, аденозиндифосфат
• АКДС — анатоксин коклюшно-дифтерийно-столбнячный
• АКТГ — адренокортикотропный гормон
• АКШ — аортокоронарное шунтирование
• АЛТ — аланинаминотрансфераза
• амер. — американский
• АМК — азот мочевины крови
• АМФ — аденозинмонофосфорная кислота, аденозинмонофосфат
• АНА — антинуклеарные антитела
• анат. — анатомический
• англ. — английский
• АНЦА — антинейтрофильные цитоплазматические антитела
• АПФ — ангиотензин-превращающий фермент
• АРВТ — антиретровирусная терапия
• АРП — активность ренина в плазме крови
• АСК — аминосалициловая кислота
• ACT — аспартатаминотрансфераза
• АТл — антитело
• АТФ — аденозинтрифосфорная кислота, аденозинтрифосфат
• АуД — аутосомно-доминантный
• АуР — аутосомно-рецессивный
• АФП — α-фетопротеин
• АФС — антифосфолипидный синдром
• АХЭ — ацетилхолинэстераза
• АЦХ — ацетилхолин
• АЧТВ — активированное частичное тромбопластиновое время
• БА — бронхиальная астма
• БАД — биологически активная добавка
• БАЛ — бронхоальвеолярный лаваж
• БАР — биполярное аффективное расстройство (I или II типа)
• БКК — большой круг кровообращения
• БЛНПГ — блокада левой ножки пучка Гиса
• БМСЭ — бюро медико-социальной экспертизы
• БП — брюшная полость
• БПНПГ — блокада правой ножки пучка Гиса
• БРА — блокатор рецепторов ангиотензина
• БРД - болезнь Розаи-Дорфмана
• БРМ — базовые реанимационные мероприятия
• БРНС — быстро разрешившееся необъяснимое событие
• БЦЖ — бацилла Кальметта-Герена
• в т.ч. — в том числе
• в. — век
• в/ — внутри... в сложносоставных словах (напр.
• в/сосудистый, в/черепной и т.п.)
• в/а — внутриартериально
• в/в — внутривенно
• в/к — внутрикожно
• в/м — внутримышечно
• вв. — века
• в-во — вещество
• ВБП — внебольничная пневмония
• ВВЭ — военно-врачебная экспертиза
• ВГД — внутриглазное давление
• ВГЧ — вирус герпеса человека
• ВДП — верхние дыхательные пути
• ВЖК — внутрижелудочковое кровоизлияние
• ВЗК — воспалительные заболевания кишечника
• ВЗОМТ — воспалительные заболевания органов малого таза
• ВИП — вазоактивный интестинальный пептид
• ВИЧ — вирус иммунодефицита человека
• ВМП — высокотехнологичная медицинская помощь
• ВМС — внутриматочное средство (спираль)
• ВН — вирусная нагрузка
• ВНС — вегетативная нервная система
• ВОВ — Великая Отечественная война
• ВОГМ — высокогорный отек головного мозга
• ВОЗ — Всемирная организация здравоохранения
• ВОЛ — высокогорный отек легких
• ВОМК — врач, осуществляющий медицинский контроль
• ВОП — врач общей практики
• ВПВ — верхняя полая вена
• ВПГ — вирус простого герпеса
• ВПР — врожденные пороки развития
• ВПС — врожденный порок сердца
• ВПЧ — вирус папилломы человека
• ВРТ — вспомогательные репродуктивные технологии
• ВСВИ - воспалительный синдром восстановления иммунитета
• ВСО — водно-солевой обмен
• ВЧД — внутричерепное давление
• ВЧИВЛ — высокочастотная искусственная вентиляция легких (HFV)
• ВЭБ — вирус Эпштейна-Барр
• г — грамм
• г. — год
• Г-6-ФД — глюкозо-6-фосфатдегидрогеназа
• ГАМК — гамма-аминомасляная кислота
• ГБ — гипертоническая болезнь
• ГБН — гемолитическая болезнь новорожденного
• ГБО — гипербарическая оксигенация
• ГГПТ — γ-глутамилтранспептидаза
• ГЗТ — гиперчувствительность замедленного типа
• гист. — гистологический
• ГК — грудная клетка
• ГКМП — гипертрофическая кардиомиопатия
• ГКС — глюкокортикостероид(ы)
• ГЛГ — гемофагоцитарный лимфогистиоцитоз
• ГЛПС — геморрагическая лихорадка с почечным синдромом
• ГМ — головной мозг
• ГМ-КСФ — гранулоцитарно-макрофагальный колониестимулирующий фактор
• ГМФ — гуанозинмонофосфат
• ГнРГ — гонадотропин-рилизинг-гормон
• ГНТ — гиперчувствительность немедленного типа
• ГПОД — грыжа пищеводного отверстия диафрагмы
• ГРДС — гипоксическая реакция дыхательной системы
• греч. — греческий
• ГТФ — гуанозинтрифосфат
• ГУС — гемолитико-уремический синдром
• Гц — герц
• ГЭБ — гематоэнцефалический барьер
• ГЭР — гастроэзофагеальный рефлюкс
• ГЭРБ — гастроэзофагеальная рефлюксная болезнь
• дБ — децибел
• ДВС — диссеминированное внутрисосудистое свертывание
• ДГПЖ — доброкачественная гиперплазия предстательной железы
• ДГТ — дигидротестостерон
• ДД — дифференциальная диагностика, дифференциально-диагностический
• ДДБА — длительно действующие β₂-агонисты
• ДДК — дифференциально-диагностический критерий (критерии)
• ДИ — доверительный интервал
• ДК — диагностический критерий
• ДКА — диабетический кетоацидоз
• ДКМП — дилатационная кардиомиопатия
• ДМЖП — дефект межжелудочковой перегородки
• ДМПП — дефект межпредсердной перегородки
• ДМС — добровольное медицинское страхование
• ДН — дыхательная недостаточность
• ДНК — дезоксирибонуклеиновая кислота
• ДНТ — дефекты нервной трубки
• ДОФА — дигидроксифенилаланин
• ДП — дыхательные пути
• ДПК — двенадцатиперстная кишка
• ДПМ — дата последней менструации
• ДПП — давление в правом предсердии
• др. — другие
• ДТП — дорожно-транспортное происшествие
• ДЦП — детский церебральный паралич
• ЕД — единица действия
• ЖВП — желчевыводящие пути
• ЖДА — железодефицитная анемия
• ЖЕЛ — жизненная емкость легких
• ЖКБ — желчекаменная болезнь
• ЖКК — желудочно-кишечное кровотечение
• ЖКТ — желудочно-кишечный тракт
• ЖНВЛП — жизненно необходимые и важные лекарственные препараты (список, перечень)
• ЖТ — желудочковая тахикардия
• ЗВУР — задержка внутриутробного развития
• ЗЛ — здоровые люди (лица)
• ЗНО — злокачественное новообразование
• ЗО — здравоохранение
• ЗОЖ — здоровый образ жизни
• ЗСН — застойная сердечная недостаточность
• иАПФ — ингибиторы ангиотензин-превращающего фермента
• ИБС — ишемическая болезнь сердца
• ИВЛ — искусственная вентиляция легких
• ИГКС — ингаляционные глюкокортикостероиды
• ИЗЛ — интерстициальные заболевания легких
• ИКД — имплантируемый кардиовертер-дефибриллятор
• ИКП — иммунокомпрометированные пациенты
• ИЛ — интерлейкин
• ИЛДБ — интегрированное лечение детских болезней
• ИМ — инфаркт миокарда
• ИМАО — ингибитор(ы) моноаминоксидазы
• ИМбпБТ — инфаркт миокарда без подъема сегмента ST
• ИМП — инфекция мочевых (мочевыводящих) путей
• ИМпST — инфаркт миокарда с подъемом сегмента ST
• ИМТ — индекс массы тела
• ИОЛ — интраокулярная линза
• ИПП — ингибиторы протонной помпы (протонного насоса)
• ИППП — инфекции, передаваемые половым путем
• ИСС — индивидуальные спасательные средства
• истор. — историческое
• итал. — итальянский
• ИТП — идиопатическая тромбоцитопеническая пурпура
• ИТШ — инфекционно-токсический шок
• ИФА — иммуноферментный анализ
• КА — коронарная(ые) артерия(и)
• КАГ — коронарография
• КБМП - качество и безопасность медицинской помощи
• кВ — киловольт
• кг — килограмм
• КДАИ - Clostridium difficile-ассоциированная инфекция
• КДБА — короткодействующие β2-агонисты
• КДД — конечно-диастолическое давление
• КДО — конечно-диастолический объем
• КДР — конечно-диастолический размер
• кит. — китайский
• ккал — килокалория
• кл. — клетки, клеток
• КМП — качество медицинской помощи
• КоА — коэнзим А, кофермент А
• КОЕ — колониеобразующая единица
• КОК — комбинированные оральные контрацептивы
• КПТ — когнитивно-поведенческая терапия
• КР — клинические рекомендации
• КСД — конечно-систолическое давление
• КСО — конечно-систолический объем
• КСР — конечно-систолический размер
• КТ — компьютерная томография
• КТВР — компьютерная томография высокого разрешения
• КТГ — кардиотокография
• КФК — креатинфосфокиназа
• КЩС — кислотно-щелочное состояние
• л — литр
• л/о — ложноотрицательный
• л/п — ложноположительный
• ЛА — легочная артерия
• ЛАГ — легочная артериальная гипертензия лат. — латинский
• ЛГ — лютеинизирующий гормон
• ЛДГ — лактатдегидрогеназа
• ЛЖ — левый желудочек
• ЛЖВ - людей, живущих с ВИЧ
• ЛОР — имеющий отношение к оториноларингологии (ЛОР-врач, ЛОР-органы)
• ЛП — лекарственный препарат
• ЛПВП — липопротеины высокой плотности
• ЛПНП — липопротеины низкой плотности
• ЛПОНП — липопротеины очень низкой плотности
• ЛПУ — лечебно-профилактическое учреждение ЛС — лекарственное средство
• ЛУ — лимфатический(ие) узел(лы)
• ЛФК — лечебная физкультура
• м.б. — может (мог, могут, могли) быть
• М/Ж — соотношение мужчин и женщин
• максД — максимальная доза
• максНД — максимальная начальная доза
• максРД — максимальная разовая доза
• максСД — максимальная суточная доза
• МАНК — метод амплификации нуклеиновых кислот
• МАО — моноаминоксидаза
• МВП — мочевыводящие пути
• мг — миллиграмм
• МДБ — мышечная дистрофия Беккера
• МДД — мышечная дистрофия Дюшенна
• МДМА — метилендиоксиметамфетамин
• ME — международная единица
• мед. — медицинский
• мес — месяц
• МЖ — молочная железа
• МЖП — межжелудочковая перегородка
• М3 — министерство здравоохранения
• мин — минут(а)
• минД — минимальная доза
• минСД — минимальная суточная доза
• МКБ — мочекаменная болезнь
• МКБ-10 — Международная классификация болезней 10-го пересмотра
• МКБ-11 —Международная классификация болезней 11-го пересмотра
• мкВ — микровольт
• мкг — микрограмм
• МКК — малый круг кровообращения
• мкл — микролитр
• мл — миллилитр
• млн — миллион
• млрд — миллиард
• мм — миллиметр
• мм рт.ст. — миллиметр ртутного столба
• ммоль — миллимоль
• МНН — международное непатентованное наименование
• МНО — международное нормализованное отношение
• МО — медицинская организация
• МП — медицинская помощь
• МПН — миелопролиферативные новообразования
• МПС — мочеполовая система
• МР — магнитно-резонансный
• МР-венография — МРТ вен и синусов головного мозга
• мРНК — матричная РНК
• МРТ — магнитно-резонансная томография
• МРХПГ — магнитно-резонансная холангиопанкреатография
• мс — миллисекунда
• МСКТ — мультиспиральная компьютерная томогра-
• фия
• МСЭ — медико-социальная экспертиза
• МТ — масса тела
• мтДНК — митохондриальная дезоксирибонуклеиновая кислота
• МТР — масса тела при рождении
• н.э. — нашей эры
• НА — нервная анорексия
• НАД — никотинамидадениндинуклеотид
• НАДН — никотинамидадениндинуклеотид (восстановленный)
• НАДФ — никотинамидадениндинуклеотидфосфат
• НАЖБП — неалкогольная жировая болезнь печени напр. — например
• НАСГ — неалкогольный стеатогепатит
• НБ — нервная булимия
• НДО — негативный детский опыт
• нед — недели
• нем. — немецкий
• НИВЛ — неинвазивная вентиляция легких
• НЛР — нежелательная лекарственная реакция
• нм — нанометр
• НМГ — низкомолекулярный гепарин
• НМИЦ — национальный медицинский исследовательский центр
• НМП — неотложная медицинская помощь
• НМТ — низкая масса тела
• НПА — нормативно-правовой акт
• НПВ — нижняя полая вена
• НПВС — нестероидные противовоспалительные средства
• НС — нервная система
• НСГ — нейросонография
• НЭК — некротический энтероколит
• НЯК — неспецифический язвенный колит
• ОАК — общий анализ крови
• ОАМ — общий анализ мочи
• ОАП — открытый артериальный проток
• ОБП — органы брюшной полости
• ОГБ — острая горная болезнь
• ОГМ — отек головного мозга
• ОДН — острая дыхательная недостаточность
• ОДП — обструкция дыхательных путей
• ОЖСС — общая железосвязывающая способность сыворотки
• ОЗ — организация здравоохранения
• ок. — около
• ОКР — обсессивно-компульсивное расстройство
• ОКС — острый коронарный синдром
• ОЛЛ — острый лимфобластный лейкоз
• ОМП - оказание медицинской помощи
• ОМС — обязательное медицинское страхование
• ОМТ — органы малого таза
• ОНМК — острое нарушение мозгового кровообращения
• ОНМП — отделение неотложной (медицинской) помощи
• ОНМТ — очень низкая масса тела
• ООЗ — органы (организации/управления) здравоохранения
• ООЛ — остаточный объем легких
• ООН — Организация Объединенных Наций
• ОПЖ — ожидаемая продолжительность жизни
• ОПН — острая почечная недостаточность
• ОПП — острое повреждение почек
• ОПСС — общее периферическое сосудистое сопротивление
• ОРВИ — острая респираторная вирусная инфекция
• ОРДС — острый респираторный дистресс-синдром
• ОРЗ — острое респираторное заболевание
• ОРИТ — отделение реанимации и интенсивной терапии (ICU)
• ОСВО — общее содержание воды в организме
• ОФВ — объем форсированного выдоха
• ОФВ₁ — объем форсированного выдоха за 1-ю секунду
• ОЦК — объем циркулирующей крови
• п.з. — поле зрения (микроскопа)
• п/к — подкожно
• ПАВ — психоактивные вещества
• ПВ — протромбиновое время
• ПВК — периферический венозный катетер
• ПВЛ — перивентрикулярная лейкомаляция
• Пг — простагландин
• ПГГ — программа государственных гарантий оказания гражданам РФ бесплатной медицинской помощи
• ПДКВ — положительное давление конца выдоха (PEEP)
• ПЖ — правый желудочек
• ПЖЖ — поджелудочная железа
• ПЖК — подкожная жировая клетчатка (гиподерма)
• ПИ - полицитемию истинную
• ПКА — почечный канальцевый ацидоз
• ПКМД — поясно-конечностная мышечная дистрофия
• ПЛСГ — пятнистая лихорадка Скалистых гор
• ПМДР — предменструальное дисфорическое расстройство
• ПМК — пролапс митрального клапана
• ПМС — предменструальный синдром
• ПМФ — первичный миелофиброз
• ПМСП — первичная медико-санитарная помощь
• ПНА — передняя нисходящая артерия
• ПНЖК — полиненасыщенные жирные кислоты
• ПОРИТ — педиатрическое отделение реанимации и интенсивной терапии
• ПОТ — постуральная ортостатическая тахикардия
• ППВ — пневмококковая полисахаридная вакцина
• ППОАК — прямые пероральные антикоагулянты ППТ — площадь поверхности тела
• ПСА — простатоспецифический антиген
• ПСВ — пиковая скорость выдоха
• ПСВХ — прогрессирующий семейный внутрипеченочный холестаз
• ПТ — психотерапия
• ПТВ — протромбиновое время
• ПТГ — паратиреоидный гормон
• ПТИ — протромбиновый индекс
• ПТСР — посттравматическое стрессовое расстройство
• ПФЭ — пищевой фолатный эквивалент
• ПЦР — полимеразная цепная реакция
• ПШГ — пурпура Шенлейна-Геноха
• ПЩЖ — паращитовидные железы
• ПЭТ — позитронно-эмиссионная томография р/ —раз в ... (с, мин, ч, сут и т.п.)
• РА — ревматоидный артрит
• РААС — ренин-ангиотензин-альдостероновая система
• разг. — разговорный
• разл. — различный
• РАС — расстройство аутистического спектра
• РДС — респираторный дистресс-синдром
• рим. — римский
• РИФ — реакция иммунофлюоресценции
• РКИ — рандомизированные клинические исследования
• РКМП — рестриктивная кардиомиопатия
• РИГА — реакция непрямой гемагглютинации
• РНК — рибонуклеиновая кислота
• РОГК — рентгенография (рентгенограмма) органов грудной клетки
• РОЛСНС — рекомендации по оценке и лечению при сортировке в неотложных ситуациях
• РИГА — реакция прямой гемагглютинации
• р-р — раствор
• р-ритель — растворитель
• РРК — рецепторы ретиноевой кислоты
• РРМ — расширенные реанимационные мероприятия
• РСВ — респираторно-синцитиальный вирус
• РСД — расстройство стереотипных движений
• РСК — реакция связывания комплемента
• РТГА — реакция торможения гемагглютинации
• РТНГА — реакция торможения непрямой гемагглютинации
• РФ — Российская Федерация
• РХР — ретиноевые Х-рецепторы
• РЧА — радиочастотная абляция
• РЭС — ретикулоэндотелиальная система
• с — секунда
• св-во — свойство
• СВДС — синдром внезапной детской смерти
• СГЯ — синдром гиперстимуляции яичников
• СД — сахарный диабет
• СД-1 — сахарный диабет 1 -го типа
• СД-2 — сахарный диабет 2-го типа
• СДВГ — синдром дефицита внимания и гиперактивности
• СЕ — субъединица
• СЖК — свободные жирные кислоты
• СЗСТ — системное(ые) заболевание(я) соединительной ткани
• СИЗ — средства индивидуальной защиты
• СИОЗС — селективный ингибитор обратного захвата серотонина
• СИОЗСН — селективные ингибиторы обратного захвата серотонина и норэпинефрина
• СКА — серповидно-клеточная анемия
• СКВ — серповидно-клеточная болезнь
• СКВ — системная красная волчанка
• СКФ — скорость клубочковой фильтрации
• СЛР — сердечно-легочная реанимация
• см — сантиметр
• см вод.ст. — сантиметр водяного столба
• СМЖ — спинномозговая жидкость
• СМИ — средства массовой информации
• СМО — страховая медицинская организация
• СМП — скорая медицинская помощь
• СМЭ — судебно-медицинская экспертиза
• СН — сердечная недостаточность
• СНСАДГ — синдром неадекватной секреции АДГ
• СОАС — синдром обструктивного апноэ сна (во сне)
• совр. — современный
• СОЭ — скорость оседания эритроцитов
• СПИД — синдром приобретенного иммунодефицита
• СПКЯ — синдром поликистозных яичников
• СПОН — синдром полиорганной недостаточности
• СРБ — С-реактивный белок
• СРК — синдром раздраженного кишечника
• СрСД — средняя суточная доза
• ССВ — синдром Стерджа-Вебера
• ССВР — синдром системной воспалительной реакции
• ССЗ — сердечно-сосудистые заболевания
• ССС — сердечно-сосудистая система
• СССУ — синдром слабости синусового узла
• СТ — Синдром Туретта
• СТГ — соматотропный гормон
• СТР — стойкое (хроническое) моторное или вокальное тикозное расстройство
• сут — сутки
• СХУ — синдром хронической усталости
• т.д. — так далее
• т.е. — то есть
• т.к. — так как
• т.о. — таким образом
• т.п. — тому подобное
• Т3 — трийодтиронин
• Т4 — тироксин
• ТАНК — тест амплификации нуклеиновых кислот
• ТБС — тазобедренный сустав
• ТГВ — тромбоз глубоких вен
• ТГСК — трансплантация гемопоэтических стволовых клеток
• ТИА — транзиторная ишемическая атака
• ТИАБ — тонкоигольная аспирационная биопсия
• ТМО — твердая мозговая оболочка
• TH — торговое наименование лекарственных средств
• ТПГГ — территориальная программа государственных гарантий оказания гражданам РФ бесплатной медицинской помощи
• ТПМ — травматическое повреждение мозга
• ТТ — температура тела
• ТТГ — тиреотропный гормон
• ТФР — трансформирующий фактор роста
• ТЦА — трициклические антидепрессанты
• тыс. — тысяча
• ТЭД —транзиторная эритробластопения детского возраста
• ТЭЛА — тромбоэмболия легочной артерии
• ТЭО — тромбоэмболические осложнения
• УЗДС — ультразвуковое дуплексное сканирование
• УЗИ — ультразвуковое исследование
• устар. — устаревший
• УФ — ультрафиолетовый
• УФО — ультрафиолетовое облучение
• ФАП — фельдшерско-акушерский пункт
• ФВ — фракция выброса
• ФВД — функции внешнего дыхания
• ФЖ — фибрилляция желудочков
• ФЖЕЛ — форсированная жизненная емкость легких
• ФЗ — Федеральный закон
• физиол. — физиологический
• ФК — функциональный класс
• ФКС — фиброколоноскопия
• ФКУ — фенилкетонурия
• ФН — физическая нагрузка
• ФНО — фактор некроза опухоли
• ФОМС — федеральный фонд обязательного медицинского страхования
• ФОС — фосфорорганические соединения
• ФП — фибрилляция предсердий
• фр. — французский
• ФСГ — фолликулостимулирующий гормон
• ФСГС — фокально-сегментарный гломерулосклероз
• ФЭГДС — фиброэзофагогастродуоденоскопия
• ХБП — хроническая болезнь почек
• ХГЧ — хорионический гонадотропин человека
• ХДН — хроническая дыхательная недостаточность
• хим. — химический
• ХНЗЛ — хронические неспецифические заболевания легких
• ХОБЛ — хроническая обструктивная болезнь легких
• ХПН — хроническая почечная недостаточность
• ХС — холестерин
• ХСН — хроническая сердечная недостаточность
• XT — химиотерапия
• ЦВБ - цереброваскулярные болезни
• ЦВД — центральное венозное давление
• ЦБК — центральный венозный катетер
• ЦИК — циркулирующие иммунные комплексы
• ЦМВ — цитомегаловирус
• ЦНС — центральная нервная система
• ЦОГ — циклооксигеназа
• ЦПД — церебральное перфузионное давление
• ЦСТС — церебральный сольтеряющий синдром
• ч — час
• ЧД — частота дыхания
• ЧДД — частота дыхательных движений
• ЧКВ — чрескожное коронарное вмешательство
• ЧМН — черепно-мозговые нервы
• ЧМТ — черепно-мозговая травма
• ЧН — черепные нервы
• ЧС — чувствительность/специфичность (ЧС 97%/87%)
• ЧСС — частота сердечных сокращений
• ЧТВ — частичное тромбопластиновое время
• ШКГ — шкала комы Глазго
• ШОП — шейный отдел позвоночника
• ЩЖ — щитовидная железа
• ЩФ — щелочная фосфатаза
• ЭАР — эквивалент активности ретинола
• ЭГДС — эзофагогастродуоденоскопия
• ЭДТА — этилендиаминтетрауксусная кислота (этилендиаминтетраацетат)
• ЭКГ — электрокардиография
• ЭКМО — экстракорпоральная мембранная оксигенация
• ЭКО — экстракорпоральное оплодотворение
• ЭКС — электрокардиостимулятор, элекгрокардиостимуляция
• ЭМГ — электромиография
• ЭМК — электронная медицинская карта
• ЭМП — экстренная медицинская помощь
• ЭНМП — экстренная и неотложная медицинская помощь
• ЭНМТ — экстремально низкая масса тела
• ЭРХПГ —эндоскопическая ретроградная холангиопанкреатография
• ЭТ — эссенциальная тромбоцитемия
• ЭТТ — эндотрахеальная трубка
• ЭхоКГ — эхокардиография
• ЭЭГ — электроэнцефалография
• ЮДМ — ювенильный дерматомиозит
• ЮИА — ювенильный идиопатический артрит
• ЯБ — язвенная болезнь
• АА — амилоид A (amyloid А)
• ААР — Американская академия педиатрии (American Academy of Pediatrics)
• AASLD — Американская ассоциация по изучению заболеваний печени (American Association for the Study of Liver Diseases)
• ABC — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение» (Airways-Breathing-Circulation)
• АВСАЗ — белковый член АТФ-связывающей кассеты АЗ
• АВСВ11 —ген АТФ-связывающей кассеты, 11-й член подсемейства В (ATP-binding cassette, subfamily В member 11)
• АВСВ4 — ген АТФ-связывающей кассеты, 4-й член подсемейства В (ATP-binding cassette 4 gene)
• АВСС2 — ген, кодирующий 2-й член подсемейства С АТФ-связывающих кассет (ATP-binding cassette sub-family С member 2)
• ABCDE — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение-не-врологический статус-внешний вид» (Airways-Breathing-Circulation-Disability-Exposure)
• ABCG5/G8 — гетеродимер переносчика АТФ-связывающей кассеты ABCG5 и ABCG8 (heterodimer of ATP-binding cassette transporter ABCG5 and ABCG8)
• AC — до еды (при назначениях) — ante cibum
• АСЕР — Американская коллегия врачей неотложной помощи (American College of Emergency Physicians)
• ACOG — Американская коллегия акушеров и гинекологов (American College of Obstetricians and Gynecologists)
• AHA — Американская кардиологическая ассоциация (American Heart Association)
• ALTE — очевидное опасное для жизни событие (apparent life-threatening event)
• ANP — предсердный натрийуретический пептид (atrial natriuretic peptide)
• APLS — курсы расширенных реанимационных мероприятий в педиатрии, спонсируемые Американской академией педиатрии и Американской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
• ARPKD — аутосомно-рецессивный поликистоз почек ASCVD-риск — риск развития атеросклеротического сердечно-сосудистого заболевания (Arteriosclerotic Cardiovascular Disease)
• AVPU — шкала для оценки уровня сознания («в ясном сознании»; «реакция на вербальные раздражители»; «реакция на боль»; «без сознания») (alert, verbal, pain, unresponsive)
• BCS — митохондриальный шаперон BCS1 (mitochondrial chaperone BCS1)
• BIN — биноминальная номенклатура живой природы
• B(i)PAP — режим искусственной вентиляции легких с двумя уровнями положительного давления (bilevel positive airway pressure)
• BNP — мозговой натрийуретический пептид В-типа [В (brain)-type natriuretic peptide]
• BRUE — быстро разрешившиеся необъяснимые события (brief resolved unexplained events)
• BSEP — насос выведения солей желчных кислот (bile salt export pump)
• CADASIL — церебральная аутосомно-доминантная артериопатия с подкорковыми инфарктами и лейкоэнцефалопатией (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
• CAPS — криопирин-ассоциированный периодический синдром (cryopyrin-associated periodic syndrome)
• CBIT — комплексное поведенческое воздействие при тиках (comprehensive behavioral intervention for tics)
• CD — кластеры дифференцировки (clusters of differentiation)
• CDC — Центр по контролю и профилактике заболеваний, США (Center for Disease Control and Prevention)
• CDG — врожденные нарушения гликозилирования (congenital disorder of glycosylation)
• CFTR — трансмембранный регулятор муковисцидоза (cystic fi brosis transmembrane regulator)
• CH — гемолитический комплемент (hemolytic complement)
• CLLS — шкала оценки острой горной болезни озера Луиз у детей (Children’s Lake Louise Score)
• сМОАТ — каналикулярный мультиспецифический органический анионный транспортер (canalicular multispecific organic anion transporter)
• CMT — Шарко-Мари-Тута болезнь (Charcot-Marie-Tooth disease)
• CPAP — постоянное положительное давление в дыхательных путях (constant positive airway pressure)
• CTLA — цитотоксический Т-лимфоцитарный антиген (cytotoxic T-lymphocytic antigen)
• CYP — цитохром общий
• DAF — фактор ускорения распада (decay-accelerating factor)
• DAMP — рецепторы молекулярного фрагмента, ассоциированного с повреждением (damage-associated molecular pattern)
• DASH — диетические подходы к борьбе с гипертонией (dietary approaches to stop hypertension)
• DGAT1 — диацилглицерин-1-ацилтрансфераза (diacylglycerol acyltransferase 1)
• DHR — дигидрородамин (dihydrorhodamine)
• DSM — Диагностическое и статистическое руководство по психическим расстройствам (Diagnostic and Statistical Manual of Mental Disorders)
• EAST syndrome — эпилепсия, атаксия, сенсоневральная тугоухость и тубулопатия (epilepsy, ataxia, sensorineural hearing loss, and tubulopath)
• EBM — доказательная медицина (evidance based medicine)
• EPCAM — молекула адгезии эпителиальных клеток (epithelial cell adhesion molecule)
• ESC — Европейское общество кардиологии (European Society of Cardiology)
• EXIT — лечение плода вне матки во время родов (ех utero intrapartum treatment)
• FcRs — Fc-рецепторы — белок, расположенный на поверхности нескольких видов клеток иммунной системы (естественных киллеров, макрофагов, нейтрофилов и тучных клеток) FDA — Комитет по контролю за лекарственными веществами и пищевыми добавками, США (Food and Drug Administration)
• FFR — фракционный резерв кровотока (fractional flow reserve)
• FGF-23 — фактор роста фибробластов-23 (fibroblast growth factor-23)
• FIC 1 —семейный внутрипеченочный холестаз 1-го типа, болезнь Байлера (familial intrahepatic cholestasis)
• FiO₂ — фракция кислорода (во вдыхаемом воздухе, газовой смеси)
• FISH — флуоресцентная in situ гибридизация (fluorescence in situ hybridization)
• FLAIR — восстановление инверсии с ослаблением жидкости (fluid-attenuated inversion recovery)
• FMF — семейная средиземноморская лихорадка (familial mediterranean fever)
• FODMAP — ферментируемые олиго-, ди-, моносахариды и полиолы (fermentable oligo-, di-, monosaccharides and polyols)
• FoxP3 —транскрипционный фактор семейства Forkhead Р3
• GATA — gata-связывающий белок
• DVL — трансплантат против лейкоза (graft versus leukemia)
• HADH — гидроксилацил-КоА-дегидрогеназа (Hydroxyacyl-Coenzyme A dehydrogenase)
• HAV — вирус гепатита В (hepatitis A virus)
• Hb — гемоглобин
• HBcAg — сердцевинный антиген вируса гепатита В HBeAg — антиген вируса гепатита В
• HBsAg — поверхностный антиген вируса гепатита В
• HBV — вирус гепатита В (hepatitis В virus)
• HCV — вирус гепатита С (hepatitis С virus)
• HDV — вирус гепатита D (hepatitis D virus)
• HELLP — HELLP-синдром (гемолиз, повышенный уровень печеночных ферментов, низкий уровень тромбоцитов) (hemolysis, elevated liver enzymes, low platelets)
• HEV — вирус гепатита E (hepatitis E virus)
• HFNC — назальные канюли высокого потока (heated, high-flow nasal cannula)
• Hib — гемофильная палочка типа В (Haemophilus influenzae В type)
• HLA — лейкоцитарные антигены (главного комплекса гистосовместимости) человека (human leukocyte antigens)
• HR — отношение рисков (hazard ratio)
• HRT — терапия отмены привычки (habit reversal therapy)
• Ht — гематокрит
• HTLV — Т-лимфотропный вирус человека (human T-lymphotropic virus)
• IFN — интерферон
• Ig — иммуноглобулин
• IgA — иммуноглобулин A
• IgE — иммуноглобулин E
• IgG — иммуноглобулин G
• IgM — иммуноглобулин M
• IL — интерлейкин
• IPEX — Х-сцепленный синдром иммунной дисрегуляции, полиэндокринопатии и энтеропатии (immunedysregulation polyendocrinopathy enteropathy, X-linked)
• IQ — коэффициент умственного развития (intelligence quotient)
• JAK — янус-киназа (janus kinase)
• LFA — антиген, активирующий функцию лейкоцитов (lymphocyte function-associated antigen)
• LT — лейкотриен
• MALT — лимфоидная ткань слизистой оболочки (mucosa-associated lymphoid tissue)
• MASP — МСЛ-ассоциированная сериновая протеаза (MBL-associated serine protease)
• MBL — маннозосвязывающий лектин (mannose-binding lectin)
• MCP — мембранный белок-кофактор (membrane cofactor protein)
• MDR3 — белок множественной лекарственной устойчивости 3 (multidrug resistance protein 3)
• MELAS — митохондриальная энцефалопатия, лактоацидоз и инсультоподобные эпизоды (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
• MELD — модель для оценки терминальной стадии заболеваний печени, предназначена для оценки относительной тяжести заболевания и прогноза жизни у пациентов с терминальной стадией печеночной недостаточности (ожидающих трансплантации печени) (model for end-stage liver disease)
• MERRF — миоклоническая эпилепсия с рваными красными волокнами (myoclonic epilepsy with ragged red fibers)
• MHC — главный комплекс гистосовместимости (major histocompatibility complex)
• Mr — кажущаяся молекулярная масса
• MRP — белок с множественной лекарственной устойчивостью (multidrug-resistant protein)
• MRSA — метициллинрезистентный золотистый стафилококк
• MSSA — метициллинчувствительный золотистый стафилококк
• mTOR — мишень рапамицина у млекопитающих (mammalian target of rapamycin)
• NB! — важно, обратить внимание (nota bene)
• NICE — Национальный институт здоровья и клинического совершенствования (качества медицинской помощи) Великобритании (National Institute for Health and Clinical Excellence)
• NK — естественные клетки-киллеры (natural killer) NMDA — И-метил-В-аспартат (N-methyl-D-aspartate)
• NNT — число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (number need to treatment)
• OR — отношение шансов (odds ratio)
• paCO₂ — парциальное давление углекислого газа в артериальной крови
• PALS — курсы расширенных реанимационных мероприятий в педиатрии (Pediatric Advanced Life Support)
• PANDAS — аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
• PANS — острый нейропсихиатрический синдром в детском возрасте (pediatric acute-onset neuropsychiatric syndrome)
• paO₂ — парциальное давление кислорода в артериальной крови
• PAS — фуксинсернистая кислота, реактив Шиффа (periodic acid-Shiff)
• PC — после еды (при назначениях) (post cibum) рСО₂ — парциальное давление углекислого газа
• PCSK-9 — пропротеиновая конвертаза субтилизинкексинового типа 9 (proprotein convertase subtilisin/kexin type 9)
• PFAPA — периодическая лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (periodic fevers with aphthous stomatitis, pharyngitis and adenitis)
• PFIC — семейный внутрипеченочный холестаз (familial intrahepatic cholestasis)
• Pg — простагландин
• pH — водородный показатель
• PIM — показатель летального исхода у детей (pediatric index of mortality)
• piO₂ — парциальное давление кислорода во вдыхаемом воздухе
• рО₂ — парциальное давление кислорода
• POLG — субъединица ДНК-полимеразы γ
• PRISA II — оценка риска госпитализации у детей II (pediatric risk of admission)
• PRISM — риск летального исхода у детей (pediatric risk of mortality)
• PRN — при (по) необходимости (pro re nata — при возникновении обстоятельств)
• PRSS — ген сериновой протеазы
• PS — примечание (post scriptum)
• PUVA-терапия — псорален-ультрафиолет А-терапия (psoralen and ultraviolet А)
• Q#H — каждые # часов (при назначениях) (quaque... hora)
• QAM — каждое утро (при назначениях) (quaque ante meridiem)
• QPM — каждый вечер (при назначениях) (quaque post meridiem)
• RAG — ген, активирующий рекомбиназу
• RePEAT — пересмотренный инструмент для оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
• RF — ревматоидный фактор
• Rh — резус(-фактор)
• Rh«-» — резус-отрицательн(ый)
• Rh«+» — резус-положительн(ый)
• ROHHAD — быстро развивающееся ожирение с дисфункцией гипоталамуса, гиповентиляцией и спонтанной дисрегуляцией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
• ROMK — почечный наружный мозговой калиевый канал (renal outer medullary К)
• RR — относительный риск (relative risk или risk ratio)
• RW — реакция Вассермана (reaction of Wassermann)
• SaO₂ — сатурация артериальной крови кислородом
• SatO₂ — насыщение крови кислородом
• ScvO₂ — насыщение кислородом центральной венозной крови (central venous oxygen saturation)
• SD — стандартное отклонение (standart deviation)
• SFTPA — ген сурфактантного белка A
• SFTPB — ген сурфактантного белка В
• SFTPC — ген сурфактантного белка С
• SPINK — ингибитор сериновой протеазы (serine protease inhibitor kazal)
• SpO₂ — насыщение (сатурация) гемоглобина кислородом
• spp. — виды (при родовом имени микроорганизмов)
• Src. — источник информации, библиографическая ссылка (source)
• STAT1 — сигнальный преобразователь и активатор транскрипции 1 (signal transducer and activator of transcription)
• TA — Международная анатомическая терминология
• TCR — Т-клеточный рецептор (T-cell receptor)
• TIPS —трансъюгулярный внутрипеченочный портосистемный шунт; малоинвазивная хирургическая операция, проводимая под контролем рентгеноскопии (transjugular intrahepatic portosystemic shunt)
• TLR — Толл-подобный рецептор (Toll-like receptor)
• TNF — фактор некроза опухоли (tumor necrosis factor)
• TORCH — токсоплазмоз, краснуха, цитомегаловирусная инфекция, герпес и другие инфекции (toxoplasmosis, other infections, rubella, cytomegalovirus herpes simplex)
• TPM — мутация тропомиозина (mutation of the tropomyosin)
• TRAP — синдром обратной артериальной перфузии близнецов (twin reversed arterial perfusion)
• TRAPS — периодический синдром, ассоциированный с рецептором фактора некроза опухоли (tumor necrosis factor receptor-associated periodic syndrome)
• TRPM — катионный канал с транзиторным рецепторным потенциалом, подсемейство М (transient receptor potential cation channel, subfamily M)
• VEGF — фактор роста эндотелия сосудов (vascular endothelial growth factor)
• VO₂ — потребление кислорода
• WPW — синдром Вольфа-Паркинсона-Уайта (Wolff-Parkinson-White)
• XLA — Х-сцепленная агаммаглобулинемия (X-linked agammaglobulinemia)
• αDG-RD — дистрофии, связанные с α-дистрогликанами (alpha dystroglycan-related dystrophies)
• β-ХГЧ — β-субъединица хорионического гонадотропина человека

В ходе подготовки статей по инфекционным заболеваниям в терапии для пользователей сайта МедУнивер использованы труды следующих авторов:

1. Mitja O, Hays R, Ipai A, et al. Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomized trial. Lancet. 2012; 379: 342–347.
2. Marks M, Mitja O, Bottomley C, et al. Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea. Lancet Glob Health. 2018; 6: e401–e410.
3. Smajs D, Strouhal M, Knauf S. Genetics of human and animal uncultivable treponemal pathogens. Infect Genet Evol. 2018; 61: 92–107.
4. Klegarth AR, Ezeonwu CA, Rompis A, et al. Survey of treponemal infections in free-ranging and captive macaques, 1999-2012. Emerg Infect Dis. 2017; 23: 816–819.
5. Marks M, Yin YP, Chen XS, et al. Metaanalysis of the performance of a combined treponemal and nontreponemal rapid diagnostic test for syphilis and yaws. Clin Infect Dis. 2016; 63: 627–633.
6. Noguera-Julian M, Gonzalez-Beiras C, Parera M, et al. Etiological characterization of the cutaneous ulcer syndrome in Papua New Guinea using shotgun metagenomics. Clin Infect Dis. 2019; 68: 482–489.
7. Mitja O, Houinei W, Moses P, et al. Mass treatment with single-dose azithromycin for yaws. N Engl J Med. 2015; 372: 703–710.
8. Marks M. Advances in the treatment of yaws. Trop Med Infect Dis. 2018; 3: 1–7.
9. Mikalova L, Smajs D. Low-dose versus standard-dose azithromycin for treatment of yaws. Lancet Glob Health. 2018; 6: e357–e358.
10. Mitjo O, Godornes C, Houinei W, et al. Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study. Lancet. 2018; 391: 1599–1607.
11. Torbahn G, Hofmann H, Rucker G, et al. Efficacy and safety of antibiotic therapy in early cutaneous lyme borreliosis: a network meta-analysis. JAMA Dermatol. 2018; 154: 1292–1303.
12. Cadavid D, Auwaerter PG, Rumbaugh J, et al. Antibiotics for the neurological complications of Lyme disease. Cochrane Database Syst Rev. 2016; 12: CD006978.
13. Dersch R, Freitag MH, Schmidt S, et al. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis—a systematic review. Eur J Neurol. 2015; 22: 1249–1259.
14. Berende A, ter Hofstede HJ, Vos FJ, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016; 374: 1209–1220.
15. Hinckley AF, Meek JI, Ray JA, et al. Effectiveness of residential acaricides to prevent Lyme and other tick-borne diseases in humans. J Infect Dis. 2016; 214: 182–188.
16. Warshafsky S, Lee DH, Francois LK, et al. Efficacy of antibiotic prophylaxis for the prevention of Lyme disease: an updated systematic review and meta-analysis. J Antimicrob Chemother. 2010; 65: 1137–1144.
17. Schwameis M, K?ndig T, Huber G, et al. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial. Lancet Infect Dis. 2017; 17: 322–329.
18. Bush LM, Vazquez-Pertejo MT. Tick borne illness — Lyme disease. Dis Mon. 2018; 64: 195–212.
19. Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016; 2: 1–9.
20. Nelson CA, Saha S, Kugeler KJ, et al. Incidence of clinician-diagnosed Lyme disease, United States, 2005–2010. Emerg Infect Dis. 2015; 21: 1625–1631.
21. Sanchez E, Vannier E, Wormser GP, et al. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016; 315: 1767–1777.
22. Eldin C, Parola P. Update on tick-borne bacterial diseases in travelers. Curr Infect Dis Rep. 2018; 20: 1–9.
23. Mead PS. Epidemiology of Lyme disease. Infect Dis Clin North Am. 2015; 29: 187–210.
24. Garcia-Monco JC, Benach JL. Lyme neuroborreliosis: clinical outcomes, controversy, pathogenesis, and polymicrobial infections. Ann Neurol. 2019; 85: 21–31.
25. Halperin JJ. Neuroborreliosis. J Neurol. 2017; 264: 1292–1297.
26. Yeung C, Baranchuk A. Diagnosis and treatment of Lyme carditis: JACC review topic of the week. J Am Coll Cardiol. 2019; 73: 717–726.
27. Cardenas-de la Garza JA, De la Cruz-Valadez E, Ocampo-Candiani J, et al. Clinical spectrum of Lyme disease. Eur J Clin Microbiol Infect Dis. 2019; 38: 201–208.
28. Wormser GP, Strle F, Shapiro ED, et al. A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease. Diagn Microbiol Infect Dis. 2017; 87: 163–167.
29. Lantos PM, Lipsett SC, Nigrovic LE. False positive Lyme disease IgM immunoblots in children. J Pediatr. 2016; 174: 267–269.
30. Dessau RB, van Dam AP, Fingerle V, et al. To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a position paper of ESGBOR, the ESMID study group for Lyme borreliosis. Clin Microbiol Infect. 2018; 24: 118–124.
31. Alasel M, Keusgen M. Promising alternatives for one-tier testing of Lyme borreliosis. Clin Chim Acta. 2018; 479: 148–154.
32. Marques AR. Revisiting the Lyme disease serodiagnostic algorithm: the momentum gathers. J Clin Microbiol. 2018; 56: 1–7.
33. Avikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am. 2015; 29: 269–280.
34. Weitzner E, McKenna D, Nowakowski J, et al. Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease. Clin Infect Dis. 2015; 61: 1800–1806.
35. Lantos PM. Chronic Lyme disease. Infect Dis Clin North Am. 2015; 29: 325–340.
36. Wormser GP, Pritt B. Update and commentary on four emerging tick-borne infections: Ehrlichia muris-like agent, Borrelia miyamotoi, deer tick virus, heartland virus, and whether ticks play a role in transmission of Bartonella henselae. Infect Dis Clin North Am. 2015; 29: 371–381.
37. Talagrand-Reboul E, Boyer PH, Bergstrom S, et al. Relapsing fevers: neglected tick-borne diseases. Front Cell Infect Microbiol. 2018; 8: 1–21.
38. Kingry LC, Anacker M, Pritt B, et al. Surveillance for and discovery of Borrelia species in US patients suspected of tickborne illness. Clin Infect Dis. 2018; 66: 1864–1871.
39. Osthoff M, Schibli A, Fadini D, et al. Louse-borne relapsing fever — report of four cases in Switzerland, June-December 2015. BMC Infect Dis. 2016; 16: 1–5.
40. Stone BL, Brissette CA. Host immune evasion by Lyme and relapsing fever Borrelliae: findings to lead future studies for Borrelia miyamotoi. Front Immunol. 2017; 8: 1–16.
41. Warrell DA. Louse-borne relapsing fever (Borrelia recurrentis infection). Epidemiol Infect. 2019; 147: 1–8.
42. Molloy PJ, Telford SR 3rd, Chowdri HR, et al. Borrelia miyamotoi disease in the northeastern United States: a case series. Ann Intern Med. 2015; 163: 91–98.
43. Eldin C, Parola P. Update on tick-borne bacterial diseases in travelers. Curr Infect Dis Rep. 2018; 20: 1–9.
44. Modarelli JJ, Piccione J, Ferro PJ, et al. Novel real-time PCR assays for genomic group identification of tick-borne relapsing fever species Borrelia hermsii. Diagn Microbiol Infect Dis. 2019; 93: 24–29.
45. Charan J, Saxena D, Mulla S, et al. Antibiotics for the treatment of leptospirosis: systematic review and meta-analysis of controlled trials. Int J Prev Med. 2013; 4: 501–510.
46. Schneider MC, Velasco-Hernandez J, Min KD, et al. The use of chemoprophylaxis after floods to reduce the occurrence and impact of leptospirosis outbreaks. Int J Environ Res Public Health. 2017; 14: 1–18.
47. Jimenez JIS, Marroquin JLH, Richards GA, et al. Leptospirosis: report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care. 2018; 43: 361–365.
48. Adams DA, Thomas KR, Jajosky RA, et al. Summary of notifiable infectious diseases and condi-tions — United States, 2015. MMWR Morb Mortal Wkly Rep. 2017; 64: 1–143.
49. Abdul Mutalip MH, Mahmud MAF, Lodz NA, et al. Environmental risk factors of leptospirosis in urban settings: a systematic review protocol. BMJ Open. 2019; 9: 1–5.
50. Priya SP, Sakinah S, Sharmilah K, et al. Leptospirosis: molecular trial path and immunopathogenesis correlated with dengue, malaria and mimetic hemorrhagic infections. Acta Trop. 2017; 176: 206–223.
51. Chin VK, Basir R, Nordin SA, et al. Pathology and host immune evasion during human leptospirosis: a review. Int Microbiol. 2019. [Epub ahead of print.]
52. Chin VK, Lee TY, Lim WF, et al. Leptospirosis in human: biomarkers in host immune responses. Micro-biol Res. 2018; 207: 108–115.
53. Vandroux D, Chanareille P, Delmas B, et al. Acute respiratory distress syndrome in leptospirosis. JCrit Care. 2019; 51: 165–169.
54. von Ranke FM, Zanetti G, Escuissato DL, et al. Pulmonary leptospirosis with diffuse alveolar hemorrhage: high-resolution computed tomographic findings in 16 patients. J Comput Assist Tomogr. 2016; 40: 91–95.
55. Galloway RL, Hoffmaster AR. Optimization of LipL32 PCR assay for increased sensitivity in diagnosing leptospirosis. Diagn Microbiol Infect Dis. 2015; 82: 199–200.
56. Waggoner JJ, Pinsky BA. Molecular diagnostics for human leptospirosis. Curr Opin Infect Dis. 2016; 29: 440–445.
57. Guerrier G, Lefevre P, Chouvin C, et al. Jarisch-Herxheimer reaction among patients with leptospirosis: incidence and risk factors. Am J Trop Med Hyg. 2017; 96: 791–794.
58. Taylor AJ, Paris DH, Newton PN. A systematic review of the mortality from untreated leptospirosis. PLoS Negl Trop Dis. 2015; 9: 1–13.
59. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383:424-435.
60. Lee JK, Lee JY, Kim DK, et al. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. Lancet Infect Dis. 2019;19:46-55.
61. Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs intermittent antituberculosis therapy for pulmonary tuberculosis in patient with HIV: a randomized clinical trial. JAMA Intern Med. 2018;178:485-493.
62. Blanc F-X, Sok T, Laureillard D, et al. Earlier vs later start of antiviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481.
63. Meintges G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution syndrome. AIDS. 2010;24:2381-2390.
64. Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371:1121-1130.
65. Fregonese F, Ahuja SD, Akkerman OW, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018;6:265-275
66. Duan H, Chen X, Li Z, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect. 2019;25:190-195.
67. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug resistant tuberculosis. N Engl J Med. 2012;367:1508-1518.
68. Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440-453.
69. Zenner D, Beer N, Harris RJ, et al. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167:248-255.
70. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-2166.
71. Belknap R, Holland D, Feng PJ, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167:689-697.
72. Swindells S, Ramchandani R, Gupta A, et al. One sent HIV-related tuberculosis. N Engl J Med. 2019;380:1001-1011.
73. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281-290.
74. Fox GJ, Nhung NV, Sy DN, et al. Household-contact investigation for detection of tuberculosis in Vietnam. N Engl J Med. 2018;378:221-229.
75. Van Der Meeren O, Hatherill M, Nduba V, et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2018;379:1621-1634.
76. Floyd K, Glaziou P, Zumla A, et al. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018;6:299-314.
77. Daley CL. The global fight against tuberculosis. Thorac Surg Clin. 2019;29:19-25.
78. Stewart RJ, Tsang CA, Pratt RH, et al. Tuberculosis—United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:317-323.
79. Mancuso JD, Diffenderfer JM, Ghassemieh BJ, et al. The prevalence of latent tuberculosis infection in the United States. Am J Respir Crit Care Med. 2016;194:501-509.
80. Park M, Satta G, Kon OM. An update on multidrug-resistant tuberculosis. Clin Med (Lond). 2019;19:135-139.
81. Shah NS, Auld SC, Brust JC, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med. 2017;376:243-253.
82. Shaw JA, Irusen EM, Diacon AH, et al. Pleural tuberculosis: a concise clinical review. Clin Respir J. 2018;12:1779-1786.
83. Mai NT, Thwaites GE. Recent advances in the diagnosis and management of tuberculous meningitis. Curr Opin Infect Dis. 2017;30:123-128.
84. Chang SA. Tuberculous and infectious pericarditis. Cardiol Clin. 2017;35:615-622.
85. Marais S, Roos I, Mitha A, et al. Spinal tuberculosis: clinicoradiological findings in 274 patients. Clin Infect Dis. 2018;67:89-98.
86. Roe JK, Thomas N, Gil E, et al. Blood transcriptomic diagnosis of pulmonary and extrapulmonary tuberculosis. JCI Insight. 2016;1:1-15.
87. Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med. 2017;377:1043-1054.
88. Horsburgh CR Jr, Barry CE 3rd, Lange C. Treatment of tuberculosis. N Engl J Med. 2015;373:2149-2160.
89. Nahid P, Dorman SE, Alipanah N, et al. Executive summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:853-867.
90. Furin J, Cox H, Pai M. tuberculosis. Lancet. 2019;393:1642-1656.
91. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015;163:32-39.
92. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis.
93. Millard J, Ugarte-Gil C, Moore DA. Multidrug resistant tuberculosis. BMJ. 2015;350:1-6.
94. Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018;18:e183-e198.
95. Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372:2127-2135.
96. Spaulding AB, Lai YL, Zelazny AM, et al. Geographic distribution of nontuberculous mycobacterial species identified among clinical isolates in the United States, 2009-2013. Ann Am Thorac Soc. 2017;14:1655-1661.
97. Busatto C, Vianna JS, da Silva LVJ, et al. Mycobacterium avium: an overview. Tuberculosis (Edinb). 2019;114:127-134.
98. Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015;15:968-980.
99. Park IK, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med. 2015;36:217-224.
100. Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392:880-890.
101. Gonzalez-Santiago TM, Drage LA. Nontuberculous mycobacteria: skin and soft tissue infections. Dermatol Clin. 2015;33:563-577.
102. Misch EA, Saddler C, Davis JM. Skin and soft tissue infections due to nontuberculous mycobacteria. Curr Infect Dis Rep. 2018;20:1-17.
103. Abubakar I, Gupta RK, Rangaka MX, et al. Update in tuberculosis and nontuberculous mycobacteria 2017. Am J Respir Crit Care Med. 2018;197:1248-1253.
104. Ustinova VV, Smirnova TG, Sochivko DG, et al. New assay to diagnose and differentiate between Mycobacterium tuberculosis complex and nontuberculous mycobacteria. Tuberculosis (Edinb). 2019;114:17-23.
105. Philley JV, Griffith DE. Medical management of pulmonary nontuberculous mycobacterial disease. Thorac Surg Clin. 2019;29:65-76.
106. Mitchell JD. Surgical treatment of pulmonary nontuberculous mycobacterial infections. Thorac Surg Clin. 2019;29:77-83.
107. Vogel M, Bayi PF, Ruf MT, et al. Local heat application for the treatment of Buruli ulcer: results of a phase II open label single center non comparative clinical trial. Clin Infect Dis. 2016;62:342-350.
108. Olivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195:814-823.
109. Penna GO, Buhrer-Sekula S, Kerr LRS, et al. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): results of an open label, randomized and controlled clinical trial, among multibacillary patients. PLoS Negl Trop Dis. 2017; 11: 1–19.
110. Van Veen NH, Nicholls PG, Smith WC, et al. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev. 2016; 2: CD005491.
111. World Health Organization. Global leprosy update, 2017: reducing disease burden due to leprosy. WHO Weekly Epidem Rec. 2018; 93: 444–456.
112. Saini C, Tarique M, Rai R, et al. T helper cells in leprosy: an update. Immunol Lett. 2017; 184: 61–66.
113. Fabel A, Giovanna Brunasso AM, Schettini AP, et al. Pathogenesis of leprosy: an insight into B lymphocytes and plasma cells. Am J Dermatopathol. 2019; 41: 422–427.
114. Neal JW, Gasque P. The role of primary infection of Schwann cells in the aetiology of infective inflammatory neuropathies. J Infect. 2016; 73: 402–418.
115. Franco-Paredes C, Marcos LA, Henao-Martinez AF, et al. Cutaneous mycobacterial infections. Clin Microbiol Rev. 2018; 32: 1–25.
116. Artal FJC. Infectious diseases causing autonomic dysfunction. Clin Auton Res. 2018; 32: 1–25.
117. Aamir M, Sadaf A, Khan S, et al. Recent advancement in the diagnosis and treatment of leprosy. Curr Top Med Chem. 2018; 18: 1550–1558.
118. Tatipally S, Srikantam A, Kasetty S. Polymerase chain reaction (PCR) as a potential point of care laboratory test for leprosy diagnosis-a systematic review. Trop Med Infect Dis. 2018; 3: 1–14.
119. Smith CS, Aerts A, Saunderson P, et al. Multidrug therapy for leprosy: a game changer on the path to elimination. Lancet Infect Dis. 2017; 17: e293–e297.
120. White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev. 2015; 28: 80–94.
121. Lockwood DNJ. Chronic aspects of leprosy-neglected but important. Trans R Soc Trop Med Hyg. 2019; 113: 813–817.
122. Steinmann P, Reed SG, Mirza F, et al. Innovative tools and approaches to end the transmission of Mycobacterium leprae. Lancet Infect Dis. 2017; 17: e298–e305.
123. Kim YS, Kim DM, Yoon NR, et al. Effects of rifampin and doxycycline treatments in patients with uncomplicated scrub typhus: an open-label, randomized, controlled trial. Clin Infect Dis. 2018; 67: 600–605.
124. Blanton LS. The rickettsioses: a practical update. Infect Dis Clin North Am. 2019; 33: 213–229.
125. Tomassone L, Portillo A, Nov?kov? M, et al. Neglected aspects of tick-borne rickettsioses. Parasit Vectors. 2018; 11: 1–11.
126. McFee RB. Tick borne illness: Rocky mountain spotted fever. Dis Mon. 2018; 64: 185–194.
127. Sathiamoorthi S, Smith WM. The eyes and tick-borne disease in the United States. Curr Opin Oph­thalmol. 2016; 27: 530–537.
128. Gottlieb M, Long B, Koyfman A. The evaluation and management of Rocky Mountain spotted fever in the emergency department: a review of the literature. J Emerg Med. 2018; 55: 42–50.
129. Eldin C, Parola P. Update on tick-borne bacterial diseases in travelers. Curr Infect Dis Rep. 2018; 20: 1–9.
130. Angelakis E, Bechan Y, Raoult D. The history of epidemic typhus. Microbiol Spectr. 2016; 4: 1–9.
131. Rauch J, Eisermann P, Noack B, et al. Typhus group rickettsiosis, Germany, 2010-2017. Emerg Infect Dis. 2018; 24: 1213–1220.
132. Xu G, Walker DH, Jupiter D, et al. A review of the global epidemiology of scrub typhus. PLoS Negl Trop Dis. 2017; 11: 1–27.
133. Jung LY, Jeon M, Choi SH, et al. Relative bradycardia in scrub typhus. Am J Trop Med Hyg. 2017; 97: 1316–1318.
134. Mahajan SK, Mahajan SK. Neuropsychiatric manifestations of scrub typhus. J Neurosci Rural Pract. 2017; 8: 421–426.
135. Jain D, Nand N, Giri K, et al. Scrub typhus infection, not a benign disease: an experience from a tertiary care center in Northern India. Med Pharm Rep. 2019; 92: 36–42.
136. Koralur M, Singh R, Varma M, et al. Scrub typhus diagnosis on acute specimens using serological and molecular assays: a 3-year prospective study. Diagn Microbiol Infect Dis. 2018; 91: 112–117.
137. Saraswati K, Day NPJ, Mukaka M, et al. Scrub typhus point-of-care testing: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2018; 12: 1–18.
138. Ismail N, McBride JW. Tick-borne emerging infections: ehrlichiosis and anaplasmosis. Clin Lab Med. 2017; 37: 317–340.
139. McFee RB. Tick borne illness: anaplasmosis. Dis Mon. 2018; 64: 181–184.
140. Fanoy E, Dijkstra F, van der Hoek W, et al. Familiarity of general practitioners with Q fever decreases hospitalization risk. Neth J Med. 2018; 76: 184–189.
141. Kelm DJ, White DB, Fadel HJ, et al. Pulmonary manifestations of Q fever: analysis of 38 patients. J Thorac Dis. 2017; 9: 3973–3978.
142. de Lange MMA, Gijsen LEV, Wielders CCH, et al. Should acute Q-fever patients be screened for valvulopathy to prevent endocarditis? Clin Infect Dis. 2018; 67: 360–366.
143. Mongardon N, Dubory A, Dorget A, et al. Vascular infection and vertebral destruction in a patient with Q fever. Lancet Infect Dis. 2018; 18: 226.
144. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390: 1211–1259.
145. Pisarski K. The global burden of disease of zoonotic parasitic diseases: top 5 contenders for priority consideration. Trop Med Infect Dis. 2019; 4: 1–9.
146. Plowright RK, Parrish CR, McCallum H, et al. Pathways to zoonotic spillover. Nat Rev Microbiol. 2017; 15: 502–510.
147. McMahon BJ, Morand S, Gray JS. Ecosystem change and zoonoses in the Anthropocene. Zoonoses Public Health. 2018; 65: 755–765.
148. Watts N, Adger WN, Ayeb-Karlsson S, et al. The Lancet Countdown: tracking progress on health and climate change. Lancet (London, England). 2017; 389: 1151–1164.
149. Han BA, Kramer AM, Drake JM. Global patterns of zoonotic disease in mammals. Trends Parasitol. 2016; 32: 565–577.
150. Allen T, Murray KA, Zambrana-Torrelio C. Global hotspots and correlates of emerging zoonotic diseases. Nat Commun. 2017; 8: 1–10.
151. Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015; 9: 1–19.
152. Trinh P, Zaneveld JR, Safranek S, et al. One health relationships between human, animal, and envi­ronmental microbiomes: a mini-review. Front Public Health. 2018; 6: 1–9.
153. Bonell A, Lubell Y, Newton PN, et al. Estimating the burden of scrub typhus: a systematic review. Plos Negl Trop Dis. 2017; 11: 1–17.
154. Benedict KM, Collier SA, Marder EP, et al. Case-case analyses of cryptosporidiosis and giardiasis using routine national surveillance data in the United States — 2005–2015. Epidemiol Infect. 2019; 147: 1–5.
155. Adams DA, Thomas KR, Jajosky RA, et al. Summary of notifiable infectious diseases and conditions — United States, 2015. MMWR Morb Mortal Wkly Rep. 2017; 64: 1–143.
156. Cunningham AA, Daszak P, Wood JLN. One Health, emerging infectious diseases and wildlife: two decades of progress? Philos Trans R Soc Lond B Biol Sci. 2017; 1–8.
157. Boyanova L, Koralov R, Mateva L, et al. Actinomycosis: a frequently forgotten disease. Future Microbiol. 2015; 10: 613–628.
158. Kononen E, Wade WG. Actinomyces and related organisms in human infections. Clin Microbiol Rev. 2015; 28: 419–442.
159. Paulo CO, Jordao S, Correia-Pinto J, et al. Actinomycosis, a lurking threat: a report of 11 cases and literature review. Rev Soc Bras Med Trop. 2018; 51: 7–13.
160. Bonnefond S, Catroux M, Melenotte C, et al. Clinical features of actinomycosis: a retrospective, multicenter study of 28 cases of miscellaneous presentations. Medicine (Baltimore). 2016; 95: 1–7.
161. Shikino K, Ikusaka M, Takada T. Cervicofacial actinomycosis. J Gen Intern Med. 2015; 30: 263.
162. Moturi K, Kaila V. Cervicofacial actinomycosis and its management. Ann Maxillofac Surg. 2018; 8: 361–364.
163. Sadeghi S, Azais M, Ghannoum J. Actinomycosis presenting as macroglossia: case report and review of literature. Head Neck Pathol. 2018. [Epub ahead of print.]
164. Higashi Y1, Nakamura S, Ashizawa N, et al. Pulmonary actinomycosis mimicking pulmonary aspergilloma and a brief review of the literature. Intern Med. 2017; 56: 449–453.
165. Lisa-Gracia M, Mart?n-Rivas B, Pajar?n-Guerrero M, Arn?iz-Garc?a A. Abdominal actinomycosis in the last 10 years and risk factors for appendiceal actinomycosis: review of the literature. Turk J Med Sci. 2017; 47: 98–102.
166. Garcia-Garcia A, Ramarez-Duran N, Sandoval-Trujillo H, et al. Pelivic actinomycosis. Can J Infect Dis Med Mircrobiol. 2017; 2017: 1–17.
167. Hwang CS, Lee H, Hong MP, et al. Brain abscess caused by chronic invasive actinomycosis in the nasopharynx: a case report and literature review. Medicine (Baltimore). 2018; 97: 1–4.
168. Mishra A, Prabhuraj AR, Bhat D, et al. Intracranial actinomycosis manifesting as a parenchymal mass lesion: a case report and review of literature. World Neurosurg. 2019; 122: 190–194.
169. Ravindra N, Sadashiva N, Mahadevan A, et al. Central nervous system actinomycosis — a clinicoradiologic and histopathologic analysis. World Neurosurg. 2018; 116: e362–e370.
170. Steininger C, Willinger B. Resistance patterns in clinical isolates of pathogenic Actinomyces species. J Antimicrob Chemother. 2016; 71: 422–427.
171. Bonifaz A, Tirado-Sanchez A, Calderon L, et al. Treatment of cutaneous actinomycosis with amoxicillin/clavulanic acid. J Dermatolog Treat. 2017; 28: 59–64.
172. Fatahi-Bafghi M. Nocardiosis from 1888 to 2017. Microb Pathog. 2018; 114: 369–384.
173. Conville PS, Brown-Elliott BA, Smith T, et al. The complexities of Nocardia taxonomy and identification. J Clin Microbiol. 2017; 56: 1–10.
174. Coussement J, Lebeaux D, van Delden C, et al. Nocardia infection in solid organ transplant recipients: a multicenter European case-control study. Clin Infect Dis. 2016; 63: 338–345.
175. Lebeaux D, Freund R, van Delden C, et al. Outcome and treatment of nocardiosis after solid organ transplantation: new insights from a European study. Clin Infect Dis. 2017; 64: 1396–1405.
176. Abreu C, Rocha-Pereira N, Sarmento A, et al. Nocardia infections among immunomodulated inflammatory bowel disease patients: a review. World J Gastroenterol. 2015; 21: 6491–6498.
177. Steinbrink J, Leavens J, Kauffman CA, et al. Manifestations and outcomes of nocardia infections: comparison of immunocompromised and nonimmunocompromised adult patients. Medicine (Baltimore). 2018; 97: 1–7.
178. Coussement J, Lebeaux D, Rouzaud C, et al. Nocardia infection in solid organ and hematopoietic stem cell transplant recipients. Curr Opin Infect Dis. 2017; 30: 545–551.
179. Ott SR, Meier N, Kolditz M, et al. Pulmonary nocardiosis in Western Europe — clinical evaluation of 43 patients and population-based estimates of hospitalization rates. Int J Infect Dis. 2019; 81: 140–148.
180. Sood R, Tyagi R, Selhi PK, et al. Role of FNA and special stains in rapid cytopathological diagnosis of pulmonary nocardiosis. Acta Cytol. 2018; 62: 178–182.
181. Mazzaferri F, Cordioli M, Segato E, et al. Nocardia infection over 5 years (2011–2015) in an Italian tertiary care hospital. New Microbiol. 2018; 41: 136–140.
182. Lebeaux D, Bergeron E, Berthet J, et al. Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010–2015. Clin Microbiol Infect. 2018. [Epub ahead of print.]
183. Restrepo A, Clark NM. Nocardia infections in solid organ transplantation: guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation. Clin Transplant. 2019. [Epub ahead of print.]
184. Tashiro H, Takahashi K, Kusaba K, et al. Relationship between the duration of trimethoprim/sulfamethoxazole treatment and the clinical outcome of pulmonary nocardiosis. Respir Investig. 2018; 56: 166–172.
185. Xu Q, Zhan R, Feng Y, et al. Successful treatment of multifoci nocardial brain abscesses: a case report and literature review. Medicine (Baltimore). 2015; 94: 1–14.
186. Kontoyiannis DP. Antifungal resistance: an emerging reality and a global challenge. J Infect Dis. 2017; 216: S431–S435.
187. Lachenmayr SJ, Strobach D, Berking S, et al. Improving quality of antifungal use through antifungal stewardship interventions. Infection. 2019. [Epub ahead of print.]
188. Campoy S, Adrio JL. Antifungals. Biochem Pharmacol. 2017; 133: 86–96.
189. Chowdhary A, Sharma C, Meis JF. Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017; 216 (suppl 3): S436–S444.
190. Ledoux MP, Denis J, Nivoix Y, et al. Isavuconazole: a new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity. J Mycol Med. 2018; 28: 15–22.
191. Tonin FS, Steimbach LM, Borba HH, et al. Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis. J Pharm Pharmacol. 2017; 69: 1672–1683.
192. Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017; 10: 249–259.
193. Fisher MC, Hawkins NJ, Sanglard D, et al. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018; 360: 739–742.
194. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resis­tance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017; 17: e383–e392.
195. Pilmis B, Jullien V, Sobel J, et al. Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother. 2015; 70: 14–22.
196. Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2019; 16: 603–616.
197. Denning DW, Chakrabarti A. Pulmonary and sinus fungal diseases in non-immunocompromised patients. Lancet Infect Dis. 2017; 17: e357–e366.
198. Castillo CG, Kauffman CA, Miceli MH. Blastomycosis. Infect Dis Clin North Am. 2016; 30: 247–264.
199. Walkty A, Keynan Y, Karlowsky J, et al. Central nervous system blastomycosis diagnosed using the MVista Blastomyces quantitative antigen enzyme immunoassay test on cerebrospinal fluid: a case report and review of the literature. Diagn Microbiol Infect Dis. 2018; 90: 102–104.
200. Frost HM, Novicki TJ. Blastomyces antigen detection for diagnosis and management of blastomycosis. J Clin Microbiol. 2015; 53: 3660–3662.
201. McBride JA, Gauthier GM, Klein BS. Clinical manifestations and treatment of blastomycosis. Clin Chest Med. 2017; 38: 435–449.
202. Wheat LJ, Azar MM, Bahr NC, et al. Histoplasmosis. Infect Dis Clin North Am. 2016; 30: 207–227.
203. Lee PP, Lau YL. Cellular and molecular defects underlying invasive fungal infections-revelations from endemic mycoses. Front Immunol. 2017; 8: 1–22.
204. Staffolani S, Buonfrate D, Angheben A, et al. Acute histoplasmosis in immunocompetent travelers: a systematic review of literature. BMC Infect Dis. 2018; 18: 1–14.
205. Di Mango AL, Zanetti G, Penha D, et al. Endemic pulmonary fungal diseases in immunocompetent patients: an emphasis on thoracic imaging. Expert Rev Respir Med. 2019; 13: 263–277.
206. Azar MM, Hage CA. Laboratory diagnostics for histoplasmosis. J Clin Microbiol. 2017; 55: 1612–1620.
207. Richer SM, Smedema ML, Durkin MM, et al. Improved diagnosis of acute pulmonary histoplasmosis by combining antigen and antibody detection. Clin Infect Dis. 2016; 62: 896–902.
208. Azar MM, Hage CA. Clinical perspectives in the diagnosis and management of histoplasmosis. Clin Chest Med. 2017; 38: 412–415.
209. McCotter OZ, Benedict K, Engelthaler DM, et al. Update on the epidemiology of coccidioidomycosis in the United States. Med Mycol. 2019; 57: S30–S40.
210. Martinez-Del-Campo E, Kalb S, Rangel-Castilla L, et al. Spinal coccidioidomycosis: a current review of diagnosis and management. World Neurosurg. 2017; 108: 69–75.
211. Gabe LM, Malo J, Knox KS. Diagnosis and management of coccidioidomycosis. Clin Chest Med. 2017; 38: 417–433.
212. Thompson GR 3rd, Lewis JS 2nd, Nix DE, et al. Current concepts and future directions in the pharmacology and treatment of coccidioidomycosis. Med Mycol. 2019; 57: S76–S84.
213. Galgiani JN, Ampel NM, Blair JE, et al. Executive summary: 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016; 63: 717–722.
214. Chakrabarti A, Bonifaz A, Gutierrez-Galhardo MC, et al. Global epidemiology of sporotrichosis. Med Mycol. 2015; 53: 3–14.
215. Moreira JA, Freitas DF, Lamas CC. The impact of sporotrichosis in HIV-infected patients: a systematic review. Infection. 2015; 43: 267–276.
216. Rodriguez-Brito S, Camacho E, Mendoza M, et al. Differential identification of Sporothrix spp. and Leishmania spp. by conventional PCR and qPCR in multiplex format. Med Mycol. 2015; 53: 22–27.
217. Garcia Carnero LC, Lozoya P?rez NE, Gonz?lez Hern?ndez SE, et al. Immunity and treatment of sporotrichosis. J Fungi (Basel). 2018; 4: 1–14.
218. Schimke LF, Hibbard J, Martinez-Barricarte R, et al. Paracoccidioidomycosis associated with a het­erozygous STAT4 mutation and impaired IFN-? immunity. J Infect Dis. 2017; 216: 1623–1634.
219. Marques de Macedo P, Almeida-Paes R, Freitas DFS, et al. Acute juvenile paracoccidioidomycosis: a 9-year cohort study in the endemic area of Rio de Janeiro, Brazil. PLoS Negl Trop Dis. 2017; 11: 1–4.
220. Trindade AH, Meira HC, Pereira IF, et al. Oral paracoccidioidomycosis: retrospective analysis of 55 Brazilian patients. Mycoses. 2017; 60: 521–525.
221. Shikanai-Yasuda MA, Mendes RP, Colombo AL, et al. Brazilian guidelines for the clinical manage­ment of paracoccidioidomycosis. Rev Soc Bras Med Trop. 2017; 50: 715–740.
222. Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010; 50: 338–344.
223. Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016; 374: 542–554.
224. Day JN, Chau TT, Wolbers M, et al. Combination antifungal theory for cryptococcal meningitis. N Engl J Med. 2013; 368: 1291–1302.
225. Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018; 378: 1004–1017.
226. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014; 370: 2487–2498.
227. Parkes-Ratanshi R, Wakeham K, Levin J, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind randomised, placebo-controlled trial. Lancet Infect Dis. 2011; 11: 933–941.
228. Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2016; 30: 179–206.
229. Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017; 17: 873–881.
230. Lawrence DS, Boyer-Chammard T, Jarvis JN. Emerging concepts in HIV-associated cryptococcal meningitis. Curr Opin Infect Dis. 2019; 32: 16–23.
231. Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: a review of pathobiology and clinical aspects. Med Mycol. 2019; 57: 133–150.
232. Rajasingham R, Wake RM, Beyene T, et al. Cryptococcal meningitis diagnostics and screening in the era of point-of-care laboratory testing. J Clin Microbiol. 2019; 57: 1–8.
233. Gassiep I, Douglas J, Emeto TI, et al. Cryptococcal infections over a 15 year period at a tertiary facility & impact of guideline management. Mycoses. 2018; 61: 633–638.
234. Meya DB, Okurut S, Zziwa G, et al. Cellular immune activation in cerebrospinal fluid from Ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. J Infect Dis. 2015; 211: 1597–1606.
235. Pasquier E, Kunda J, De Beaudrap P, et al. Long-term mortality and disability in cryptococcal meningitis: a systematic literature review. Clin Infect Dis. 2018; 66: 1122–1132.
236. Mora DJ, Fortunato LR, Andrade-Silva LE, et al. Cytokine profiles at admission can be related to outcome in AIDS patients with cryptococcal meningitis. PLoS ONE. 2015; 10: 1–17.
237. Kullberg BJ, Vasquez J, Mootsikapun P, et al. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. J Antimicrob Chemother. 2017; 72: 2368–2377.
238. Timsit JF, Azoulay E, Schwebel C, et al. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure. The EMPIRICUS randomized clinical trial. JAMA. 2016; 316: 1555–1564.
239. Ostrosky-Zeichner L, Shoham S, Vasquez J, et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014; 58: 1219–1226.
240. Edwards JE Jr, Schwartz MM, Schmidt CS, et al. A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis-a phase 2 randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2018; 66: 1928–1936.
241. Strollo S, Lionkia MS, Adjemian J, et al. Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002–2012. Emerg Infect Dis. 2017; 23: 7–13.
242. Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. infections in patients with diabetes mellitus. J Clin Med. 2019; 8: 1–41.
243. Xiao Y, Tang J, Guo H, et al. Targeting CBLB as a potential therapeutic approach for disseminated candidiasis. Nat Med. 2016; 22: 906–914.
244. Hellstein JW, Marek CL. Candidiasis: red and white manifestations in the oral cavity. Head Neck Pathol. 2019; 13: 25–32.
245. Hoversten P, Otaki F, Katzka DA. Course of esophageal candidiasis and outcomes of patients at a single center. Clin Gastroenterol Hepatol. 2019; 17: 200–202.
246. Colombo AL, de Almeida Junior JN, Slavin MA, et al. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 2017; 17: e344–e356.
247. Pfaller MA, Castanheira M. Nosocomial candidiasis: antifungal stewardship and the importance of rapid diagnosis. Med Mycol. 2016; 54: 1–22.
248. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015; 373: 1445–1456.
249. Clancy CJ, Pappas PG, Vazquez J, et al. Detecting infections rapidly and easily for candidemia trial, part 2 (DIRECT2): a prospective, multicenter study of the T2Candida panel. Clin Infect Dis. 2018; 66: 1678–1686.
250. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 magnetic resonance assay for the diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015; 60: 892–899.
251. Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 62: 409–417.
252. Eschenauer GA, Nguyen MH, Clancy CJ. Is fluconazole or an echinocandin the agent of choice for candidemia. Ann Pharmacother. 2015; 49: 1068–1074.
253. Tang Y, Yu F, Huang L, et al. The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. J Clin Lab Anal. 2019; 33: 1–6.
254. Vergidis P, Clancy CJ, Shields RK, et al. Intra-abdominal candidiasis: the importance of early source control and antifungal treatment. PLoS ONE. 2016; 11: 1–14.
255. Aguado JM, V?zquez L, Fern?ndez-Ruiz M, et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis. 2015; 60: 405–414.
256. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016; 387: 760–769.
257. Agarwal R, Dhooria S, Singh Sehgal I, et al. A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Chest. 2018; 153: 656–664.
258. Jat KR, Walia DK, Khairwa A. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2018; 3: CD010288.
259. Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015; 162: 81–89.
260. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal disease after allogeneic hematopoietic cell transplantation. Blood. 2010; 116: 5111–5118.
261. Xia D, Sun WK, Tan MM, et al. Aerosolized amphotericin B as prophylaxis for invasive pulmonary aspergillosis: a meta-analysis. Int J Infect Dis. 2015; 30: 78–84.
262. Colombo AL, de Almeida Junior JN, Slavin MA, et al. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 2017; 17: e344–e356.
263. Denning DW, Chakrabarti A. Pulmonary and sinus fungal diseases in non-immunocompromised patients. Lancet Infect Dis. 2017; 17: e357–e366.
264. Gletsou E, Ioannou M, Liakopoulos V, et al. Aspergillosis in immunocompromised patients with haematological malignancies. J BUON. 2018; 23: 7–10.
265. Zilberberg MD, Nathanson BH, Harrington R, et al. Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009–2013. Clin Infect Dis. 2018; 67: 727–735.
266. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015; 3: 270–277.
267. Pasha AK, Lee JZ, Low SW, et al. Fungal endocarditis: update on diagnosis and management. Am J Med. 2016; 129: 1037–1043.
268. Gamaletsou MN, Rammaert B, Bueno MA, et al. Aspergillus arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases. Med Mycol. 2017; 55: 246–254.
269. Muldoon EG, Strek ME, Patterson KC. Allergic and noninvasive infectious pulmonary aspergillosis syndromes. Clin Chest Med. 2017; 38: 521–534.
270. Agarwal R, Sehgal IS, Dhooria S, et al. Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert Rev Respir Med. 2016; 10: 1317–1334.
271. Davda S, Kowa XY, Aziz Z, et al. The development of pulmonary aspergillosis and its histologic, clinical, and radiologic manifestations. Clin Radiol. 2018; 73: 913–921.
272. Kim SH, Kim MY, Hong SI, et al. Invasive pulmonary aspergillosis-mimicking tuberculosis. Clin Infect Dis. 2015; 61: 9–17.
273. Moura S, Cerqueira L, Almeida A. Invasive pulmonary aspergillosis: current diagnostic methodologies and a new molecular approach. Eur J Clin Microbiol Infect Dis. 2018; 37: 1393–1403.
274. Jenks JD, Salzer HJF, Hoenigl M. Improving the rates of Aspergillus detection: an update on current diagnostic strategies. Expert Rev Anti Infect Ther. 2019; 17: 39–50.
275. McCarthy MW, Walsh TJ. Galactomannan antigenemia as a biomarker for therapeutic response of invasive aspergillosis: implications for clinical trial design and patient care. Expert Rev Mol Diagn. 2018; 18: 601–604.
276. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24 (suppl 1): e1–e38.
277. Patterson TF, Thompson GR 3rd, Denning DW, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63: 433–442.
278. Meis JF, Chowdhary A, Rhodes JL, et al. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc Lond B Biol Sci. 2016; 371: 1–10.
279. Bassetti M, Peghin M, Vena A. Challenges and solution of invasive aspergillosis in non-neutropenic patients: a review. Infect Dis Ther. 2018; 7: 17–27.
280. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012; 67: 715–722.
281. Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am. 2016; 30: 143–163.
282. Song Y, Qiao J, Giovanni G, et al. Mucormycosis in renal transplant recipients: review of 174 reported cases. BMC Infect Dis. 2017; 17: 1–6.
283. Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019; 25: 26–34.
284. Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis — the bitter and the sweet. PLoS Pathog. 2017; 13: 1–9.
285. Ibrahim AS, Voelz K. The mucormycete-host interface. Curr Opin Microbiol. 2017; 40: 40–45.
286. Petrikkos G, Tsioutis C. Recent advances in the pathogenesis of mucormycoses. Clin Ther. 2018; 40: 894–902.
287. Manesh A, Rupali P, Sullivan MO, et al. Mucormycosis—a clinicoepidemiological review of cases over 10 years. Mycoses. 2019; 62: 391–398.
288. Nezafati S, Kazemi A, Asgari K, et al. Rhinocerebral mucormycosis, risk factors and the type of oral manifestations in patients referred to a university hospital in Tabriz, Iran. Mycoses. 2018;61:764-769.
289. Kontoyiannis DP, Yang H, Song J, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis. 2016; 16: 1–6.
290. He R, Hu C, Tang Y, et al. Report of 12 cases with tracheobronchial mucormycosis and a review. Clin Respir J. 2018; 12: 1651–1660.
291. Castrej?n-P?rez AD, Welsh EC, Miranda I, et al. Cutaneous mucormycosis. An Bras Dermatol. 2017; 92: 304–311.
292. Kaur H, Ghosh A, Rudramurthy SM, et al. Gastrointestinal mucormycosis in apparently immuno­competent hosts — a review. Mycoses. 2018; 61: 898–908.
293. Kerezoudis P, Watts CR, Bydon M, et al. Diagnosis and treatment of isolated cerebral mucormycosis: patient-level data meta-analysis and Mayo Clinic experience. World Neurosurg. 2019; 123: 425–434.
294. Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018; 56 (suppl 1): 93–101.
295. Dadwal SS, Kontoyiannis DP. Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn. 2018; 18: 845–854.
296. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Hae­matologica. 2017; 102: 433–444.
297. Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015; 70: 3116–3123.
298. Kyvernitakis A, Torres HA, Jiang Y, et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016; 22: 811. e1–811.e8.
299. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016; 16: 828–837.
300. Gebremariam T, Lin L, Liu M, et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest. 2016; 126: 2280–2294.
301. Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015; 4: CD006150.
302. Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014; 10: CD005590.
303. Utsunomiya M, Dobashi H, Odani T, et al. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther. 2017; 19: 1–10.
304. Salzer HJF, Schafer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration. 2018; 96: 52–65.
305. Ma L, Chen Z, Huang da W, et al. Genome analysis of three Pneumocystis species reveals adaptation mechanisms to life exclusively in mammalian hosts. Nat Commun. 2016; 7: 1–14.
306. Ma L, Ciss? OH, Kovacs JA. A molecular window into the biology and epidemiology of Pneumocystis spp. Clin Microbiol Rev. 2018; 31: 1–49.
307. Yiannakis EP, Boswell TC. Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evi­dence that P. jirovecii is a transmissible organism and the implications for healthcare infection control. J Hosp Infect. 2016; 93: 1–8.
308. Jiang X, Mei X, Feng D, et al. Prophylaxis and treatment of Pneumocystis jiroveci pneumonia in lym­phoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis. PLoS ONE. 2015; 10: 1–15.
309. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 2.2017. http://www.nccn.org. Accessed May 7, 2019.
310. Messiaen PE, Cuyx S, Dejagere T, et al. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review. Transpl Infect Dis. 2017; 19: 1–6.
311. Hoving JC, Kolls JK. New advances in understanding the host immune response to Pneumocystis. Curr Opin Microbiol. 2017; 40: 65–71.
312. Opata MM, Hollifield ML, Lund FE, et al. B lymphocytes are required during the early priming of CD4+ T cells for clearance of Pneumocystis infection in mice. J Immunol. 2015; 195: 611–620.
313. Kutty G, Davis AS, Ferreyra GA, et al. Beta-glucans are masked but contribute to pulmonary inflammation during Pneumocystis pneumonia. J Infect Dis. 2016; 214: 782–791.
314. Shibata S, Kikuchi T. Pneumocystis pneumonia in HIV-1-infected patients. Respir Investig. 2019. [Epub ahead of print.]
315. Calero-Bernal ML, Martin-Garrido I, Donazar-Ezcurra M, et al. Intermittent courses of corticosteroids also present a risk for Pneumocystis pneumonia in non-HIV patients. Can Respir J. 2016; 2016: 1–7.
316. Ebner L, Walti LN, Rauch A, et al. Clinical course, radiological manifestations, and outcome of Pneumocystis jirovecii pneumonia in HIV patients and renal transplant recipients. PLoS ONE. 2016; 11: e0164320.
317. Alanio A, Hauser PM, Lagrou K, et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Anti­microb Chemother. 2016; 71: 2386–2396.
318. Sasso M, Chastang-Dumas E, Bastide S, et al. Performances of four real-time PCR assays for diagnosis of Pneumocystis jirovecii pneumonia. J Clin Microbiol. 2016; 54: 625–630.
319. Fauchier T, Hasseine L, Gari-Toussaint M, et al. Detection of Pneumocystis jirovecii by quantitative PCR to differentiate colonization and pneumonia in immunocompromised HIV-positive and HIV-negative patients. J Clin Microbiol. 2016; 54: 1487–1495.
320. Le Gal S, Robert-Gangneux F, Pepino Y, et al. A misleading false-negative result of Pneumocystis real-time PCR assay due to a rare punctual mutation: a French multicenter study. Med Mycol. 2017; 55: 180–184.
321. Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016; 71: 2405–2413.
322. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed March 27, 2019.
323. White PL, Backx M, Barnes RA. Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther. 2017; 15: 435–447.
324. Fujikura Y, Manabe T, Kawana A, Kohno S. Adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in non-HIV-infected patients: a systematic review and meta-analysis of observational studies. Arch Bronconeumol. 2017; 53: 55–61.
325. Wieruszewski PM, Barreto JN, Frazee E, et al. Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcomes. Chest. 2018; 154: 636–644.
326. Montesinos I, Delforge ML, Ajjaham F, et al. Evaluation of a new commercial real-time PCR assay for diagnosis of Pneumocystis jirovecii pneumonia and identification of dihydropteroate synthase (DHPS) mutations. Diagn Microbiol Infect Dis. 2017; 87: 32–36.
327. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/sites/default/files/inline-files/oi_guidelines_pediatrics.pdf. Accessed March 27, 2019.
328. Brakemeier S, Pfau A, Zukunft B, et al. Prophylaxis and treatment of Pneumocystis jirovecii pneumonia after solid organ transplantation. Pharmacol Res. 2018; 134: 61–67.
329. Williams KM, Ahn KW, Chen M, et al. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant. 2016; 51: 573–580.
330. Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016; 71: 2397–2404.
331. Goto N, Futamura K, Okada M, et al. Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak. Clin Med Insights Circ Respir Pulm Med. 2015; 9: 81–90.
332. Emmanuel P, Dumre SP, John S, et al. Mycetoma: a clinical dilemma in resource limited settings. Ann Clin Microbiol Antimicrob. 2018; 17: 35.
333. Wong EH, Revankar SG. Dematiaceous molds. Infect Dis Clin North Am. 2016; 30: 165–178.
334. Verma P, Jha A. Mycetoma: reviewing a neglected disease. Clin Exp Dermatol. 2019; 44: 123–129.
335. Zijlstra EE, van de Sande WW, Welsh O, et al. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis. 2016; 16: 100–112.
336. McCarty TP, Baddley JW, Walsh TJ, et al. Phaeohyphomycosis in transplant recipients: results from the Transplant Associated Infection Surveillance Network (TRANSNET). Med Mycol. 2015; 53: 440–446.
337. Revankar S, Baddley J, Chen S, et al. A Mycoses Study Group international prospective study of phaeohyphomycosis: an analysis of 99 proven/probable cases. Open Forum Infect Dis. 2017; 1.
338. Alves de Medeiros AK, Lodewick E, Bogaert DJ, et al. Chronic and invasive fungal infections in a family with CARD9 deficiency. J Clin Immunol. 2016; 36: 204–209.
339. Lanternier F, Barbati E, Meinzer U, et al. Inherited CARD9 deficiency in 2 unrelated patients with invasive Exophiala infection. J Infect Dis. 2015; 211: 1241–1250.
340. Renfrow JJ, Frenkel MB, Hsu W. Fungal contamination of methylprednisolone causing recurrent lumbosacral intradural abscess. Emerg Infect Dis. 2017; 23: 552–553.
341. Fahal A, Mahgoub el S, El Hassan AM, et al. Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan. PLoS Negl Trop Dis. 2015; 1–19.
342. Fahal AH, Suliman SH, Hay R. Mycetoma: the spectrum of clinical presentation. Trop Med Infect Dis. 2018; 3: 1–11.
343. Caviedes MP, Torre AC, Eliceche ML, et al. Cutaneous phaeohyphomycosis. Int J Dermatol. 2017; 56: 415–420.
344. Kalin-Hajdu E, Hirabayashi KE, Vagefi MR, Kersten RC. Invasive fungal sinusitis: treatment of the orbit. Curr Opin Ophthalmol. 2017; 28: 522–533.
345. Bitan O, Wiener-Well Y, Segal R, Schwartz E. Mycetoma (Madura foot) in Israel: recent cases and a systematic review of the literature. Am J Trop Med Hyg. 2017; 96: 1355–1361.
346. Ahmed AA, van de Sande W, Fahal AH. Mycetoma laboratory diagnosis: review article. Plos Negl Trop Dis. 2017; 11: 1–17.
347. Gismalla MDA, Ahmed GMA, MohamedAli MM, et al. Surgical management of eumycetoma: experience from Gezira Mycetoma Center, Sudan. Trop Med Health. 2019; 47: 1–6.
348. Arenas R, Fernandez Martinez RF, Torres-Guerrero E, et al. Actinomycetoma: an update on diagnosis and treatment. Cutis. 2017; 99: E11–E15.
349. Wilby KJ. A review of the clinical pharmacokinetics and pharmacodynamics of isavuconazole. Eur J Drug Metab Pharmacokinet. 2018; 43: 281–290.
350. Burki TK. Starting from scratch — the unique neglect of mycetoma. Lancet Infect Dis. 2016; 16: 1011–1012.
351. Garcia HH, Gonzales I, Lescano AG, et al. Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, ran­domised controlled trial. Lancet Infect Dis. 2014; 14: 687–695.
352. A-Z Index, Centers for Disease Control and Prevention.
353. Centers for Disease Control and Prevention. CDC Yellow Book: health information for international travel. 2018.
354. Roussel C, Caumes E, Thellier M, et al. Artesunate to treat severe malaria in travellers: a review of efficacy and safety and practical implications. J Travel Med. 2017; 24: 1–9.
355. Tilley L, Straimer J, Gnadig NF, et al. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 2016; 32: 682–696.
356. Aldomiz-Echevarria Lois T, L?pez-Pol?n A, Norman FF, et al. Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: report on the experience of a referral centre for tropical infections in Spain. Travel Med Infect Dis. 2017; 15: 52–56.
357. Gonzolez R, Pons-Duran C, Piqueras M, et al. Mefloquine for preventing malaria in pregnant women. Cochrane Database Syst Rev. 2018; 3: CD011444.
358. Monge-Maillo B, Lopez-Velez R. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis. 2015; 60: 1398–1404.
359. Dunn AL, Reed T, Stewart C, Levy RA. Naegleria fowleri that induces primary amoebic meningoencephalitis: rapid diagnosis and rare case of survival in a 12-year-old Caucasian girl. Lab Med. 2016; 47: 149–154.
360. Bascher P, Cecchi G, Jamonneau V, et al. Human African trypanosomiasis. Lancet. 2017; 390: 2397–2409.
361. Scarim CB, Jornada DH, Machado MGM, et al. Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. Eur J Med Chem. 2019; 162: 378–395.
362. van Griensven J, Diro E. Visceral leishmaniasis: recent advances in diagnostics and treatment regimens. Infect Dis Clin North Am. 2019; 33: 79–99.
363. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg. 2017; 96: 24–45.
364. Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019; 33: 101–111.
365. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018; 392: 951–970.
366. Clements AC, Doi SA, et al. Differential effect of mass deworming and targeted deworming for soil-transmitted helminth control in children: a systematic review and meta-analysis. Lancet. 2017; 10066: 287–297.
367. Coyle CM. Neurocysticerosis: an individualized approach. Infect Dis Clin North Am. 2019; 33: 153–168.
368. White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018; 66: 1159–1163.
369. Parasites — Cysticercosis, Resources for Health Professionals.
370. Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019; 380: 215–228.
371. Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019; 380: 229–241.
372. Graves PM, Choi L, Gelband H, et al. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev. 2018; 2: CD008152.
373. Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a random­ized trial. PLoS Med. 2011; 8: 1–16.
374. Yeka A, Kigozi R, Conrad MD, et al. Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J Infect Dis. 2016; 213: 1134–1142.
375. Sirima SB, Ogutu B, Lusingu JPA, et al. Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet Infect Dis. 2016; 16: 1123–1133.
376. PREGACT study group. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med. 2016; 374: 913–927.
377. Gogtay N, Kannan S, Thatte UM, et al. Artemisinin-based combination therapy for treating uncom­plicated Plasmodium vivax malaria. Cochrane Database Syst Rev. 2013; 10: CD008492.
378. Pryce J, Hine P. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2019; 1: CD006404.
379. Toure OA, Valecha N, Tshefu AK, et al. A phase 3, double blind, randomized study of arterolane maleate-piperaquine phosphate vs artemether-lumefantrine for falciparum malaria in adolescent and adult patients in Asia and Africa. Clin Infect Dis. 2016; 62: 964–971.
380. Laman M, Moore BR, Benjamin JM, et al. Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial. PLoS Med. 2014; 11: 1–18.
381. Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016; 16: 357–365.
382. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010; 376: 1647–1657.
383. Esu E, Effa EE, Opie ON, et al. Artemether for severe malaria. Cochrane Database Syst Rev. 2014; 9: CD010678.
384. Kremsner PG, Adegnika AA, Hounkpatin AB, et al. Intramuscular artesunate for severe malaria in African children: a multicenter randomized controlled trial. PLoS Med. 2016; 13: 1–22.
385. Tiono AB, Ouedraogo A, Ouattara D, et al. Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial. Lancet. 2018; 392: 569–580.
386. Protopopoff N, Mosha JF, Lukole E, et al. Effectiveness of long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. Lancet. 2018; 391: 1577–1588.
387. Outdraogo AL, Bastiaens GJ, Tiono AB, et al. Efficacy and safety of the mosquitocidal drug iver­mectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis. 2015; 60: 357–365.
388. Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013; 368: 1111–1120.
389. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015; 386: 31–45.
390. Olotu A, Fegan G, Wambua J, et al. Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children. N Engl J Med. 2016; 374: 2519–2529.
391. Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Lancet. 2018; 391: 1608–1621.
392. Cowman AF, Healer J, Marapana D, et al. Malaria: biology and disease. Cell. 2016; 167: 610–624.
393. Karnad DR, Nor MBM, Richards GA, et al. Intensive care of severe malaria: report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care. 2018; 43: 356–360.
394. World Health Organization. World Malaria Report 2018. Geneva, Switzerland: WHO; 2018.
395. Gething PW, Casey DC, Weiss DJ, et al. Mapping Plasmodium falciparum mortality in Africa between 1990 and 2015. N Engl J Med. 2016; 375: 2435–2445.
396. Newby G, Bennett A, Larson E, et al. The path to eradication: a progress report on the malaria-eliminating countries. Lancet. 2016; 387: 1775–1784.
397. Luzolo AL, Ngoyi DM. Cerebral malaria. Brain Res Bull. 2019; 145: 53–58.
398. Mukkala AN, Kwan J, Lau R, et al. An update on malaria rapid diagnostic tests. Curr Infect Dis Rep. 2018; 20: 1–8.
399. Plewes K, Leopold SJ, Kingston HWF, et al. Malaria: what’s new in the management of malaria? Infect Dis Clin North Am. 2019; 33: 39–60.
400. Rout S, Mahapatra RK. Plasmodium falciparum: multidrug resistance. Chem Biol Drug Des. 2019; 93: 737–759.
401. World Health Organization. Guidelines for the treatment of malaria. Geneva, Switzerland: WHO; 2015.
402. Dicko A, Brown JM, Diawara H, et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomized phase 2 trial. Lancet Infect Dis. 2016; 16: 674–684.
403. Haldar K, Bhattacharjee S, Safeukui I. Drug resistance in plasmodium. Nat Rev Microbiol. 2018; 16: 156–170.
404. Rolling T, Agbenyega T, Krishna S, et al. Delayed haemolysis after artesunate treatment of severe malaria — review of the literature and perspective. Travel Med Infect Dis. 2015; 13: 143–149.
405. Goodman CD, Siregar JE, Mollard V, et al. Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. Science. 2016; 352: 349–353.
406. Greenwood B, Dicko A, Sagara I, et al. Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine. Malar J. 2017; 16: 1–5.
407. Mordm?ller B, Surat G, Lagler H, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017; 542: 445–449.
408. Pohlig G, Bernhard SC, Blum J, et al. Efficacy and safety of pafuramidine versus pentamidine maleate for treatment of first stage sleeping sickness in a randomized, comparator-controlled, international Phase 3 clinical trial. PLoS Negl Trop Dis. 2016; 10: 1–17.
409. Kansiime F, Adibaku S, Wamboga C, et al. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda. Parasit Vectors. 2018; 11: 1–11.
410. Mesu VKBK, Kalonji WM, Bardonneau C, et al. Oral fexinidazole for late-stage African Trypanasome brucci gambiense trypanasomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018; 391: 144–154.
411. Boscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. Lancet. 2017; 390: 2397–2409.
412. Aksoy S, Buscher P, Lehane M, et al. Human African trypanosomiasis control: achievements and challenges. PLoS Negl Trop Dis. 2017; 11: 1–6.
413. Bottieau E, Clerinx J. Human African trypanosomiasis: progress and stagnation. Infect Dis Clin North Am. 2019; 33: 61–77.
414. Mogk S, Bosselmann CM, Mudogo CN, et al. African trypanosomes and brain infection — an unsolved question. Biol Rev Camb Philos Soc. 2017; 92: 1675–1687.
415. Stijlemans B, De Baetselier P, Magez A, et al. African trypanosomias — associated anemia: the con­tribution of the interplay between parasites and the mononuclear phagocyte system. Front Immunol. 2018; 9: 1–15.
416. Fairlamb AH, Horn D. Melarsoprol resistance in African trypanosomiasis. Trends Parasitol. 2018; 34: 481–492.
417. Carvalho L, Martinez-Garcia M, Perez-Victoria I, et al. The oral antimalarial drug tafenoquine shows activity against Trypanosoma brucei. Antimicrob Agents Chemother. 2015; 59: 6151–6160.
418. Scarim CB, Jornada DH, Machado MGM, et al. Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. Eur J Med Chem. 2019; 162: 378–395.
419. Keating J, Yukich JO, Sutherland CS, et al. Human African trypanosomiasis prevention, treatment and control costs: a systematic review. Acta Trop. 2015; 150: 4–13.
420. Molina I, Gomez I, Prat J, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014; 370: 1899–1908.
421. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015; 373: 1295–1306.
422. Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS Trial. J Am Coll Cardiol. 2017; 69: 939–947.
423. Marti-Carvajal AJ, Kwong JS. Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy. Cochrane Database Syst Rev. 2016; 7: CD009077.
424. Robertson LJ, Devleesschauwer B, Alarcon de Noya B, et al. Trypanosoma cruzi: time for international recognition as a foodborne parasite. PLoS Negl Trop Dis. 2016; 10: 1–6.
425. Gomes C, Almeida AB, Rosa AC, et al. American trypanosomiasis and Chagas disease: sexual trans­mission. Int J Infect Dis. 2019; 81: 81–84.
426. Pan American Health Organization. Chagas disease. Available from: http://www.paho.org/hq/index.php?option=com_topics&view=article&id=10&Itemid=40743. Accessed: May 15 2019.
427. Manne-Goehler J, Umeh CA, Montgomery SP, et al. Estimating the burden of Chagas disease in the United States. PLoS Negl Trop Dis. 2016; 10: 1–7.
428. Antinori S, Galimberti L, Bianco R, et al. Chagas disease in Europe: a review for the internist in the globalized world. Eur J Intern Med. 2017; 43: 6–15.
429. Bern C. Chagas disease. N Engl J Med. 2015; 373: 456–466.
430. Echeverria LE, Morillo CA. American trypanosomiasis (Chagas disease). Infect Dis Clin North Am. 2019; 33: 119–134.
431. Perez-Molina JA, Molina I. Chagas disease. Lancet. 2018; 391: 82–94.
432. Salvador F, Sanchez-Montalva A, Valerio L, et al. Immunosuppression and Chagas disease: experience from a non-endemic country. Clin Microbiol Infect. 2015; 21: 854–860.
433. Schijman AG. Molecular diagnosis of Trypanosoma cruzi. Acta Trop. 2018; 184: 59–66.
434. Sales Junior PA, Molina I, Fonseca Murta SM, et al. Experimental and clinical treatment of Chagas disease: a review. Am J Trop Med Hyg. 2017; 97: 1289–1303.
435. Sperandio da Silva GM, Mediano MFF, Hasslocher-Moreno AM, et al. Benznidazole treatment safety: the M?decins Sans Fronti?res experience in a large cohort of Bolivian patients with Chagas’ disease. J Antimicrob Chemother. 2017; 72: 2596–2601.
436. Thakare R, Dasgupta A, Chopra S. An update on benznidazole for the treatment of patients with Chagas disease. Drugs Today (Barc). 2018; 54: 15–23.
437. Murcia L, Simon M, Carrilero B, et al. Treatment of infected women of childbearing age prevents congenital Trypanosoma cruzi infection by eliminating the parasitemia detected by PCR. J Infect Dis. 2017; 215: 1452–1458.
438. Bocchi EA, Bestetti RB, Scanavacca MI, et al. Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment. J Am Coll Cardiol. 2017; 70: 1510–1524.
439. Carmo AAL, de Sousa MR, Agudelo JF, et al. Implantable cardioverter-defibrillator in Chagas heart disease: a systematic review and meta-analysis of observational studies. Int J Cardiol. 2018; 267: 88–93.
440. Benatti RD, Oliveira GH, Bacal F. Heart transplantation for Chagas cardiomyopathy. J Heart Lung Transplant. 2017; 36: 597–603.
441. Cucunuba ZM, Nouvellet P, Peterson JK, et al. Complementary paths to Chagas disease elimination: the impact of combining vector control with etiological treatment. Clin Infect Dis. 2018; 66: S293–S300.
442. Khalil EA, Weldegebreal T, Younis BM, et al. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis. 2014; 8: 1–9.
443. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leish­maniasis in India. N Engl J Med. 2010; 362: 504–512.
444. Diro E, Blesson S, Edwards T, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl Trop Dis. 2019; 13: 1–19.
445. Saghafipour A, Mozaffari E, Rezaei F. The evaluation of intralesional glucantime and cryotherapy plus intralesional glucantime therapeutic efficacy on zoonotic cutaneous leishmaniasis: a randomized clinical trial. J Clin Pediatr. 2017; 5: 6689–6697.
446. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med. 2013; 368: 524–532.
447. Soto J, Soto P, Ajata A, et al. Topical 15% paromomycin-aquaphilic for Bolivian Leishmania braziliensis cutaneous leishmaniasis: a randomized, placebo-controlled trial. Clin Infect Dis. 2019; 68: 844–849.
448. Galvio EL, Rabello A, Cota GF. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLoS ONE. 2017; 12: 1–24.
449. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg. 2011; 84: 255–260.
450. Gadelha EPN, Ramasawmy R, da Costa Oliveira B, et al. An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region. PLoS Negl Trop Dis. 2018; 12: 1–13.
451. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018; 392: 951–970.
452. Sunyoto T, Boelaert M, Meheus F. Understanding the economic impact of leishmaniasis on house­holds in endemic countries: a systematic review. Expert Rev Anti Infect Ther. 2019; 17: 57–69.
453. van Griensven J, Diro E. Visceral leishmaniasis: recent advances in diagnostics and treatment regimens. Infect Dis Clin North Am. 2019; 33: 79–99.
454. Hossain F, Ghosh P, Khan MAA, et al. Real-time PCR in detection and quantitation of Leishmania donovani for the diagnosis of visceral leishmaniasis patients and the monitoring of their response to treatment. PLoS ONE. 2017; 12: 1–16.
455. Ben-Abid M, Galai Y, Habboul Z, et al. Diagnosis of Mediterranean visceral leishmaniasis by detec­tion of Leishmania-related antigen in urine and oral fluid samples. Acta Trop. 2017; 167: 71–72.
456. Zijlstra EE. The immunology of post-kala-azar dermal leishmaniasis (PKDL). Parasit Vectors. 2016; 9: 1–9.
457. Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2015; 16: 237–252.
458. Alves F, Bilbe G, Blesson S, et al. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin Microbiol Rev. 2018; 31: 1–30.
459. den Boer M, Das AK, Akhter F, et al. Safety and effectiveness of short-course AmBisome in the treatment of post-kala-azar dermal leishmaniasis: a prospective cohort study in Bangladesh. Clin Infect Dis. 2018; 67: 667–675.
460. Meireles CB, Maia LC, Soares GC, et al. Atypical presentations of cutaneous leishmaniasis: a sys­tematic review. Acta Trop. 2017; 172: 240–254.
461. Handler MZ, Patel PA, Kapila R, et al. Cutaneous and mucocutaneous leishmaniasis: differential diagnosis, diagnosis, histopathology, and management. J Am Acad Dermatol. 2015; 73: 911–927.
462. Taxy JB, Goldin HM, Dickie S, et al. Cutaneous Leishmaniasis: contribution of routine histopathol­ogy in unexpected encounters. Am J Surg Pathol. 2019; 43: 195–200.
463. Solomon M, Sahar N, Pavlotzky F, et al. Mucosal leishmaniasis in travelers with Leishmania braziliensis complex returning to Israel. Emerg Infect Dis. 2019; 25: 642–648.
464. Uribe-Restrepo AF, Prieto MD, Cossio A, et al. Eligibility for local therapies in adolescents and adults with cutaneous leishmaniasis from southwestern Colombia: a cross-sectional study. Am J Trop Med Hyg. 2019; 100: 306–310.
465. Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019; 33: 101–117.
466. Berbert TRN, de Mello TFP, Wolf Nassif P, et al. Pentavalent antimonials combined with other therapeutic alternatives for the treatment of cutaneous and mucocutaneous leishmaniasis: a systematic review. Dermatol Res Pract. 2018; 2018: 1–21.
467. Wolf Nassif P, DE Mello TFP, Navasconi TR, et al. Safety and efficacy of current alternatives in the topical treatment of cutaneous leishmaniasis: a systematic review. Parasitology. 2017; 144: 995–1004.
468. Pedras MJ, Carvalho JP, Silva RED, et al. Mucosal leishmaniasis: the experience of a Brazilian referral center. Rev Soc Bras Med Trop. 2018; 51: 318–323.
469. Gu?ry R, Henry B, Martin-Blondel G, et al. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: not a panacea. PLoS Negl Trop Dis. 2017; 11: 1–12.
470. Le Rutte EA, Chapman LAC, Coffeng LE, et al. Policy recommendations from transmission modeling for the elimination of visceral leishmaniasis in the Indian Subcontinent. Clin Infect Dis. 2018; 66: S301–S308.
471. Alavi SM, Alavi L. Treatment of toxoplasmic lymphadenitis with co-trimoxazole: double-blind, randomized clinical trial. Int J Infect Dis. 2010; 3: e67–e69.
472. Felix JP, Lira RP, Zacchia RS, et al. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Am J Ophthalmol. 2014; 157: 762–766.
473. Whitelaw JA, Latorre-Barragan F, Gras S, et al. Surface attachment, promoted by the actomyosin system of Toxoplasma gondii is important for efficient gliding motility and invasion. BMC Biol. 2017; 15: 1–23.
474. Bertranpetit E, Jombart T, Paradis E, et al. Phylogeography of Toxoplasma gondii points to a South American origin. Infect Genet Evol. 2017; 48: 150–155.
475. Rougier S, Montoya JG, Peyron F. Lifelong persistence of toxoplasma cysts: a questionable dogma? Trends Parasitol. 2017; 33: 93–101.
476. Sasai N, Pradipta A, Yamamoto M. Host immune response to Toxoplasma gondii. Int Immunol. 2018; 30: 113–119.
477. Ben-Harari RR, Connolly MP. High burden and low awareness of toxoplasmosis in the United States. Postgrad Med. 2019; 1–6.
478. Wallon M, Peyron F. Congenital toxoplasmosis: a plea for a neglected disease. Pathogens. 2018; 7: 1–9.
479. Lykins J, Wang K, Wheeler K, et al. Understanding toxoplasmosis in the United States through “large data” analyses. Clin Infect Dis. 2016; 63: 468–475.
480. Weidner JM, Kanatani S, Uchtenhagen H, et al. Migratory activation of parasitized dendritic cells by the protozoan Toxoplasma gondii 14-3-3 protein. Cell Microbiol. 2016; 18: 1537–1550.
481. Clough B, Frickel EM. The toxoplasma parasitophorous vacuole: an evolving host-parasite frontier. Trends Parasitol. 2017; 33: 473–488.
482. Jones JL, Bonetti V, Holland GN, et al. Ocular toxoplasmosis in the United States: recent and remote infections. Clin Infect Dis. 2015; 60: 271–273.
483. Bharti AR, McCutchan A, Deutsch R, et al. Latent Toxoplasma infection and higher Toxoplasma gondii immunoglobulin G levels are associated with worse neurocognitive functioning in HIV-infected adults. Clin Infect Dis. 2016; 63: 1655–1660.
484. Rostami A, Karanis P, Fallahi S. Advances in serological, imaging techniques and molecular diagnosis of Toxoplasma gondii infection. Infection. 2018; 46: 303–305.
485. Dhakal R, Gajurel K, Pomares C, et al. Significance of a positive Toxoplasma immunoglobulin M test result in the United States. J Clin Microbiol. 2015; 53: 3601–3605.
486. Pomares C, Montoya JG. Laboratory diagnosis of congenital toxoplasmosis. J Clin Microbiol. 2016; 54: 2448–2454.
487. Peyron F, Mc Leod R, Ajzenberg D, et al. Congenital toxoplasmosis in France and the United States: one parasite, two diverging approaches. PLoS Negl Trop Dis. 2017; 11: 1–6.
488. Opsteegh M, Kortbeek TM, Havelaar AH, et al. Intervention strategies to reduce human Toxoplasma gondii disease burden. Clin Infect Dis. 2015; 60: 101–107.
489. Gajurel K, Dhakal R, Montoya JG. Toxoplasma prophylaxis in haematopoietic cell transplant recipients: a review of the literature and recommendations. Curr Opin Infect Dis. 2015; 28: 283–292.
490. Vanathy K, Parija SC, Mandal J, et al. Cryptosporidiosis: a mini review. Trop Parasitol. 2017; 7: 72–80.
491. Checkley W, White AC Jr, Jaganath D, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015; 15: 85–94.
492. Hlavsa MC, Roellig DM, Seabolt MH, et al. Using molecular characterization to support investigations of aquatic facility-associated cryptosporidiosis — Alabama, Arizona, and Ohio, 2016. MMWR Morb Mortal Wkly Rep. 2017; 66: 493–497.
493. Bonadonna L, La Rosa G. A review and update on waterborne viral diseases associated with swimming pools. Int J Elviron Res Public Health. 2019; 16: 1–11.
494. Painter JE, Hlavsa MC, Collier SA, et al. Cryptosporidiosis surveillance—United States, 2011-2012. MMWR Surveill Summ. 2015; 64 (suppl 3): 1–14.
495. Shrivastava AK, Kumar S, Smith WA, Sahu PS. Revisiting the global problem of cryptosporidiosis and recommendations. Trop Parasitol. 2017; 7: 8–17.
496. Platts-Mills JA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health. 2015; 3: e564–e754.
497. Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhea in children: a reanalysis of the GEMS case-control study. Lancet. 2016; 388: 1291–1301.
498. GBD 2016 Diarrhoeal Diseases Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018; 18: 1211–1228.
499. Wang RJ, Li JQ, Chen YC, et al. Widespread occurrence of Cryptosporidium infections in patients with HIV/AIDS: epidemiology, clinical feature, diagnosis, and therapy. Acta Trop. 2018; 187: 257–263.
500. Costa D, Razakandrainibe R, Sautour M, et al. Human cryptosporidiosis in immunodeficient patients in France (2015–2017). Exp Parasitol. 2018; 192: 108–112.
501. Lanternier F, Amazzough K, Favennec L, et al. Cryptosporidium spp infection in solid organ transplantation: the nationwide “TRANSCRYPTO” study. Transplantation. 2017; 101: 826–830.
502. Khurana S, Chaudhary P. Laboratory diagnosis of cryptosporidiosis. Trop Parasitol. 2018; 8: 2–7.
503. Speich B, Nair G, Castellanos-Gonzalez A, et al. Treatment of Cryptosporidium: what we know, gaps, and the way forward. Curr Trop Med Rep. 2015; 2: 181–187.
504. Speich B, Croll D, Furst T, et al. Effect of sanitation and water treatment on intestinal protozoa infection: a systematic review and metaanalysis. Lancet Infect Dis. 2016; 16: 87–99.
505. Rehn M, Wallensten A, Widerstrom M, et al. Post-infection symptoms following two large waterborne outbreaks of Cryptosporidium hominis in Northern Sweden, 2010–2011. BMC Public Health. 2015; 15: 1–6.
506. Pasupulet V, Escobedo AA, Despande A, et al. Efficacy of 5-nitromidazoles for the treatment of giardiasis: a systematic review of randomized controlled trials. PLoS Negl Trop Dis. 2014; 8: 1–11.
507. Escobedo AA, Ballesteros J, Gonzalez-Fraile E, et al. A meta-analysis of the efficacy of albendazole compared with tinidazole as treatments for Giardia infections in children. Acta Trop. 2016; 153: 120–127.
508. Ryan U, Hijjawi N, Feng Y, et al. Giardia: an under-reported foodborne parasite. Int J Parasitol. 2019; 49: 1–11.
509. Minetti C, Chalmers RM, Beeching NJ, et al. Giardiasis. BMJ. 2016; 355: 1–9.
510. Faria CP, Zanini GM, Dias GS, et al. New multilocus genotypes of Giardia lamblia human isolates. Infect Genet Evol. 2017; 54: 128–137.
511. Certad G, Viscogliosi E, Chab? M, et al. Pathogenic mechanisms of Cryptosporidium and Giardia. Trends Parasitol. 2017; 33: 561–576.
512. Hamilton KA, Waso M, Reyneke B, et al. Cryptosporidium and Giardia in wastewater and surface water environments. J Environ Qual. 2018; 47: 1006–1023.
513. Painter JE, Gargano JW, Collier SA, et al. Giardiasis surveillance — United States, 2011–2012. MMWR Surveill Summ. 2015; 64 (suppl 3): 15–25.
514. Reses HE, Gargano JW, Liang JL, et al. Risk factors for sporadic Giardia infection in the USA: a case-control study in Colorado and Minnesota. Epidemiol Infect. 2018; 146: 1071–1078.
515. Rogawski ET, Bartelt LA, Platts-Mills JA, et al. Determinants and impact of Giardia infection in the first 2 years of life in the MAL-ED birth cohort. J Pediatric Infect Dis Soc. 2017; 6: 153–160.
516. Einarsson E, Ma’ayeh S, Svard SG. An up-date on Giardia and giardiasis. Curr Opin Microbiol. 2016; 34: 47–52.
517. Bartelt LA, Platts-Mills JA. Giardia: a pathogen or commensal for children in high-prevalence settings? Curr Opin Infect Dis. 2016; 29: 502–507.
518. Donowitz JR, Alam M, Kabir M, et al. A prospective longitudinal cohort to investigate the effects of early life giardiasis on growth and all cause diarrhea. Clin Infect Dis. 2016; 63: 792–797.
519. Fink MY, Singer SM. The intersection of immune responses, microbiota, and pathogenesis in giardiasis. Trends Parasitol. 2017; 33: 901–913.
520. Soriano-Arandes A, Garcia-Carrasco E, Serre-Delcor N, et al. Travelers’ diarrhea in children at risk: an observational study from a Spanish database. Pediatr Infect Dis J. 2016; 35: 392–395.
521. Mero S, Kirveskari J, Antikainen J, et al. Multiplex PCR detection of Cryptosporidium sp, Giardia lamblia and Entamoeba histolytica directly from dried stool samples from Guinea-Bissauan children with diarrhea. Infect Dis (Lond). 2017; 49: 655–663.
522. Nabarro LE, Lever RA, Armstrong M, et al. Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008-2013. Clin Microbiol Infect. 2015; 21: 791–796.
523. Carter ER, Nabarro LE, Hedley L, et al. Nitroimidazole-refractory giardiasis: a growing problem requiring rational solutions. Clin Microbiol Infect. 2017; 24: 37–42.
524. Lalle M, Hanevik K. Treatment-refractory giardiasis: challenges and solutions. Infect Drug Resist. 2018; 11: 1921–1933.
525. Pandey S, Gupta GK, Wanjari SJ, et al. Comparative study of tinidazole versus metronidazole in treatment of amebic liver abscess: a randomized control trial. Indian J Gastroenterol. 2018; 37: 196–201.
526. Gwairgi MA, Ghildyal R. Nuclear transport in Entamoeba histolytica: knowledge gap and therapeutic potential. Parasitology. 2018; 145: 1378–1387.
527. Noor Z, Watanabe K, Abhyankar MM, et al. Role of eosinophils and tumor necrosis factor alpha in Interleukin-25-Mediated protection from amebic colitis. MBio. 2017; 8: 1–10.
528. Gilchrist CA, Petri SE, Schneider BN, et al. Role of the gut microbiota of children in diarrhea due to the protozoan parasite Entamoeba histolytica. J Infect Dis. 2016; 213: 1579–1585.
529. Ali IK. Intestinal amebae. Clin Lab Med. 2015; 35: 393–422.
530. Kantor M, Abrantes A, Estevez A, et al. Entamoeba histolytica: updates in clinical manifestation, pathogenesis, and vaccine development. Can J Gastroenterol Hepatol. 2018; 2018: 1–6.
531. Mohidin B, Green SF, Duggineni S. Amoebic liver abscess. QJM. 2018; 111: 821–822.
532. Lachish T, Wieder-Finesod A, Schwartz E. Amebic liver abscess in Israeli travelers: a retrospective study. Am J Trop Med Hyg. 2016; 94: 1015–1019.
533. Guevara T, Vicuna Y, Costales D, et al. Use of real-time polymerase chain reaction to differentiate between pathogenic Entamoeba histolytica and the nonpathogenic Entamoeba dispar in Ecuador. Am J Trop Med Hyg. 2019; 100: 81–82.
534. Saidin S, Othman N, Noordin R. Update on laboratory diagnosis of amoebiasis. Eur J Clin Microbiol Infect Dis. 2019; 38: 15–38.
535. Horiki N, Furukawa K, Kitade T, et al. Endoscopic findings and lesion distribution in amebic colitis. J Infect Chemother. 2015; 21: 444–448.
536. Min X, Feng M, Guan Y, et al. Evaluation of the C-terminal fragment of Entamoeba histolytica Gal/GalNAc lectin intermediate subunit as a vaccine candidate against amebic liver abscess. PLoS Negl Trop Dis. 2016; 10: 1–17.
537. Shirley DT, Farr L, Watanabe K, et al. A review of the global burden, new diagnostics, and current therapeutics for amebiasis. Open Forum Infect Dis. 2018; 5: 1–9.
538. Lorenzo-Morales J, Khan NA, Walochnik J. An update on Acanthamoeba keratitis: diagnosis, patho­genesis and treatment. Parasite. 2015; 22: 1–19.
539. Ong TYY, Khan NA, Siddiqui R. Brain-eating amoebae: predilection sites in the brain and disease outcome. J Clin Microbiol. 2018; 55: 1989–1997.
540. Kissinger P, Muzny CA, Mena LA, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis. 2018; 18: 1251–1259.
541. Gray JS, Estrada-Pe?a A, Zintl A. Vectors of babesiosis. Annu Rev Entomol. 2019; 64: 149–165.
542. Vannier EG, Diuk-Wasser MA, Ben Mamoun C, et al. Babesiosis. Infect Dis Clin North Am. 2015; 29: 357–370.
543. Woolley AE, Montgomery MW, Savage WJ, et al. Post-babesiosis warm autoimmune hemolytic anemia. N Engl J Med. 2017; 376: 939–946.
544. Wang G, Wormser GP, Zhuge J, et al. Utilization of a real-time PCR assay for diagnosis of Babesia microti infection in clinical practice. Ticks Tick Borne Dis. 2015; 6: 376–382.
545. Kletsova EA, Spitzer ED, Fries BC, et al. Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone. Ann Clin Microbiol Antimicrob. 2017; 16: 1–17.
546. Krause PJ. Human babesiosis. Int J Parasitol. 2019; 49: 165–174.
547. Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia microti in the U.S. blood supply. N Engl J Med. 2016; 375: 2236–2245.
548. Villatoro T, Karp JK. Transfusion-transmitted babesiosis. Arch Pathol Lab Med. 2019; 143: 130–134.
549. Menezes CB, Frasson AP, Tasca T. Trichomoniasis—are we giving the deserved attention to the most common non-viral sexually transmitted disease worldwide? Microb Cell. 2016; 3: 404–419.
550. Meites E, Gaydos CA, Hobbs MM, et al. A review of evidence-based care of symptomatic trichomoniasis and asymptomatic Trichomonas vaginalis infections. Clin Infect Dis. 2015; 61 (suppl 8): S837–S848.
551. Bouchemal K, Bories C, Loiseau PM. Strategies for prevention and treatment of Trichomonas vaginalis infections. Clin Microbiol Rev. 2017; 30: 811–825.
552. Gaydos CA, Klausner JD, Pai NP, et al. Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis in women and men. Sex Transm Infect. 2017; 93: 531–535.
553. Fayer R, Esposito DH, Dubey JP. Human infections with Sarcocystis species. Clin Microbiol Rev. 2015; 28: 295–311.
554. Lai KK, Goyne HE, Hernandez-Gonzalo D, et al. Cystoisospora belli infection of the gallbladder in immunocompetent patients: a clinicopathologic review of 18 cases. Am J Surg Pathol. 2016; 40: 1070–1074.
555. Han B, Weiss LM. Microsporidia: obligate intracellular pathogens within the fungal kingdom. Microbiol Spectr. 2017; 5: 1–17.
556. Baird A, Wiebe S, Zunt JR, et al. Evidence-based guideline: treatment of parenchymal neurocysti­cercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 80: 1424–1429.
557. Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014; 14: 687–695.
558. Zhao BC, Jiang HY, Ma WY, et al. Albendazole and corticosteroids for the treatment of solitary cysticercal granuloma: a network meta-analysis. PLoS Negl Trop Dis. 2016; 10: 1–15.
559. Garcia HH, Gonzales I, Lescano AG, et al. Enhanced steroid dosing reduces seizures during anti­parasitic treatment for cysticercosis and early after. Epilepsia. 2014; 55: 1452–1459.
560. Garcia HH, Gonzalez AE, Tsang VC, et al. Elimination of Taenia solium transmission in northern Peru. N Engl J Med. 2016; 374: 2335–2344.
561. Webb C, Cabada MM. Intestinal cestodes. Curr Opin Infect Dis. 2017; 30: 504–510.
562. Coral-Almeida M, Gabri?l S, Abatih EN, et al. Taenia solium human cysticercosis: a systematic review of sero-epidemiological data from endemic zones around the world. PLoS Negl Trop Dis. 2015; 9: 1–20.
563. Moyano LM, O’Neal S, Ayvar V, et al. High prevalence of asymptomatic neurocysticercosis in an endemic rural community in Peru. PLoS Negl Trop Dis. 2016; 10: 1–11.
564. Gripper LB, Welburn SC. Neurocysticercosis infection and disease — a review. Acta Trop. 2017; 166: 218–224.
565. Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017; 372: 202–210.
566. Coyle CM. Neurocysticerosis: an individualized approach. Infect Dis Clin North Am. 2019; 33: 153–168.
567. White AC Jr, Coyle CE, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: practice guidelines by the Infectious Diseases Society (IDSA) of America and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018; 66: 1159–1163.
568. Tamarozzi F, Akhan O, Cretu CM, et al. Prevalence of abdominal cystic echinococcosis in rural Bulgaria, Romania, and Turkey: a cross-sectional, ultrasound-based, population study from the HERACLES project. Lancet Infect Dis. 2018; 18: 769–778.
569. Mihmanli M, Idiz UO, Kaya C, et al. Current status of diagnosis and treatment of hepatic echinococcosis. World J Hepatal. 2016; 8: 1169–1181.
570. Barosa R, Pinto J, Caldeira A, Pereira E. Modern role of clinical ultrasound in liver abscess and echinococcosis. J Med Ultrason. 2017; 44: 239–245.
571. Kern P, Menezes da Silva A, Akhan O, et al. The echinococcoses: diagnosis, clinical management and burden of disease. Adv Parasitol. 2017; 96: 259–369.
572. Nabarro LE, Amin Z, Chiodini PL. Current management of cystic echinococcosis: a survey of specialist practice. Clin Infect Dis. 2015; 60: 721–728.
573. Stojkovic M, Rosenberger KD, Steudle F, et al. Watch and wait management of inactive cystic echinococcosis — does the path to inactivity matter — analysis of a prospective patient cohort. PLoS Negl Trop Dis. 2016; 10: 1–10.
574. Gottstein B, Stojkovic M, Vuitton DA, et al. Threat of alveolar echinococcosis to public health—a challenge for Europe. Trends Parasitol. 2015; 31: 407–412.
575. Bulakci M, Kartal MG, Yilmaz S, et al. Multimodality imaging in diagnosis and management of alveolar echinococcosis: an update. Diagn Interv Radiol. 2016; 22: 247–256.
576. Danso-Appiah A, Olliaro PL, Donegan S, et al. Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev. 2013; 2: CD000528.
577. Porez del Villar L, Burguillo FJ, Lopez-Abon J, et al. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS ONE. 2012; 7: 1–15.
578. Xu LL, Jiang B, Duan JH, et al. Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths. PLoS Negl Trop Dis. 2014; 8: 1–10.
579. Sayasone S, Odermatt P, Vonghachack Y, et al. Efficacy and safety of tribendimidine against Opis­thorchis viverrini: two randomised, parallel-group, single-blind, dose-ranging, phase 2 trials. Lancet Infect Dis. 2016; 16: 1145–1153.
580. Sayasone S, Keiser J, Meister I, et al. Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial. Lancet Infect Dis. 2018; 18: 155–161.
581. Tchuento L-AT, Rollinson D, Stothard JR, et al. Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies. Infect Dis Poverty. 2017; 6: 42–55.
582. King CH, Sutherland LJ, Bertsch D. Systemic review and meta-analysis of the impact of chemical-based mollusciciding for control of Schistosoma mansoni and S. haematobium transmission. Plos Negl Trop Dis. 2015; 9: 1–23.
583. De Almeida TVVS, Fernandes JS, Lopes DM, et al. Schistosoma mansoni antigens alter activation markers and cytokine profile in lymphocytes of patients with asthma. Acta Trop. 2017; 166: 268–279.
584. McManus DP, Dunne DW, Sacko M, et al. Schistosomiasis. Nat Rev Dis Primers. 2018; 4: 1–19.
585. Ogongo P, Kariuki TM, Wilson RA. Diagnosis of schistosomiasis mansoni: an evaluation of existing methods and research towards single worm pair detection. Parasitology. 2018; 6: 1–12.
586. Wu Y, Liu J, Lin Y, et al. Diagnosis, monitoring, and control of schistosomiasis — an update. J Biomed Nanotechnol. 2018; 14: 430–455.
587. Kittur N, Castleman JD, Campbell CH Jr, et al. Comparison of Schistosoma mansoni prevalence and intensity of infection, as determined by the circulating cathodic antigen urine assay or the Kato-Katz fecal assay: a systematic review. Am J Trop Med Hyg. 2016; 94: 605–610.
588. Utzinger J, Becker SL, van Lieshout L, et al. New diagnostic tools in schistosomiasis. Clin Microbiol Infect. 2015; 21: 529–542.
589. Hotez PJ, Bottazzi ME, Bethony J, et al. Advancing the development of a human schistosomiasis vaccine. Trends Parasitol. 2019; 35: 104–108.
590. Abou-El-Naga IF. Towards elimination of schistosomiasis after 5000 years of endemicity in Egypt. Acta Trop. 2018; 181: 112–121.
591. Toor J, Alsallaq R, Truscott JE, et al. Are we on our way to achieving the 2020 goals for schistosomiasis morbidity control using current World Health Organization guidelines? Clin Infect Dis. 2018; 66: S245–S252.
592. Webb CM, Cabada MM. Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection. Curr Opin Infect Dis. 2018; 31: 409–414.
593. Machicado C, Machicado JD, Maco V, et al. Association of Fasciola hepatica infection with liver fibrosis, cirrhosis, and cancer: a systematic review. PLoS Negl Trop Dis. 2016; 10: 1–11.
594. Zheng S, Zhu Y, Zhao Z, et al. Liver fluke infection and cholangiocarcinoma: a review. Parasitol Res. 2017; 116: 11–19.
595. Harrington D, Lamberton PHL, McGregor A. Human liver flukes. Lancet Gastroenterol Hepatol. 2017; 2: 680–689.
596. Qian MB, Utzinger J, Keiser J, et al. Clonorchiasis. Lancet. 2016; 387: 800–810.
597. Feng M, Cheng X. Parasite-associated cancers (blood flukes/liver flukes). Adv Exp Med Biol. 2017; 1018: 193–205.
598. Fischer PU, Weil GJ. North American paragonimiasis: epidemiology and diagnostic strategies. Expert Rev Anti Infect Ther. 2015; 13: 779–786.
599. Bahr NC, Trotman RL, Samman H, et al. Eosinophilic meningitis due to infection with Paragonimus kellicotti. Clin Infect Dis. 2017; 64: 1271–1274.
600. Moser W, Schindler C, Keiser J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ. 2017; 358: 1–10.
601. Adegnika AA, Zinsou JF, Issifou S, et al. Randomized, controlled, assessor-blind clinical trial to assess the efficacy of single-versus repeated-dose albendazole to treat Ascaris lumbricoides, Trichuris trichiura, and hookworm infection. Antimicrob Agents Chemother. 2014; 58: 2535–2540.
602. Moser W, Coulibaly JT, Ali SM, et al. Efficacy and safety of tribendimidine, tribendimidine plus ivermectin, tribendimidine plus oxantel, pamoate, and albendazole plus oxantel pamoate against hookworm and concomitant soil-transmitted helminth infection in Tanzania and C?te d’Ivoire: a randomised, controlled, single-blinded, non-inferiority trial. Lancet Infect Dis. 2017; 17: 1162–1171.
603. Knopp S, Mohammed KA, Speich B, et al. Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial. Clin Infect Dis. 2010; 51: 1420–1428.
604. Suputtamongkol Y, Premasathian N, Bhumimuang K, et al. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis. 2011; 5: 1–7.
605. King CL, Suamani J, Sanuku N, et al. A trial of a triple-drug treatment for lymphatic filariasis. N Engl J Med. 2018; 379: 1801–1810.
606. Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018; 392: 1207–1216.
607. Abegunde AT, Ahuja RM, Okafor NJ. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis. Cochrane Database Syst Rev. 2016: CD011146.
608. Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG. Soil-transmitted helminth infections. Lancet. 2018; 391: 252–265.
609. Lamberton PH, Jourdan PM. Human ascariasis: diagnostics update. Curr Trop Med Rep. 2015; 2: 189–200.
610. Farrell SH, Coffeng LE, Truscott JE, et al. Investigating the effectiveness of current and modified World Health Organization guidelines for the control of soil-transmitted helminth infections. Clin Infect Dis. 2018; 66: S253–S259.
611. Osbjornsdottir KH, Means AR, Werkman M, Walson JL. Prospects for elimination of soil-transmitted helminths. Curr Opin Infect Dis. 2017; 30: 482–488.
612. Loukas A, Hotez PJ, Diemert D, et al. Hookworm infection. Nat Rev Dis Primers. 2016; 2: 1–18.
613. Krolewiecki A, Nutman TB. Strongyloidiasis: a neglected tropical disease. Infect Dis Clin North Am. 2019; 33: 135–151.
614. Martinez-Perez A, Roure Diez S, Belhassen-Garcia M, et al. Management of severe strongyloidiasis attended at reference centers in Spain. PLoS Negl Trop Dis. 2018; 12: 1–12.
615. Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016; 1: CD007745.
616. Repetto SA, Ruybal P, Batalla E, et al. Strongyloidiasis outside endemic areas: longterm parasitological and clinical follow-up after ivermectin treatment. Clin Infect Dis. 2018; 66: 1558–1565.
617. Ma G, Holland CV, Wang T, et al. Human toxocariasis. Lancet Infect Dis. 2018; 18: e14–e24.
618. Rostami A, Gamble HR, Dupouy-Camet J, et al. Meat sources of infection for outbreaks of human trichinellosis. Food Microbiol. 2017; 64: 65–71.
619. Wilson NO, Hall RL, Montgomery SP, et al. Trichinellosis surveillance — United States, 2008–2012. MMWR Surveill Summ. 2015; 64: 1–8.
620. Nunes MC, Guimaraes Junior MH, Diamantino AC, et al. Cardiac manifestations of 6 parasitic diseases. Heart. 2017; 103: 651–658.
621. Barratt J, Chan D, Sandaradura I, et al. Angiostrongylus cantonensis: a review of its distribution, molecular biology and clinical significance as a human pathogen. Parasitology. 2016; 143: 1087–1118.
622. Showler AJ, Kubofcik J, Ricciardi A, et al. Differences in the clinical and laboratory features of imported onchocerciasis in endemic individuals and temporary residents. Am J Trop Med Hyg. 2019; 100: 1216–1222.
623. Kamgno J, Pion SD, Chesnais CB, et al. A test-and-not-treat strategy for onchocerciasis in Loa loa-endemic areas. N Engl J Med. 2017; 377: 2044–2052.
624. Whittaker C, Walker M, Pion SDS, et al. The population biology and transmission dynamics of Loa loa. Trends Parasitol. 2018; 34: 335–350.
625. Han Y, Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and meta-analysis. Int Immunopharmacol. 2017; 42: 168–175.
626. Abdul Basit S, Dawood A, Ryan J, et al. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol. 2017; 10: 707–716.
627. Zhu GQ, Zou ZL, Zheng JN, et al. Systematic review and network meta-analysis of randomized controlled trials: comparative effectiveness and safety of direct-acting antiviral agents for treatment-naive hepatitis C genotype 1. Medicine (Baltimore). 2016; 95: 1–10.
628. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370: 1879–1888.
629. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1483–1493.
630. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015; 373: 2599–2607.
631. Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017; 376: 2134–2146.
632. Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017; 67: 263–271.
633. Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017; 377: 1448–1455.
634. Tamori A, Hai H, Uchida-Kobayashi S, et al. Outcomes for cirrhotic patients with hepatitis C virus 1b treated with asunaprevir and daclatasvir combination. Ann Hepatol. 2017; 16: 734–741.
635. Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017; 2: 585–594.
636. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370: 1983–1992.
637. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther. 2013; 18: 651–661.
638. Beigel JH, Bao Y, Beeler J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, ran­domised phase 2 trial. Lancet Infect Dis. 2017; 17: 1255–1265.
639. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018; 379: 913–923.
640. Lee HM, Banini BA. Updates on chronic HBV: current challenges and future goals. Curr Treat Options Gastroenterol. 2019. [Epub ahead of print.]
641. Singh KP, Crane M, Audsley J, et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017; 31: 2035–2052.
642. AASLD, IDSA, IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Дата просмотра: 28 июня 2019 г.
643. Soriano V, Labarga P, Fernandez-Montero JV, et al. Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opin Drug Metab Toxicol. 2017; 13: 807–816.
644. Sawleshwarkar S, Dwyer DE. Antivirals for herpes simplex viruses. BMJ. 2015; 351: 1–5.
645. Deckx L, De Sutter AI, Guo L, et al. Nasal decongestants in monotherapy for the common cold.Cochrane Database Syst Rev. 2016; 10: CD009612.
646. AlBalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. Cochrane Database Syst Rev. 2013; 6: CD008231.
647. De Sutter AI, Saraswat A, van Driel ML. Antihistamines for the common cold. Cochrane Database Syst Rev. 2015; 11: CD009345.
648. De Sutter AI, van Driel ML, Kumar AA, et al. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database Syst Rev. 2012; 2: CD004976.
649. Hemili H, Fitzgerald JT, Petrus EJ, et al. Zinc acetate lozenges may improve the recovery rate of common cold patients: an individual patient data meta-analysis. Open Forum Infect Dis. 2017; 4: 1–6.
650. Karsch-V?lk M, Barrett B, Kiefer D, et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2014; 2: CD000530.
651. Simancas-Racines D, Franco JV, Guerra CV, et al. Vaccines for the common cold. Cochrane Database Syst Rev. 2017; 5: CD002190.
652. Hemili H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013; 1: CD000980.
653. Karsch-Volk M, Barrett B, Linde K. Echinacea for preventing and treating the common cold. JAMA. 2015; 313: 618–619.
654. Grande AJ, Keogh J, Hoffmann TC, et al. Exercise versus no exercise for the occurrence, severity and duration of acute respiratory infections. Cochrane Database Syst Rev. 2015; 6: CD010596.
655. Greenberg SB. Update on human rhinovirus and coronavirus infections. Semin Respir Crit Care Med. 2016; 37: 555–571.
656. Szilagyi PG, Blumkin A, Treanor JJ, et al. Incidence and viral aetiologies of acute respiratory illnesses (ARIs) in the United States: a population-based study. Epidemiol Infect. 2016; 144: 2077–2086.
657. Shaw Stewart PD. Seasonality and selective trends in viral acute respiratory tract infections. Med Hypotheses. 2016; 86: 104–119.
658. Basnet S, Palmenberg AC, Gern JE. Rhinoviruses and their receptors. Chest. 2019; 155: 1018–1025.
659. Janicki Deverts D, Cohen S, Doyle WJ. Dispositional affect moderates the stress-buffering effect of social support on risk for developing the common cold. J Pers. 2017; 85: 675–686.
660. Eccles R, Dicpinigaitis P, Turner RB, et al. Characterization of urge to cough and cough symptoms associated with the common cold: results of a US internet survey. Postgrad Med. 2016; 128: 485–491.
661. Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016; 164: 425–434.
662. Varghese BM, Dent E, Chilver M, et al. Epidemiology of viral respiratory infections in Australian working-age adults (20-64 years): 2010-2013. Epidemiol Infect. 2018; 146: 619–626.
663. Prill MM, Dahl RM, Midgley CM, et al. Severe respiratory illness associated with rhinovirus during the enterovirus D68 outbreak in the United States, August 2014 — November 2014. Clin Infect Dis. 2018; 66: 1528–1534.
664. Karppinen S, Terasjarvi J, Auranen K, et al. Acquisition and transmission of Streptococcus pneumoniae are facilitated during rhinovirus infection in families with children. Am J Respir Crit Care Med. 2017; 196: 1172–1180.
665. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013; 368: 1791–1799.
666. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis. 2018; 217: 1356–1364.
667. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017; 390: 946–958.
668. Kestler M, Mu?oz P, Mateos M, et al. Respiratory syncytial virus burden among adults during flu season: an underestimated pathology. J Hosp Infect. 2018; 100: 463–468.
669. Colosia AD, Yang J, Hillson E, et al. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS ONE. 2017; 12: 1–20.
670. Lee N, Chan MC, Lui GC, et al. High viral load and respiratory failure in adults hospitalized for respiratory syncytial virus infections. J Infect Dis. 2015; 212: 1237–1240.
671. Cawcutt K, Kalil AC. Pneumonia with bacterial and viral coinfection. Curr Opin Crit Care. 2017; 23: 385–390.
672. Abbas S, Raybould JE, Sastry S, et al. Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles. Int J Infect Dis. 2017; 62: 86–93.
673. DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015; 373: 2048–2058.
674. Stevens M, Rusch S, DeVincenzo J, et al. Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study. J Infect Dis. 2018; 218: 748–756.
675. Xing Y, Proesmans M. New therapies for acute RSV infections: where are we? Eur J Pediatr. 2019; 178: 131–138.
676. Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018; 18: e245–e311.
677. Falloon J, Yu J, Esser MT, et al. An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. J Infect Dis. 2017; 216: 1362–1370.
678. Kwon YS, Park SH, Kim MA, et al. Risk of mortality associated with respiratory syncytial virus and influenza infection in adults. BMC Infect Dis. 2017; 1–9.
679. Fernandes RM, Oleszczuk M, Woods CR, et al. The Cochrane Library and safety of systemic corticosteroids for acute respiratory conditions in children: an overview of reviews. Evid Based Child Health. 2014; 9: 733–747.
680. Bjornson C, Russell K, Vandermeer B, et al. Nebulized epinephrine for croup in children. Cochrane Database Syst Rev. 2013; 10: CD006619.
681. Branche AR, Falsey AR. Parainfluenza virus infection. Semin Respir Crit Care Med. 2016; 37: 538–554.
682. Thea DM, Seidenberg P, Park DE, et al. Limited utility of polymerase chain reaction in induced sputum specimens for determining the causes of childhood pneumonia in resource-poor settings: findings from the Pneumonia Etiology Research for Child Health (PERCH) Study. Clin Infect Dis. 2017; 64 (suppl 3): S289–S300.
683. Benet T, Sanchez Picot V, Messaoudi M, et al. Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study. Clin Infect Dis. 2017; 65: 604–612.
684. Xiao NG, Duan ZJ, Xie ZP, et al. Human parainfluenza virus types 1-4 in hospitalized children with acute lower respiratory infections in China. J Med Virol. 2016; 88: 2085–2091.
685. Abedi GR, Prill MM, Langley GE, et al. Estimates of parainfluenza virus-associated hospitalizations and cost among children aged less than 5 years in the United States, 1998–2010. J Pediatric Infect Dis Soc. 2016; 5: 7–13.
686. Russell E, Ison MG. Parainfluenza virus in the hospitalized adult. Clin Infect Dis. 2017; 65: 1570–1576.
687. Russell E, Yang A, Tardrew S, et al. Parainfluenza virus in hospitalized adults: a 7-year retrospective study. Clin Infect Dis. 2019; 68: 298–305.
688. Seo S, Xie H, Leisenring WM, et al. Risk factors for parainfluenza virus lower respiratory tract disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25: 163–171.
689. Waghmare A, Wagner T, Andrews R, et al. Successful treatment of parainfluenza virus respiratory tract infection with DAS181 in 4 immunocompromised children. J Pediatric Infect Dis Soc. 2015; 4: 114–118.
690. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018; 18: 95–107.
691. Demicheli V, Jefferson T, Ferroni E, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018; 2: CD001269.
692. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013; 310: 1711–1720.
693. Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017; 376: 2427–2436.
694. Kumar D, Campbell P, Hoschler K, et al. Randomized controlled trial of adjuvanted versus nonadjuvanted influenza vaccine in kidney transplant recipients. Transplantation. 2016; 100: 662–669.
695. Yin JK, Heywood AE, Georgousakis M, et al. Systematic review and meta-analysis of indirect protection afforded by vaccinating children against seasonal influenza: implications for policy. Clin Infect Dis. 2017; 65: 719–728.
696. Nakamura S, Miyazaki T, Izumikawa K, et al. Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with influenza A and B viruses: a multicenter randomized controlled study. Open Forum Infect Dis. 2017; 4: 1–8.
697. Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med. 2017; 5: 135–146.
698. Beigel JH, Bao Y, Beeler J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. 2017; 17: 1255–1265.
699. Whitley R, Laughlin A, Carson S, et al. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials. Antivir Ther. 2015; 20: 709–719.
700. Wang CH, Chung FT, Lin SM, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med. 2014; 42: 313–321.
701. Hung IFN, To KKW, Chan JFW, et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest. 2017; 151: 1069–1080.
702. Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015; 385: 1729–1737.
703. Venkatesan S, Myles PR, Leonardi-Bee J, et al. Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis. Clin Infect Dis. 2017; 64: 1328–1334.
704. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018; 379: 913–923.
705. Neher RA, Bedford T, Daniels RS, et al. Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses. Proc Natl Acad Sci USA. 2016; 113: E1701–E1709.
706. Hirve S, Newman LP, Paget J, et al. Influenza seasonality in the tropics and subtropics — when to vaccinate? PLoS ONE. 2016; 11: 1–12.
707. Ewing A, Lee EC, Viboud C, et al. Contact, travel, and transmission: the impact of winter holidays on influenza dynamics in the United States. J Infect Dis. 2017; 215: 732–739.
708. Bui CM, Chughtai AA, Adam DC, et al. An overview of the epidemiology and emergence of influenza A infection in humans over time. Arch Public Health. 2017; 75: 1–7.
709. Su S, Gu M, Liu D, et al. Epidemiology, evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China. Trends Microbiol. 2017; 25: 713–728.
710. Gostic KM, Ambrose M, Worobey M, et al. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science. 2016; 354: 722–726.
711. Gounder AP, Boon ACM. Influenza pathogenesis: the effect of host factors on severity of disease. J Immunol. 2019; 202: 341–350.
712. Sellers SA, Hagan RS, Hayden FG, et al. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017; 11: 372–393.
713. Merckx J, Wali R, Schiller I, et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis. Ann Intern Med. 2017; 167: 394–409.
714. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 influenza season. MMWR Recomm Rep. 2017; 66: 1–20.
715. Treanor JJ. Clinical practice: influenza vaccination. N Engl J Med. 2016; 375: 1261–1268.
716. Fell DB, Azziz-Baumgartner E, Baker MG, et al. Influenza epidemiology and immunization during pregnancy: final report of a World Health Organization working group. Vaccine. 2017; 35: 5738–5750.
717. Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, 2011–12 through 2014–15. Clin Infect Dis. 2017; 64: 544–550.
718. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019; 68: 895–902.
719. Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment. J Investig Med. 2018; 66: 957–965.
720. Zheng S, Tang L, Gao H, et al. Benefit of early initiation of neuraminidase inhibitor treatment to hospitalized patients with avian influenza A(H7N9) virus. Clin Infect Dis. 2018; 66: 1054–1060.
721. Ison MG. Antiviral treatments. Clin Chest Med. 2017; 38: 139–153.
722. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018; 378: 345–353.
723. Hiwarkar P, Amrolia P, Sivaprakasam P, et al. Brincidofovir is highly efficacious in controlling adeno­viremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017; 129: 2033–2037.
724. Grimley MS, Chemaly RF, Englund JA, et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial. Biol Blood Marrow Transplant. 2017; 23: 512–521.
725. Kuschner RA, Russell KL, Abuja M, et al. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. Vaccine. 2013; 31: 2963–2971.
726. Kajon AE, Lamson DM, Bair CR, et al. Adenovirus type 4 respiratory infections among civilian adults, northeastern United States, 2011–2015(1). Emerg Infect Dis. 2018; 24: 201–209.
727. Clemmons NS, McCormic ZD, Gaydos JC, et al. Acute respiratory disease in US Army trainees 3 years after reintroduction of adenovirus vaccine 1. Emerg Infect Dis. 2017; 23: 95–98.
728. Tan D, Zhu H, Fu Y, et al. Severe community-acquired pneumonia caused by human adenovirus in immunocompetent adults: a multicenter case series. PLoS ONE. 2016; 11: 1–12.
729. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015; 373: 415–427.
730. Kajon AE, Ison MG. Severe infections with human adenovirus 7d in 2 adults in family, Illinois, USA, 2014. Emerg Infect Dis. 2016; 22: 730–733.
731. Jhanji V, Chan TC, Li EY, et al. Adenoviral keratoconjunctivitis. Surv Ophthalmol. 2015; 60: 435–443.
732. Lee YJ, Prockop SE, Papanicolaou GA. Approach to adenovirus infections in the setting of hema­topoietic cell transplantation. Curr Opin Infect Dis. 2019; 30: 377–387.
733. Florescu DF, Schaenman JM. Adenovirus in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019. [Epub ahead of print.]
734. Hiwarkar P, Kosulin K, Cesaro S, et al. Management of adenovirus infection in patients after haematopoietic stem cell transplantation: state-of-the-art and real-life current approach: a position statement on behalf of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation. Rev Med Virol. 2018; 28: 1–7.
735. Ramsay ID, Attwood C, Irish D, et al. Disseminated adenovirus infection after allogeneic stem cell transplant and the potential role of brincidofovir—case series and 10 year experience of management in an adult transplant cohort. J Clin Virol. 2017; 96: 73–79.
736. Qian C, Campidelli A, Wang Y, et al. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial. J Hematol Oncol. 2017; 10: 1–4.
737. U.S. Department of Health & Human Services. Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS).
738. World Health Organization. Severe acute respiratory syndrome (SARS).
739. U.S. Department of Health & Human Services. Centers for Disease Control and Prevention. Middle East respiratory syndrome (MERS).
740. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). Accessed June 8, 2019.
741. Alraddadi BM, Watson JT, Almarashi A, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis. 2016; 22: 49–55.
742. Kim SW, Park JW, Jung HD, et al. Risk factors for transmission of Middle East respiratory syndrome coronavirus infection during the 2015 outbreak in South Korea. Clin Infect Dis. 2017; 64: 551–557.
743. Arabi YM, Balkhy HH, Hayden FG, et al. Middle East respiratory syndrome. N Engl J Med. 2017; 376: 584–594.
744. Ahmed AE, Al-Jahdali H, Alshukairi AN, et al. Early identification of pneumonia patients at increased risk of Middle East respiratory syndrome coronavirus infection in Saudi Arabia. Int J Infect Dis. 2018; 70: 51–56.
745. Sikkema RS, Farag E, Himatt S, et al. Risk factors for primary Middle East respiratory syndrome coronavirus infection in camel workers in Qatar during 2013-2014: a case-control study. J Infect Dis. 2017; 215: 1702–1705.
746. Bello S, Meremikwu MM, Ejemot-Nwadiaro RI, et al. Routine vitamin A supplementation for the prevention of blindness due to measles infection in children. Cochrane Database Syst Rev. 2016; 8: CD007719.
747. Schoeps A, Nebi? E, Fisker AB, et al. No effect of an additional early dose of measles vaccine on hospitalization or mortality in children: a randomized controlled trial. Vaccine. 2018; 36: 1965–1971.
748. Low N, Bavdekar A, Jeyaseelan L, et al. A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med. 2015; 372: 1519–1529.
749. Young MK, Nimmo GR, Cripps AW, et al. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev. 2014; 4: CD010056.
750. Jiang Y, Qin Y, Chen M. Host-pathogen interactions in measles virus replication and anti-viral immu­nity. Viruses. 2016; 8: 1–16.
751. Fiebelkorn AP, Redd SB, Gasta?aduy PA, et al. A comparison of postelimination measles epidemiol­ogy in the United States, 2009–2014 versus 2001–2008. J Pediatric Infect Dis Soc. 2017; 6: 40–48.
752. Dabbagh A, Patel MK, Dumolard L, et al. Progress toward regional measles elimination — worldwide, 2000–2016. MMWR Morb Mortal Wkly Rep. 2017; 66: 1148–1153.
753. Measles vaccines: WHO position paper — April 2017. Wkly Epidemiol Rec. 2017; 92: 205–227.
754. Global routine vaccination coverage, 2015. Wkly Epidemiol Rec. 2016; 91: 537–543.
755. Orenstein WA, Hinman A, Nkowane B, et al. Measles and rubella global strategic plan 2012–2020 midterm review. Vaccine. 2018; 36: A1–A34.
756. Furuse Y, Oshitani H. Global transmission dynamics of measles in the measles elimination era. Viruses. 2017; 9: 1–10.
757. Guerra FM, Bolotin S, Lim G, et al. The basic reproduction number (R0) of measles: a systematic review. Lancet Infect Dis. 2017; 17: e420–e428.
758. Hyle EP, Rao SR, Jentes ES, et al. Missed opportunities for measles, mumps, rubella vaccination among departing U.S. adult travelers receiving pretravel health consultations. Ann Intern Med. 2017; 167: 77–84.
759. Hahne SJ, Nic Lochlainn LM, van Burgel ND, et al. Measles outbreak among previously immunized healthcare workers, the Netherlands, 2014. J Infect Dis. 2016; 214: 1980–1986.
760. Bhattacharjee S, Yadava PK. Measles virus: background and oncolytic virotherapy. Biochem Biophys Rep. 2018; 13: 58–62.
761. Moss WJ. Measles. Lancet. 2017; 390: 2490–2502.
762. Famularo G. Koplik’s spots and measles. Am J Med. 2018; 131: e249–e250.
763. Oya M, Hakozaki Y, Kubota T. Modified measles. Intern Med. 2017; 56: 885.
764. Korman AM, Alikhan A, Kaffenberger BH. Viral exanthems: an update on laboratory testing of the adult patient. J Am Acad Dermatol. 2017; 76: 538–550.
765. World Health Organization. Measles vaccines: WHO position paper, April 2017 — recommendations. Vaccine. 2019; 37: 219–222.
766. Arciuolo RJ, Jablonski RR, Zucker JR, et al. Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting — New York City, 2013. Clin Infect Dis. 2017; 65: 1843–1847.
767. Watanabe S, Shirogane Y, Sato Y, et al. New insights into measles virus brain infections. Trends Microbiol. 2019; 27: 164–175.
768. Wendorf KA, Winter K, Zipprich J, et al. Subacute sclerosing panencephalitis: the devastating measles complication that might be more common than previously estimated. Clin Infect Dis. 2017; 65: 226–232.
769. Grant GB, Reef SE, Patel M, et al. Progress in rubella and congenital rubella syndrome control and elimination—worldwide, 2000-2016. MMWR Morb Mortal Wkly Rep. 2017; 66: 1256–1260.
770. Pandolfi E, Gesualdo F, Rizzo C, et al. Global seroprevalence of rubella among pregnant and child­bearing age women: a meta-analysis. Eur J Public Health. 2017; 27: 530–537.
771. Hagstam P, B?ttiger B, Winqvist N. Measles and rubella seroimmunity in newly arrived adult immi­grants in Sweden. Infect Dis (Lond). 2019; 51: 122–130.
772. Orenstein WA, Cairns L, Hinman A, et al. Measles and rubella global strategic plan 2012-2020 midterm review report: background and summary. Vaccine. 2018; 36 (suppl 1): A35–A42.
773. Schwarz ER. Consequences of perinatal infections with rubella, measles, and mumps. Curr Opin Virol. 2017; 27: 71–77.
774. Korman AM, Alikhan A, Kaffenberger BH. Viral exanthems: an update on laboratory testing of the adult patient. J Am Acad Dermatol. 2017; 76: 538–550.
775. Siira L, Nokleby H, Barlinn R, et al. Response to third rubella vaccine dose. Hum Vaccin Immunother. 2018; 1–6.
776. Shah M, Quinlisk P, Weigel A, et al. Mumps outbreak in a highly vaccinated university-affiliated setting before and after a measles-mumps-rubella vaccination campaign—Iowa, July 2015–May 2016. Clin Infect Dis. 2018; 66: 81–88.
777. O’Leary ST, Kimberlin DW, Maldonado YA. Update from the Advisory Committee on Immunization Practices. J Pediatric Infect Dis Soc. 2018; 7: 93–99.
778. Fields VS, Safi H, Waters C, et al. Mumps in a highly vaccinated Marshallese community in Arkansas, USA: an outbreak report. Lancet Infect Dis. 2019; 19: 185–192.
779. Bockelman C, Frawley TC, Long B, et al. Mumps: an emergency medicine-focused update. J Emerg Med. 2018; 54: 207–214.
780. Rolfes MA, Millman AJ, Talley P, et al. Influenza-associated parotitis during the 2014-2015 influenza season in the United States. Clin Infect Dis. 2018; 67: 485–492.
781. O’Leary ST, Maldonado YA, Byington CL. Update from the Advisory Committee on Immunization Practices. J Pediatric Infect Dis Soc. 2017; 6: 215–218.
782. Cardemil CV, Dahl RM, James L, et al. Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med. 2017; 377: 947–956.
783. Marin M, Marlow M, Moore KL, et al. Recommendation of the Advisory Committee on Immuniza­tion Practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep. 2018; 67: 33–38.
784. Clemmons N, Hickman C, Lee A, et al. Manual for surveillance of vaccine-preventable diseases. Chapter 9: mumps. Atlanta, GA: Centers for Disease Control and Prevention; 2008.
785. Kawasaki H, Kosugi I, Meguro S, et al. Pathogenesis of developmental anomalies of the central nervous system induced by congenital cytomegalovirus infection. Pathol Int. 2017; 67: 72–82.
786. Arslan F, Yilmaz M, Paksoy Y, et al. Cytomegalovirus-associated transverse myelitis: a review of nine well-documented cases. Infect Dis (Lond). 2015; 47: 7–12.
787. Wendorf KA, Winter K, Zipprich J, et al. Subacute sclerosing panencephalitis: the devastating measles complication that might be more common than previously estimated. Clin Infect Dis. 2017; 65: 226–232.
788. Orenstein WA, Cairns L, Hinman A, et al. Measles and rubella global strategic plan 2012–2020 midterm review report: background and summary. Vaccine. 2018; 36 (suppl 1): A35–A42.
789. Schwab N, Schneider-Hohendorf T, Melzer N, et al. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology. 2017; 88: 1197–1205.
790. Misbah SA. Progressive multi-focal leukoencephalopathy — driven from rarity to clinical mainstream by iatrogenic immunodeficiency. Clin Exp Immunol. 2017; 188: 342–352.
791. Muftuoglu M, Olson A, Marin D, et al. Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med. 2018; 379: 1443–1451.
792. Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019; 380: 1597–1605.
793. Zhai S, Brew BJ. Progressive multifocal leukoencephalopathy. Handb Clin Neurol. 2018; 152: 123–137.
794. Balasubramanian SK, Sadaps M, Thota S, et al. Rational management approach to pure red cell aplasia. Haematologica. 2018; 103: 221–230.
795. Janovitz T, Wong S, Young NS, et al. Parvovirus B19 integration into human CD36+ erythroid progenitor cells. Virology. 2017; 511: 40–48.
796. Weseslindtner L, Aberle JH, Hedman L, et al. The chemokine CXCL-10 is a marker of infection stage in individuals with DNAemia due to parvovirus B19. J Infect Dis. 2017; 215: 214–220.
797. Qiu J, Soderlund-Venermo M, Young NS. Human parvoviruses. Clin Microbiol Rev. 2017; 30: 43–113.
798. Obeid KM. Infections with DNA viruses, adenovirus, polyomaviruses, and parvovirus B19 in hema­topoietic stem cell transplant recipients and patients with hematologic malignancies. Infect Dis Clin North Am. 2019; 33: 501–521.
799. Wolfromm A, Rodriguez C, Michel M, et al. Spectrum of adult Parvovirus B19 infection according to the underlying predisposing condition and proposals for clinical practice. Br J Haematol. 2015; 170: 192–199.
800. Ornoy A, Ergaz Z. Parvovirus B19 infection during pregnancy and risks to the fetus. Birth Defects Res. 2017; 109: 311–323.
801. Ogunsile FJ, Currie KL, Rodeghier M, et al. History of parvovirus B19 infection is associated with silent cerebral infarcts. Pediatr Blood Cancer. 2018; 65: 1–4.
802. Fullerton HJ, Luna JM, Wintermark M, et al. Parvovirus B19 infection in children with arterial ischemic stroke. Stroke. 2017; 48: 2875–2877.
803. Korman AM, Alikhan A, Kaffenberger BH. Viral exanthems: an update on laboratory testing of the adult patient. J Am Acad Dermatol. 2017; 76: 538–550.
804. van der Wouden JC, van der Sande R, Kruithof EJ, et al. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017; 5: CD004767.
805. Oliveira GP, Rodrigues RAL, Lima MT, et al. Poxvirus host range genes and virus-host spectrum: a critical review. Viruses. 2017; 9: 1–17.
806. Costantino V, Kunasekaran MP, Chughtai AA, et al. How valid are assumptions about re-emerging smallpox? A systematic review of parameters used in smallpox mathematical models. Mil Med. 2018; 183: e200–e207.
807. Emergence of monkeypox in West Africa and Central Africa, 1970-2017. Wkly Epidemiol Rec. 2018; 93: 125–132.
808. Leendertz SAJ, Stern D, Theophil D, et al. A cross-sectional serosurvey of anti-orthopoxvirus antibodies in central and western Africa. Viruses. 2017; 9: 1–12.
809. Vora NM, Li Y, Geleishvili M, et al. Human infection with a zoonotic orthopoxvirus in the country of Georgia. N Engl J Med. 2015; 372: 1223–1230.
810. Springer YP, Hsu CH, Werle ZR, et al. Novel orthopoxvirus infection in an Alaska resident. Clin Infect Dis. 2017; 64: 1737–1741.
811. Schrick L, Tausch SH, Dabrowski PW, et al. An early American smallpox vaccine based on horsepox. N Engl J Med. 2017; 377: 1491–1492.
812. Osadebe LU, Manthiram K, McCollum AM, et al. Novel poxvirus infection in 2 patients from the United States. Clin Infect Dis. 2015; 60: 195–202.
813. Doshi RH, Guagliardo SAJ, Doty JB, et al. Epidemiologic and ecologic investigations of monkeypox, Likouala Department, Republic of the Congo, 2017. Emerg Infect Dis. 2019; 25: 281–289.
814. Oliveira JS, Figueiredo PO, Costa GB, et al. Vaccinia virus natural infections in Brazil: the good, the bad, and the ugly. Viruses. 2017; 9: 1–21.
815. Caravaglio JV, Khachemoune A. Orf virus infection in humans: a review with a focus on advances in diagnosis and treatment. J Drugs Dermatol. 2017; 16: 684–689.
816. Leung AKC, Barankin B, Hon KLE. Molluscum contagiosum: an update. Recent Pat Inflamm Allergy Drug Discov. 2017; 11: 22–31.
817. Petersen BW, Damon IK, Pertowski CA, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm Rep. 2015; 64: 1–26.
818. Chittick G, Morrison M, Brundage T, et al. Short-term clinical safety profile of brincidofovir: a favorable benefit-risk proposition in the treatment of smallpox. Antiviral Res. 2017; 143: 269–277.
819. Melamed S, Israely T, Paran N. Challenges and achievements in prevention and treatment of smallpox. Vaccines (Basel). 2018; 6: 1–20.
820. Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018; 379: 44–53.
821. Forbat E, Al-Niaimi F, Ali FR. Molluscum contagiosum: review and update on management. Pediatr Dermatol. 2017; 34: 504–515.
822. Melnikow J, Henderson JT, Burda BU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018; 320: 687–705.
823. Bertolotti A, Dupin N, Bouscarat F, et al. Cryotherapy to treat anogenital warts in nonimmunocom­promised adults: systematic review and meta-analysis. J Am Acad Dermatol. 2017; 77: 518–526.
824. Zhu YP, Jia ZW, Dai B, et al. Relationship between circumcision and human papillomavirus infection: a systematic review and meta-analysis. Asian J Androl. 2017; 19: 125–131.
825. Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018; 5: CD009069.
826. Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017; 390: 2143–2159.
827. Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA. 2016; 316: 2411–2421.
828. D’Addario M, Redmond S, Scott P, et al. Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis. Vaccine. 2017; 35: 2892–2901.
829. McQuillan G, Kruszon-Moran D, Markowitz LE, et al. Prevalence of HPV in adults aged 18–69: United States, 2011–2014. NCHS Data Brief. 2017; 280: 1–8.
830. de Sanjose S, Brotons M, Pavon MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018; 47: 2–13.
831. Gravitt PE, Winer RL. Natural history of HPV infection across the lifespan: role of viral latency. Viruses. 2017; 9: 1–10.
832. Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction-National Health and Nutrition Examination Survey, United States, 2003–2014. J Infect Dis. 2017; 216: 594–603.
833. Lewis RM, Markowitz LE, Gargano JW, et al. Prevalence of genital human papillomavirus among sexually experienced males and females aged 14-59 years, United States, 2013–2014. J Infect Dis. 2018; 217: 869–877.
834. Sonawane K, Suk R, Chiao EY, et al. Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. Ann Intern Med. 2017; 167: 714–724.
835. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7–34.
836. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention. HPV-associated cancer statistics. Atlanta, GA: 2017. https://www.cdc.gov/cancer/hpv/statistics/. Дата просмотра: 13 мая 2019 г.
837. Mourad M, Jetmore T, Jategaonkar AA, et al. Epidemiological trends of head and neck cancer in the United States: a SEER population study. J Oral Maxillofac Surg. 2017; 75: 2562–2572.
838. Krzowska-Firych J, Lucas G, Lucas C, et al. An overview of human papillomavirus (HPV) as an etiological factor of the anal cancer. J Infect Public Health. 2019; 12: 1–6.
839. Douglawi A, Masterson TA. Penile cancer epidemiology and risk factors: a contemporary review. Curr Opin Urol. 2019; 29: 145–149.
840. Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018; 320: 674–686.
841. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64: 1–137.
842. Phillips A, Patel C, Pillsbury A, et al. Safety of human papillomavirus vaccines: an updated review. Drug Saf. 2018; 41: 329–346.
843. Niccolai LM, Meek JI, Brackney M, et al. Declines in human papillomavirus (HPV)-associated high-grade cervical lesions after introduction of HPV vaccines in Connecticut, United States, 2008–2015. Clin Infect Dis. 2017; 65: 884–889.
844. Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018; 36: 262–267.
845. Hollier LM, Eppes C. Genital herpes: oral antiviral treatments. BMJ Clin Evid. 2015; 2015: 1–17.
846. Chi CC, Wang SH, Delamere FM, et al. Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane Database Syst Rev. 2015; 8: CD010095.
847. Le Cleach L, Trinquart L, Do G, et al. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database Syst Rev. 2014; 8: CD009036.
848. Abdool Karim SS, Abdool Karim Q, Kharsany AB, et al. Tenofovir gel for the prevention of herpes simplex virus type 2 infection. N Engl J Med. 2015; 373: 530–539.
849. Gnann JW Jr, Skoldenberg B, Hart J, et al. Herpes simplex encephalitis: lack of clinical benefit of long-term valacyclovir therapy. Clin Infect Dis. 2015; 61: 683–691.
850. Gnann JW Jr, Whitley RJ. Clinical practice. Genital herpes. N Engl J Med. 2016; 375: 666–674.
851. Jarrin I, Sellier P, Lopes A, et al. Etiologies and management of aseptic meningitis in patients admitted to an internal medicine department. Medicine (Baltimore). 2016; 95: 1–9.
852. Luzzati R, D’Agaro P, Busca A, et al. Herpes simplex virus (HSV) pneumonia in the non-ventilated immunocompromised host: burden and predictors. J Infect. 2019; 78: 127–133.
853. Akkaya O, Guvenc HI, Yuksekkaya S, et al. Real-time PCR detection of the most common bacteria and viruses causing meningitis. Clin Lab. 2017; 63: 827–832.
854. Sawleshwarkar S, Dwyer DE. Antivirals for herpes simplex viruses. BMJ. 2015; 351: 1–5.
855. Feltner C, Grodensky C, Ebel C, et al. Serologic screening for genital herpes: an updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016; 316: 2531–2543.
856. Gnann JW Jr, Whitley RJ. Herpes simplex encephalitis: an update. Curr Infect Dis Rep. 2017; 19: 1–12.
857. Sironi M, Peri AM, Cagliani R, et al. TLR3 mutations in adult patients with herpes simplex virus and varicella-zoster virus encephalitis. J Infect Dis. 2017; 215: 1430–1434.
858. Armangue T, Moris G, Cantarin-Extremera V, et al. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology. 2015; 85: 1736–1743.
859. Wang A, Wohrley J, Rosebush J. Herpes simplex virus in the neonate. Pediatr Ann. 2017; 46: e42–e46.
860. Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014; 2: CD006866.
861. Wang SL, Wang H, Nie HY, et al. The efficacy of pregabalin for acute pain control in herpetic neuralgia patients: a meta-analysis. Medicine (Baltimore). 2017; 96: 1–9.
862. Marin M, Marti M, Kambhampati A, et al. Global varicella vaccine effectiveness: a meta-analysis. Pediatrics. 2016; 137: 1–12.
863. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015; 372: 2087–2096.
864. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016; 375: 1019–1032.
865. Macartney K, Heywood A, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev. 2014; 6: CD001833.
866. Kawai K, Yawn BP, Wollan P, et al. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis. 2016; 63: 221–226.
867. Pham MA, Bednarczyk RA, Becker ER, et al. Trends in U.S. community hospitalizations due to herpes zoster: 2001-2015. Vaccine. 2019; 37: 882–888.
868. Lo Presti C, Curti C, Montana M, et al. Chickenpox: an update. Med Mal Infect. 2019; 49: 1–8.
869. Dayan RR, Peleg R. Herpes zoster — typical and atypical presentations. Postgrad Med. 2017; 129: 567–571.
870. Schmidt SA, Mor A, Schonheyder HC, et al. Herpes zoster as a marker of occult cancer: a systematic review and meta-analysis. J Infect. 2017; 74: 215–235.
871. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology. 2016; 87: 94–102.
872. Kim SH, Choi SM, Kim BC, et al. Risk factors for aseptic meningitis in herpes zoster patients. Ann Dermatol. 2017; 29: 283–287.
873. Gilden D, White T, Khmeleva N, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015; 84: 1948–1955.
874. Park SY, Kim JY, Kim JA, et al. Diagnostic usefulness of varicella-zoster virus real-time polymerase chain reaction analysis of DNA in saliva and plasma specimens from patients with herpes zoster. J Infect Dis. 2017; 217: 51–57.
875. Song D, He A, Xu R, et al. Efficacy of pain relief in different postherpetic neuralgia therapies: a network meta-analysis. Pain Physician. 2018; 21: 19–32.
876. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018; 67: 103–108.
877. Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older. Clin Infect Dis. 2017; 64: 785–793.
878. Bernstein DI, Munoz FM, Callahan ST, et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial. Vaccine. 2016; 34: 313–319.
879. Mumtaz K, Faisal N, Husain S, et al. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2015; 15: 472–481.
880. Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015; 162: 1–10.
881. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014; 370: 1781–1789.
882. Revello MG, Lazzarotto T, Guerra B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014; 370: 1316–1326.
883. Cowley NJ, Owen A, Shiels SC, et al. Safety and efficacy of antiviral therapy for prevention of cyto­megalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. JAMA Intern Med. 2017; 177: 774–783.
884. Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019; 29: 1–6.
885. Bilavsky E, Pardo J, Attias J, et al. Clinical implications for children born with congenital cytomega­lovirus infection following a negative amniocentesis. Clin Infect Dis. 2016; 63: 33–38.
886. Naing ZW, Scott GM, Shand A, et al. Congenital cytomegalovirus infection in pregnancy: a review of prevalence, clinical features, diagnosis and prevention. Aust N Z J Obstet Gynaecol. 2016; 56: 9–18.
887. Thomasini RL, Pereira DS, Pereira FSM, et al. Aged-associated cytomegalovirus and Epstein-Barr virus reactivation and cytomegalovirus relationship with the frailty syndrome in older women. PLoS ONE. 2017; 12: 1–12.
888. Papazian L, Hraiech S, Lehingue S, et al. Cytomegalovirus reactivation in ICU patients. Intensive Care Med. 2016; 42: 28–37.
889. Yadav SK, Saigal S, Choudhary NS, et al. Cytomegalovirus infection in liver transplant recipients: current approach to diagnosis and management. J Clin Exp Hepatol. 2017; 7: 144–151.
890. Fuji S, Einsele H, Kapp M. Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options. Curr Opin Infect Dis. 2017; 30: 372–376.
891. Lichtner M, Cicconi P, Vita S, et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis. 2015; 211: 178–186.
892. Razonable RR. Role of letermovir for prevention of cytomegalovirus infection after allogeneic hae­matopoietic stem cell transplantation. Curr Opin Infect Dis. 2018; 31: 286–291.
893. Frange P, Leruez-Ville M. Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections. Med Mal Infect. 2018; 48: 495–502.
894. Rezk E, Nofal YH, Hamzeh A, et al. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev. 2015; 11: CD004402.
895. De Paor M, O’Brien K, Fahey T, et al. Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. 2016; 12: CD011487.
896. Chen J, Sathiyamoorthy K, Zhang X, et al. Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus. Nat Microbiol. 2018; 3: 172–180.
897. Lennon P, Crotty M, Fenton JE. Infectious mononucleosis. BMJ. 2015; 350: 1–7.
898. Ebell MH, Call M, Shinholser J, et al. Does this patient have infectious mononucleosis? The rational clinical examination systematic review. JAMA. 2016; 315: 1502–1509.
899. Wemel AC, Mayet A, Bellier S, et al. Severe infectious mononucleosis in immunocompetent adults. Med Mal Infect. 2017; 47: 540–545.
900. Thompson DF, Ramos CL. Antibiotic-induced rash in patients with infectious mononucleosis. Ann Pharmacother. 2017; 51: 154–162.
901. Niller HH, Bauer G. Epstein-Barr virus: clinical diagnostics. Methods Mol Biol. 2017; 1532: 33–55.
902. Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int J Hematol. 2017; 105: 406–418.
903. Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018; 378: 549–562.
904. Dunleavy K, Little RF, Wilson WH. Update on Burkitt lymphoma. Hematol Oncol Clin North Am. 2016; 30: 1333–1343.
905. Farrell PJ. Epstein-Barr virus and cancer. Annu Rev Pathol. 2019; 14: 29–53.
906. Lukas RV, Gondi V, Stupp R, et al. Primary central nervous system lymphoma — part 2: modern therapeutic management and future directions. Oncology (Williston Park). 2018; 32: e11–e19.
907. Chua MLK, Wee JTS, Hui EP, et al. Nasopharyngeal carcinoma. Lancet. 2016; 387: 1012–1024.
908. Chan KCA, Woo JKS, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017; 377: 513–522.
909. Shao X, Xu Y, Xu X, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults: a retrospective analysis of 23 patients in China. Isr Med Assoc J. 2018; 20: 80–85.
910. Kimura H, Cohen JI. Chronic active Epstein-Barr virus disease. Front Immunol. 2017; 8: 1–6.
911. Phillips AA, Fields P, Hermine O, et al. Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 2019; 104: 993–1003.
912. Bangham CRM. Human T cell leukemia virus type 1: persistence and pathogenesis. Annu Rev Immunol. 2018; 36: 43–71.
913. Giam CZ, Semmes OJ. HTLV-1 infection and adult T-cell leukemia/lymphoma — a tale of two proteins: tax and HBZ. Viruses. 2016; 8: 1–23.
914. Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood. 2017; 129: 1071–1081.
915. Bangham CR, Araujo A, Yamano Y, et al. HTLV-1-associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primers. 2015; 1: 1–17.
916. Malpica L, Pimentel A, Reis IM, et al. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018; 2: 607–620.
917. Nosaka K, Iwanaga M, Imaizumi Y, et al. Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: a nationwide survey. Cancer Sci. 2017; 108: 2478–2486.
918. Khanlari M, Ramos JC, Sanchez SP, et al. Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. Mod Pathol. 2018; 31: 1046–1063.
919. Bravo FG. Infective dermatitis: a purely cutaneous manifestation of HTLV-1 infection. Semin Diagn Pathol. 2019. [Epub ahead of print.]
920. Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017; 23: 1826–1838.
921. Katsuya H, Shimokawa M, Ishitsuka K, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017; 130: 39–47.
922. Kataoka K, Iwanaga M, Yasunaga JI, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018; 131: 215–225.
923. Sato T, Coler-Reilly ALG, Yagishita N, et al. Mogamulizumab (anti-CCR4) in HTLV-1-associated myelopathy. N Engl J Med. 2018; 378: 529–538.
924. Terada Y, Kamoi K, Komizo T, et al. Human T cell leukemia virus type 1 and eye diseases. J Ocul Pharmacol Ther. 2017; 33: 216–223.
925. Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013; 381: 2024–2032.
926. Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014; 370: 818–828.
927. Abedi GR, Watson JT, Pham H, et al. Enterovirus and human parechovirus surveillance—United States, 2009-2013. MMWR Morb Mortal Wkly Rep. 2015; 64: 940–943.
928. Polioeradication.org. Global wild poliovirus 2012–2017.
929. Jorba J, Diop OM, Iber J, et al. Update on vaccine-derived polioviruses — worldwide, January 2016 — June 2017. MMWR Morb Mortal Wkly Rep. 2017; 66: 1185–1191.
930. Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine — worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016; 65: 934–938.
931. Noor A, Krilov LR. Enterovirus infections. Pediatr Rev. 2016; 37: 505–515.
932. Gosert R, Heininger U, Hirsch HH. Enterovirus detection in patients with acute gastroenteritis in Switzerland. J Med Virol. 2018; 90: 685–691.
933. Harvala H, Broberg E, Benschop K, et al. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. J Clin Virol. 2018; 101: 11–17.
934. Hopkins SE. Acute flaccid myelitis: etiologic challenges, diagnostic and management considerations. Curr Treat Options Neurol. 2017; 19: 1–7.
935. Teoh HL, Mohammad SS, Britton PN, et al. Clinical characteristics and functional motor outcomes of enterovirus 71 neurological disease in children. JAMA Neurol. 2016; 73: 300–307.
936. Chong PF, Kira R, Mori H, et al. Clinical features of acute flaccid myelitis temporally associated with an enterovirus D68 outbreak: results of a nationwide survey of acute flaccid paralysis in Japan, August-December 2015. Clin Infect Dis. 2018; 66: 653–664.
937. Van Haren K, Ayscue P, Waubant E, et al. Acute flaccid myelitis of unknown etiology in California, 2012–2015. JAMA. 2015; 314: 2663–2671.
938. Hasbun R, Rosenthal N, Balada-Llasat JM, et al. Epidemiology of meningitis and encephalitis in the United States, 2011–2014. Clin Infect Dis. 2017; 65: 359–363.
939. Ahlbrecht J, Hillebrand LK, Schwenkenbecher P, et al. Cerebrospinal fluid features in adults with enteroviral nervous system infection. Int J Infect Dis. 2018; 68: 94–101.
940. Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018; 37: 391–398.
941. Cai K, Wang Y, Guo Z, et al. Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China. BMC Infect Dis. 2019; 19: 1–8.
942. Leroux-Roels G, Cramer JP, Mendelman PM, et al. Safety and immunogenicity of different formula­tions of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial. J Infect Dis. 2018; 217: 597–607.
943. Bines JE, At Thobari J, Satria CD, et al. Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth. N Engl J Med. 2018; 378: 719–730.
944. Isanaka S, Guindo O, Langendorf C, et al. Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger. N Engl J Med. 2017; 376: 1121–1130.
945. Sarker SA, Jakel M, Sultana S, et al. Anti-rotavirus protein reduces stool output in infants with diar­rhea: a randomized placebo-controlled trial. Gastroenterology. 2013; 145: 740–748.
946. Marchetti F, Bonati M, Maestro A, et al. Oral ondansetron versus domperidone for acute gastroen­teritis in pediatric emergency departments: multicenter double blind randomized controlled trial. PLoS ONE. 2016; 11: 1–15.
947. Mahapatro S, Mahilary N, Satapathy AK, et al. Nitazoxanide in acute rotavirus diarrhea: a random­ized control trial from a developing country. J Trop Med. 2017; 2017: 1–5.
948. Tate JE, Burton AH, Boschi-Pinto C, et al. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016; 62: S96–S105.
949. Shah MP, Hall AJ. Norovirus illnesses in children and adolescents. Infect Dis Clin North Am. 2018; 32: 103–118.
950. Ettayebi K, Crawford SE, Murakami K, et al. Replication of human noroviruses in stem cell-derived human enteroids. Science. 2016; 353: 1387–1393.
951. Kanai Y, Komoto S, Kawagishi T, et al. Entirely plasmid-based reverse genetics system for rotaviruses. Proc Natl Acad Sci USA. 2017; 114: 2349–2354.
952. de Graaf M, van Beek J, Koopmans MP. Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol. 2016; 14: 421–433.
953. Cannon JL, Barclay L, Collins NR, et al. Genetic and epidemiologic trends of norovirus outbreaks in the United States from 2013 to 2016 demonstrated emergence of novel GII.4 recombinant viruses. J Clin Microbiol. 2017; 55: 2208–2221.
954. Burnett E, Jonesteller CL, Tate JE, et al. Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. J Infect Dis. 2017; 215: 1666–1672.
955. Nair N, Feng N, Blum LK, et al. VP4- and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans. Sci Transl Med. 2017; 9: 1–13.
956. O’Brien SJ, Sanderson RA, Rushton SP. Control of norovirus infection. Curr Opin Gastroenterol. 2019; 35: 14–19.
957. Markkula J, Hemming-Harlo M, Salminen MT, et al. Rotavirus epidemiology 5-6 years after universal rotavirus vaccination: persistent rotavirus activity in older children and elderly. Infect Dis (Lond). 2017; 49: 388–395.
958. Tate JE, Mwenda JM, Armah G, et al. Evaluation of intussusception after monovalent rotavirus vac­cination in Africa. N Engl J Med. 2018; 378: 1521–1528.
959. Enweronu-Laryea CC, Armah G, Sagoe KW, et al. Sustained impact of rotavirus vaccine introduction on rotavirus gastroenteritis hospitalizations in children <5 years of age, Ghana, 2009–2016. Vaccine. 2018; 36: 7131–7134.
960. Davey RT Jr, Dodd L, Proschan MA, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016; 375: 1448–1456.
961. Gotuzzo E, Yactayo S, Cordova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013; 89: 434–444.
962. Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017; 376: 330–341.
963. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ?a Suffit!). Lancet. 2017; 389: 505–518.
964. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015; 373: 1195–1206.
965. Hidalgo J, Richards GA, Jim?nez JIS, et al. Viral hemorrhagic fever in the tropics: report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care. 2017; 42: 366–372.
966. Emanuel J, Marzi A, Feldmann H. Filoviruses: ecology, molecular biology, and evolution. Adv Virus Res. 2018; 100: 189–221.
967. Bausch DG. West Africa 2013 Ebola: from virus outbreak to humanitarian crisis. Curr Top Microbiol Immunol. 2017; 411 :63–92.
968. Sarute N, Ross SR. New world arenavirus biology. Annu Rev Virol. 2017; 4: 141–158.
969. Geisbert TW. Predicting outcome and improving treatment for Lassa fever. Lancet Infect Dis. 2018; 18: 594–595.
970. Kenawy MA, Abdel-Hamid YM, Beier JC. Rift Valley fever in Egypt and other African countries: historical review, recent outbreaks and possibility of disease occurrence in Egypt. Acta Trop. 2018; 181: 40–49.
971. Hamer DH, Angelo K, Caumes E, et al. Fatal yellow fever in travelers to Brazil, 2018. MMWR Morb Mortal Wkly Rep. 2018; 67: 340–341.
972. Spengler JR, Bente DA, Bray M, et al. Second international conference on Crimean-Congo hemorrhagic fever. Antiviral Res. 2018; 150: 137–147.
973. Dean NE, Halloran ME, Yang Y, et al. Transmissibility and pathogenicity of Ebola virus: a systematic review and meta-analysis of household secondary attack rate and asymptomatic infection. Clin Infect Dis. 2016; 62: 1277–1286.
974. Malvy D, McElroy AK, de Clerck H, et al. Ebola virus disease. Lancet. 2019; 393: 936–948.
975. Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017; 358: 929–932.
976. de Almeida RR, Paim B, de Oliveira SA, et al. Dengue hemorrhagic fever: a state-of-the-art review focused in pulmonary involvement. Lung. 2017; 195: 389–395.
977. Scaggs Huang FA, Schlaudecker E. Fever in the returning traveler. Infect Dis Clin North Am. 2018; 32: 163–188.
978. Sigfrid L, Reusken C, Eckerle I, et al. Preparing clinicians for (re-)emerging arbovirus infectious diseases in Europe. Clin Microbiol Infect. 2018; 24: 229–239.
979. Reusken CB, Ieven M, Sigfrid L, et al. Laboratory preparedness and response with a focus on arbo­viruses in Europe. Clin Microbiol Infect. 2018; 24: 221–228.
980. Lamontagne F, Fowler RA, Adhikari NK, et al. Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet. 2018; 391: 700–708.
981. Cl?ment C, Adhikari NKJ, Lamontagne F. Evidence-based clinical management of Ebola virus disease and epidemic viral hemorrhagic fevers. Infect Dis Clin North Am. 2019; 33: 247–264.
982. Всемирная организация здравоохранения. Interim infection prevention and control guidance for care of patients with suspected or confirmed filovirus haemorrhagic fever in health-care settings, with focus on Ebola. Сентябрь 2014 г.
983. Shearer FM, Moyes CL, Pigott DM, et al. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017; 17: 1209–1217.
984. Venkatraman N, Silman D, Folegatti PM, et al. Vaccines against Ebola virus. Vaccine. 2018; 36: 5454–5459.
985. Jung J, Ko SJ, Oh HS, et al. Protective effectiveness of inactivated hantavirus vaccine against hemor­rhagic fever with renal syndrome. J Infect Dis. 2018; 217: 1417–1420.
986. Fischer WA 2nd, Vetter P, Bausch DG, et al. Ebola virus disease: an update on post-exposure pro­phylaxis. Lancet Infect Dis. 2018; 18: e183–e192.
987. de La Vega MA, Caleo G, Audet J, et al. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest. 2015; 125: 4421–4428.
988. Uyeki TM, Mehta AK, Davey RT Jr, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016; 374: 636–646.
989. Shantha JG, Mattia JG, Goba A, et al. Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) study: reverse transcription-polymerase chain reaction and cataract surgery outcomes of Ebola sur­vivors in Sierra Leone. EBioMedicine. 2018; 30: 217–224.
990. Deen GF, Broutet N, Xu W, et al. Ebola RNA persistence in semen of Ebola virus disease survi­vors—final report. N Engl J Med. 2017; 377: 1428–1437.
991. Mateer EJ, Huang C, Shehu NY, et al. Lassa fever-induced sensorineural hearing loss: a neglected public health and social burden. PLoS Negl Trop Dis. 2018; 12: 1–11.
992. Всемирная организация здравоохранения. Clinical care for survivors of Ebola virus disease. Временное руководство 2016 г.
993. Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015; 372: 113–123.
994. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015; 373: 1195–1206.
995. Centers for Disease Control and Prevention. Approximate geographic distribution of Dermacentor andersoni ticks and counties of residence for confirmed and probable Colorado tick fever (CTF) virus disease cases, United States, 2002–2012. Accessed May 14, 2019.
996. Castro MC, Wilson ME, Bloom DE. Disease and economic burdens of dengue. Lancet Infect Dis. 2017; 17: e70–e78.
997. Chang CJ, Chen CS, Tien CJ, et al. Epidemiological, clinical and climatic characteristics of dengue fever in Kaohsiung City, Taiwan with implication for prevention and control. PLoS ONE. 2018; 13: 1–15.
998. Wilder-Smith A, Ooi EE, Horstick O, et al. Dengue. Lancet. 2019; 393: 350–363.
999. de Almeida RR, Paim B, de Oliveira SA, et al. Dengue hemorrhagic fever: a state-of-the-art review focused in pulmonary involvement. Lung. 2017; 195: 389–395.
1000. Muller DA, Depelsenaire AC, Young PR. Clinical and laboratory diagnosis of dengue virus infection. J Infect Dis. 2017; 215: S89–S95.
1001. Gurugama P, Jayarajah U, Wanigasuriya K, et al. Renal manifestations of dengue virus infections. J Clin Virol. 2018; 101: 1–6.
1002. Rajapakse S, de Silva NL, Weeratunga P, et al. Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review. Trans R Soc Trop Med Hyg. 2017; 111: 433–439.
1003. Wichmann O, Vannice K, Asturias EJ, et al. Live-attenuated tetravalent dengue vaccines: the needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. Vaccine. 2017; 35: 5535–5542.
1004. Burakoff A, Lehman J, Fischer M, et al. West Nile virus and other nationally notifiable arboviral diseases — United States, 2016. MMWR Morb Mortal Wkly Rep. 2018; 67: 13–17.
1005. Saxena V, Bolling BG, Wang T. West Nile virus. Clin Lab Med. 2017; 37: 243–252.
1006. Hawkes MA, Carabenciov ID, Wijdicks EFM, et al. Critical West Nile neuroinvasive disease. Neurocrit Care. 2018; 29: 47–53.
1007. Pierce KK, Whitehead SS, Kirkpatrick BD, et al. A live attenuated chimeric West Nile virus vaccine, rWN/DEN4Delta30, is well tolerated and immunogenic in flavivirus-naive older adult volunteers. J Infect Dis. 2017; 215: 52–55.
1008. Silvas JA, Aguilar PV. The emergence of severe fever with thrombocytopenia syndrome virus. Am J Trop Med Hyg. 2017; 97: 992–996.
1009. Downs JW, Flood DT, Orr NH, et al. Sandfly fever in Afghanistan—a sometimes overlooked disease of military importance: a case series and review of the literature. US Army Med Dep J. 2017; 60–66.
1010. Hartman A. Rift Valley fever. Clin Lab Med. 2017; 37: 285–301.
1011. Yactayo S, Staples JE, Millot V, et al. Epidemiology of Chikungunya in the Americas. J Infect Dis. 2016; 214: S441–S445.
1012. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med. 2015; 372: 1231–1239.
1013. Sutaria RB, Amaral JK, Schoen RT. Emergence and treatment of chikungunya arthritis. Curr Opin Rheumatol. 2018; 30: 256–263.
1014. Jain J, Nayak K, Tanwar N, et al. Clinical, serological, and virological analysis of 572 chikungunya patients from 2010 to 2013 in India. Clin Infect Dis. 2017; 65: 133–140.
1015. Reisinger EC, Tschismarov R, Beubler E, et al. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet. 2019; 392: 2718–2727.
1016. Rezza G, Chen R, Weaver SC. O’nyong-nyong fever: a neglected mosquito-borne viral disease. Pathog Glob Health. 2017; 111: 271–275.
1017. Waggoner JJ, Rojas A, Mohamed-Hadley A, et al. Real-time RT-PCR for Mayaro virus detection in plasma and urine. J Clin Virol. 2018; 98: 1–4.
1018. Liu X, Tharmarajah K, Taylor A. Ross River virus disease clinical presentation, pathogenesis and current therapeutic strategies. Microbes Infect. 2017; 19: 496–504.
1019. Mejta CR, L?pez-V?lez R. Tropical arthritogenic alphaviruses. Reumatol Clin. 2018; 14: 97–105.
1020. Dubischar KL, Kadlecek V, Sablan B Jr, et al. Safety of the inactivated Japanese encephalitis virus vaccine IXIARO in children: an open-label, randomized, active-controlled, phase 3 study. Pediatr Infect Dis J. 2017; 36: 889–897.
1021. Huang LM, Lin TY, Chiu CH, et al. Concomitant administration of live attenuated Japanese encepha­litis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. Vaccine. 2014; 32: 5363–5369.
1022. Burakoff A, Lehman J, Fischer M, et al. West Nile virus and other nationally notifiable arboviral diseases—United States, 2016. MMWR Morb Mortal Wkly Rep. 2018; 67: 13–17.
1023. Mehta R, Gerardin P, de Brito CAA, et al. The neurological complications of chikungunya virus: a systematic review. Rev Med Virol. 2018; 28: 1–24.
1024. Lynch DR, Rattelle A, Dong YN, et al. Anti-NMDA receptor encephalitis: clinical features and basic mechanisms. Adv Pharmacol. 2018; 82: 235–260.
1025. Berlin D, Gilani AI, Grewal AK, et al. Eastern equine encephalitis. Pract Neurol. 2017; 17: 387–391.
1026. Forrester NL, Wertheim JO, Dugan VG, et al. Evolution and spread of Venezuelan equine encephalitis complex alphavirus in the Americas. PLoS Negl Trop Dis. 2017; 11: 1–19.
1027. Sunwoo JS, Lee ST, Jung KH, et al. Clinical characteristics of severe Japanese encephalitis: a case series from South Korea. Am J Trop Med Hyg. 2017; 97: 369–375.
1028. Capeding MR, Alberto ER, Bouckenooghe A, et al. Five-year antibody persistence following a Japanese encephalitis chimeric virus vaccine (JE-CV) booster in JE-CV-primed children in the Philippines. J Infect Dis. 2018; 217: 567–571.
1029. Yun SI, Lee YM. Zika virus: an emerging flavivirus. J Microbiol. 2017; 55: 204–219.
1030. Baud D, Gubler DJ, Schaub B, et al. An update on Zika virus infection. Lancet. 2017; 390: 2099–2109.
1031. da Silva IRF, Frontera JA, Bispo de Filippis AM, et al. Neurologic complications associated with the Zika virus in Brazilian adults. JAMA Neurol. 2017; 74: 1190–1198.
1032. Nithiyanantham SF, Badawi A. Maternal infection with Zika virus and prevalence of congenital disorders in infants: systematic review and meta-analysis. Can J Public Health. 2019. [Epub ahead of print.]
1033. Hoen B, Schaub B, Funk AL, et al. Pregnancy outcomes after ZIKV infection in French territories in the Americas. N Engl J Med. 2018; 378: 985–994.
1034. Brasil P, Pereira JP Jr, Moreira ME, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016; 375: 2321–2334.
1035. Gaudinski MR, Coates EE, Houser KV, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018; 15: 1–20.
1036. White GS, Symmes K, Sun P, et al. Reemergence of St. Louis encephalitis virus, California, 2015. Emerg Infect Dis. 2016; 22: 2185–2188.
1037. Beran J, Lattanzi M, Xie F, et al. Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence. Vaccine. 2018. [Epub ahead of print.]
1038. Fatmi SS, Zehra R, Carpenter DO. Powassan virus — a new reemerging tick-borne disease. Front Public Health. 2017; 5: 1–12.
1039. Sharma SC, Raison N, Khan S, et al. Male circumcision for the prevention of human immunodeficiency virus (HIV) acquisition: a meta-analysis.BJU Int. 2018;121:515-526.
1040. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.N Engl J Med. 2015;373:2237-2246.
1041. Riddell J 4th, Amico KR, Mayer KH.HIV preexposure prophylaxis: a review. JAMA.2018;319:1261-1268.
1042. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infectedadults in Haiti.N Engl J Med. 2010;363:257-265.
1043. Bekker LG, Alleyne G, Baral S, et al. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. Lancet. 2018;392:312-358.
1044. Shrivastava R, Fonjungo PN, Kebede Y, et al. Role of public-private partnerships in achieving UNAIDS HIV treatment targets. BMC Health Serv Res. 2019;19:1-10.
1045. Gaolathe T, Wirth KE, Holme MP, et al. Botswana’s progress toward achieving the 2020 UNAIDS 90–90–90 antiretroviral treatment and virologic suppression goals: results of a population-based survey. Lancet HIV. 2016;3:e221-e230.
1046. Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. CurrOpin HIV AIDS. 2016;11:492-500.
1047. Grabowski MK, Serwadda DM, Gray RH, et al. HIV prevention efforts and incidence of HIV in Uganda. N Engl J Med. 2017;377:2154-2166.
1048. Vermund SH, Sheldon EK, Sidat M. Southern Africa: the highest priority region for HIV prevention and care interventions. Curr HIV/AIDS Rep. 2015;12:191-195.
1049. Jung IY, Rupasinghe D, Woolley I, et al. Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific. J Int AIDS Soc. 2019;22:1-13.
1050. Bailey H, Turkova A, Thorne C. Syphilis, hepatitis C and HIV in Eastern Europe. CurrOpin Infect Dis. 2017;30:93-100.
1051. Centers for Disease Control and Prevention; 1997. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2014. HIV Surveillance Supplemental Report 2016;21(No. 4). https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-2.pdf Accessed May 24, 2019.
1052. Singh S, Song R, Johnson AS, et al. HIV incidence, prevalence, and undiagnosed infections in U.S. men who have sex with men. Ann Intern Med. 2018;168:685-694.
1053. Robb ML, Eller LA, Kibuuka H, et al. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med. 2016;374:2120-2130.
1054. Parekh BS, Ou CY, Fonjungo PN, et al. Diagnosis of human immunodeficiency virus infection. Clin Microbiol Rev. 2019;32:1-55.
1055. DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men—United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:830-832.
1056. Peruski AH, Dong X, Selik RM. Trends in testing algorithms used to diagnose HIV infection, 2011- 2015, United States and 6 dependent areas. J Clin Virol. 2018;103:19-24.
1057. Robb ML, Eller LA, Kibuuka H, et al. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med. 2016;374:2120-2130.
1058. Crowell TA, Colby DJ, Pinyakorn S, et al. Acute retroviral syndrome is associated with high viral burden, CD4 depletion, and immune activation in systemic and tissue compartments. Clin Infect Dis. 2018;66:1540-1549.
1059. Roan NR. Resident T cells stand up to HIV. Sci Immunol. 2018;3:1-4.
1060. Crowell TA, Gebo KA, Blankson JN, et al. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis. 2015;211:1692-1702.
1061. Mikulak J, Oriolo F, Zaghi E, et al. Natural killer cells in HIV-1 infection and therapy. AIDS. 2017;31:2317-2330.
1062. Moir S, Fauci AS. B-cell responses to HIV infection. Immunol Rev. 2017;27:33-48.
1063. Migueles SA, Connors M. Success and failure of the cellular immune response against HIV-1. Nat Immunol. 2015;16:563-570.
1064. Basilissi M, Tincati C, Merlini E, et al. Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression. PLoS ONE. 2019;14:1-11.
1065. HIV/AIDS Data and Statistics. 2018.
1066. Hellmund C, Lever AM. Coordination of genomic RNA packaging with viral assembly in HIV-1. Viruses. 2016;8:1-13.
1067. Bracq L, Xie M, Benichou S, Bouchet J. Mechanisms for cell-to-cell transmission of HIV-1. Front Immunol. 2018;9:1-14.
1068. Joseph SB, Swanstrom R. The evolution of HIV-1 entry phenotypes as a guide to changing target cells. J Leukoc Biol. 2018;103:421-431.
1069. Kou J, Kuang YQ. Mutations in chemokine receptors and AIDS. Prog Mol Biol Transl Sci. 2019;161:113-124.
1070. Jiang X, Feyertag F, Meehan C, et al. Characterising the diverse mutational pathways associated with R5-tropic maraviroc resistance: HIV-1 that uses the drug-bound CCR5 coreceptor. J Virol. 2015;89: 11457-11472.
1071. Bettiker RL, Koren DE, Jacobson JM. Ibalizumab. CurrOpin HIV AIDS. 2018;13:354-358.
1072. Mamede JI, Cianci GC, Anderson MR, Hope TJ. Early cytoplasmic uncoating is associated with infectivity of HIV-1. Proc Natl Acad Sci USA. 2017;114:E7169-E7178.
1073. Larsen KP, Mathiharan YK, Kappel K, et al. Architecture of an HIV-1 reverse transcriptase initiation complex. Nature. 2018;557:118-122.
1074. Engelman AN, Cherepanov P. Retroviral intasomes arising. CurrOpin Struct Biol. 2017;47:23-29.
1075. Tomasini MD, Johnson DS, Mincer JS, et al. Modeling the dynamics and kinetics of HIV-1 Gag during viral assembly. PLoS ONE. 2018;13:1-31.
1076. Kamada AJ, Bianco AM, Zupin L, et al. Protective role of BST2 polymorphisms in mother-to-child transmission of HIV-1 and adult AIDS progression. J Acquir Immune DeficSyndr. 2016;72: 237-241.
1077. Mzingwane ML, Tiemessen CT. Mechanisms of HIV persistence in HIV reservoirs. Rev Med Virol. 2017;27:1-12.
1078. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
1079. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
1080. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
1081. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for het- erosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
1082. Choopanya K, Martin M, Sutharasami P, et al. Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand: a randomized, double-blind, placebo-controlled trial. Lancet. 2013;381:2083-2090.
1083. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-2246.
1084. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
1085. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509-518.
1086. Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121-2132.
1087. Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133-2143.
1088. Gonthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Siciety – USA Panel. JAMA. 2016;316:191-210.
1089. Bernard CL, Brandeau ML, Humphreys K, et al. Cost-effectiveness of HIV preexposure prophylaxis for people who inject drugs in the United States. Ann Intern Med. 2016;165:10-19.
1090. Riddell J 4th, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA.2018;319:1261-1268.
1091. Desai M, Field N, Grant R, et al. Recent advances in pre-exposure prophylaxis for HIV.BMJ. 2017;359:1-16.
1092. Heumann CL. Biomedical approaches to HIV prevention in women. Curr Infect Dis Rep. 2018;20:1-6.
1093. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society—USA Panel. JAMA. 2018;320:379-396.
1094. Tan DHS, Hull MW, Yoong D, et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017;189:E1448-E1458.
1095. Ford N, Mayer KH. World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. Clin Infect Dis. 2015; 60(suppl 3):S161-S164.
1096. Ghosn J, Taiwo B, Seedat S, et al. HIV. Lancet. 2018;392:685-697.
1097. Reddon H, Marshall BDL, Milloy MJ. Elimination of HIV transmission through novel and established prevention strategies among people who inject drugs. Lancet HIV. 2019; 6:e128-e136.
1098. Dashti A, DeVico AL, Lewis GK, et al. Broadly neutralizing antibodies against HIV: back to blood. Trends Mol Med. 2019;25:228-240.
1099. Severe P, Juste MA, Ambroise A, et al.Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.N Engl J Med. 2010;363:257-265.
1100. Lundgren JD, Babiker AG, Gordin F, et al.Initiation of antiretroviral therapy in early asymptomatic HIV infection.N Engl J Med. 2015;373:795-807.
1101. TEMPRANO ANRS 12136 Study Group; Danel C, Moh R, et al.A trial of early antiretrovirals and isoniazid preventive therapy in Africa.N Engl J Med. 2015;373:808-822.
1102. Cohen MS, Chen YQ, McCauley M, et al.Antiretroviral therapy for the prevention of HIV-1 trans- mission.N Engl J Med. 2016;375:830-839.
1103. Lennox JL, Landovitz RJ, Ribaudo HJ, et al.Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.Ann Intern Med. 2014;161:461-471.
1104. Molina JM, Clotet B, van Lunzen J, et al.Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.Lancet HIV. 2015;2:e127-e136.
1105. Sax PE, Wohl D, Yin MT, et al.Tenofovir alafenamide versus tenofovir disoproxil fumarate, cofor- mulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.Lancet. 2015;385:2606-2615.
1106. Gallant J, Lazzarin A, Mills A, et al.Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063-2072.
1107. Sax PE, Pozniak A, Montes ML, et al.Coformulatedbictegravir, emtricitabine, and tenofovir alaf- enamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.Lancet. 2017;390:2073-2082.
1108. Llibre JM, Hung CC, Brinson C, et al.Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non- inferiority SWORD-1 and SWORD-2 studies.Lancet. 2018;391:839-849.
1109. Cahn P, Madero JS, Arribas JR, et al.Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.Lancet. 2019;393:143-155.
1110. Eron JJ, Cooper DA, Steigbigel RT, et al.Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.Lancet Infect Dis. 2013;13:587-596.
1111. Tashima KT, Smeaton LM, Fichtenbaum CJ, et al.HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: a randomized, controlled trial.Ann Intern Med. 2015;163:908-917.
1112. Molina JM, Capitant C, Spire B, et al.On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.N Engl J Med. 2015;373:2237-2246.
1113. McCormack S, Dunn DT, Desai M, et al.Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.Lancet. 2016;387:53-60.
1114. Baeten JM, Donnell D, Ndase P, et al.Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.N Engl J Med. 2012;367:399-410.
1115. Thigpen MC, Kebaabetswe PM, Paxton LA, et al.Antiretroviral preexposure prophylaxis for het- erosexual HIV transmission in Botswana.N Engl J Med. 2012;367:423-434.
1116. Choopanya K, Martin M, Suntharasamai P, et al.Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double- blind, placebo-controlled phase 3 trial.Lancet. 2013;381:2083-2090.
1117. Van Damme L, Corneli A, Ahmed K, et al.Preexposure prophylaxis for HIV infection among African women.N Engl J Med. 2012;367:411-422.
1118. Marrazzo JM, Ramjee G, Richardson BA, et al.Tenofovir-based preexposure prophylaxis for HIV infection among African women.N Engl J Med. 2015;372:509-518.
1119. Lohse N, Obel N. Update of survival for persons with HIV infection in Denmark. Ann Intern Med. 2016;165:749-750.
1120. Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. CurrOpin HIV AIDS. 2016;11: 492-500.
1121. Panel on Antiretroviral Guidelines for Adults and Adolescents. Рекомендации по применению антиретровирусных препаратов у ВИЧ-1-инфицированных взрослых и подростков. Department of Health and Human Services (10/25/18). http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed April 19, 2019.
1122. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320:379-396.
1123. European AIDS Clinical Society (EACS). European Guidelines for treatment of HIV-positive adults in Europe.October 2018, version 9.1. http://www.eacsociety.org/files/guidelines_9.1-english.pdf.Accessed April 19, 2019.
1124. World Health Organization.Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Second Edition June 2016.Accessed June 15, 2017.
1125. Ghosn J, Taiwo B, Seedat S, et al.HIV.Lancet. 2018;3 92:685-697.
1126. Clutter DS, Jordan MR, Bertagnolio S, et al.HIV-1 drug resistance and resistance testing.Infect Genet Evol. 2016;46:292-307.
1127. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission.Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States; December 7, 2018. Accessed April 19, 2019.
1128. Ryom L, Lundgren JD, El-Sadr W, et al.Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.Lancet HIV. 2018;5: e291-e300.
1129. Biver E, Calmy A, Aubry-Rozier B, et al.Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.Osteoporos Int. 2019;30:1125-1135.
1130. Zanetti HR, Mendes EL, Palandri Chagas AC, et al.Triad of the ischemic cardiovascular disease in people living with HIV?Association between risk factors, HIV infection, and use of antiretroviral therapy.CurrAtheroscler Rep. 2018;20:1-6.
1131. Bernstein HB, Wegman AD.HIV infection: antepartum treatment and management.Clin Obstet Gynecol. 2018;61:122-136.
1132. Centers for Disease Control and Prevention.Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States; 2018. Accessed April 19, 2019.
1133. U.S. Public Health Service.Preexposure prophylaxis for the prevention of HIV infection in the United States—2017. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf.Accessed April 19, 2019.
1134. Margolis DM. Towards an HIV cure: a view of a developing field.J Infect Dis. 2017;215: S109-S110.
1135. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015;163:32-39.
1136. Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomized, placebo-controlled trial. Lancet Infect Dis. 2014;14:563-571.
1137. Eshun-Wilson I, Okwen MP, Richardson M, et al. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7:CD009012.
1138. Aberg J, Powderly W. HIV: primary and secondary prophylaxis for opportunistic infections. BMJ Clin Evid. 2010;2010:1-34.
1139. Beachler DC, Sugar EA, Margolick JB, et al. Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol. 2015; 181:40-53.
1140. Samandari T, Tedaldi E, Armon C, et al. Incidence of hepatitis C virus infection in the Human Immu- nodeficiency Virus Outpatient Study cohort, 2000-2013. Open Forum Infect Dis. 2017;4:1-10.
1141. Farid Y, Martin C, Delforge M, et al. Epidemiology and clinical management of HIV-HBV coinfected patients in a large AIDS Reference Center in Belgium. Acta Clin Belg. 2018:1-6.
1142. Cesarman E, Damania B, Krown SE, et al. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5:1-21.
1143. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138:1100-1112.
1144. Twigg HL 3rd, Knox KS, Zhou J, et al. Effect of advanced HIV infection on the respiratory microbiome. Am J Respir Crit Care Med. 2016;194:226-235.
1145. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807.
1146. Mangili A, Falutz J, Mamputu JC, et al. Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-Infected patients with excess abdominal fat. PLoS ONE. 2015;10:1-14.
1147. Overton ET, Chan ES, Brown TT, et al. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med. 2015;162:815-824.
1148. Kunisaki KM, Niewoehner DE, Collins G, et al; INSIGHT START Pulmonary Substudy Group. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. Lancet Respir Med. 2016;4:980-989.
1149. Escota GV, O’Halloran JA, Powderly WG, Presti RM. Understanding mechanisms to promote suc- cessful aging in persons living with HIV. Int J Infect Dis. 2018;66:56-64.
1150. Thakur KT, Boubour A, Saylor D, et al. Global HIV neurology: a comprehensive review. AIDS. 2019;33:163-184.
1151. Kugathasan R, Collier DA, Haddow LJ, et al. Diffuse white matter signal abnormalities on magnetic resonance imaging are associated with human immunodeficiency virus type 1 viral escape in the central nervous system among patients with neurological symptoms. Clin Infect Dis. 2017;64:1059-1065.
1152. Clifford DB. HIV-associated neurocognitive disorder. CurrOpin Infect Dis. 2017;30:117-122. Clifford KM, Samboju V, Cobigo Y, et al. Progressive brain atrophy despite persistent viral suppres- sion in HIV patients older than 60 years. J Acquir Immune DeficSyndr. 2017;76:289-297.
1153. Kucab P, Bhattacharya P. Epidemiology of acquired immune deficiency syndrome and cerebrovascular disease in a post antiretroviral era. J Stroke Cerebrovasc Dis. 2017;26:1197-1203.
1154. Cohen SD, Kopp JB, Kimmel PL. Kidney diseases associated with human immunodeficiency virus infection. N Engl J Med. 2017;377:2363-2374.
1155. Kooij KW, Vogt L, Wit F, et al. Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus-infected middle-aged individuals compared with human immu- nodeficiency virus-uninfected controls. J Infect Dis. 2017;216:622-631.
1156. Kasembeli AN, Duarate R, Ramsay M, et al. APOL1 risk variants are strongly associated with HIV- associated nephropathy in black South Africans. J Am Soc Nephrol. 2015;26:2882-2890.
1157. Nobakht E, Cohen SD, Rosenberg AZ, Kimmel PL. HIV-associated immune complex kidney disease. Nat Rev Nephrol. 2016;12:291-300.
1158. Rungtivasuwan K, Avihingsanon A, Thammajaruk N, et al. Influence of ABCC2 and ABCC4 poly- morphisms on tenofovir plasma concentrations in Thai HIV-infected patients. Antimicrob Agents Chemother. 2015;59:3240-3245.
1159. Vishnu P, Aboulafia DM. Haematological manifestations of human immune deficiency virus infec- tion. Br J Haematol. 2015;171:695-709.
1160. Vangipuram R, Tyring SK. AIDS-associated malignancies. Cancer Treat Res. 2019;177:1-21.
1161. Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpesvirus-Associated multicentric Castleman disease. Hematol Oncol Clin North Am. 2018;32:75-88.
1162. Cesarman E, Damania B, Krown SE, et al. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5:1-21.
1163. Practice Bulletin No. 157: cervical cancer screening and prevention. Obstet Gynecol. 2016;127: e1-e2a.
1164. Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378: 1029-1041.
1165. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138:1100-1112.
1166. Erqou S, Lodebo BT, Masri A, et al. Cardiac dysfunction among people living with HIV: a systematic review and meta-analysis.
1167. JACC Heart Fail. 2019;7:98-108.
1168. Lake JE, Stanley TL, Apovian CM, et al. Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection. Clin Infect Dis. 2017;64:1422-1429.
1169. Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60:1242-1251.
1170. Koay WLA, Siems LV, Persaud D. The microbiome and HIV persistence: implications for viral remissions and cure. CurrOpin HIV AIDS. 2018;13:61-68.
1171. Thompson CG, Gay CL, Kashuba ADM. HIV persistence in gut-associated lymphoid tissues: phar- macological challenges and opportunities. AIDS Res Hum Retroviruses. 2017;33:513-523.
1172. Di Bella S, Friedrich AW, Garc?a-Almod?var E, et al. Clostridium difficile infection among hospitalized HIV-infected individuals: epidemiology and risk factors: results from a case-control study (2002- 2013). BMC Infect Dis. 2015;15:1-8.
1173. Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol. 2017;2:211-223.
1174. Maurice JB, Patel A, Scott AJ, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017;31:1621-1632.
1175. Altman K, Vanness E, Westergard RP. Кожные проявления вируса иммунодефицита человека: клиническое обновление. Curr Infect Dis Rep. 2015;17:1-12.
1176. Tarikci N, Kocat?rk E, G?ng?r ?, et al. Pruritus in systemic diseases: a review of etiological factors and new treatment modalities. ScientificWorldJournal. 2015;2015:1-8.
1177. Asgari MM, Ray GT, Quesenberry CP Jr, et al. Association of multiple primary skin cancers with human immunodeficiency virus infection, CD4 count, and viral load. JAMA Dermatol. 2017;153:892-896.
1178. Gallitano SM, McDermott L, Brar K, et al. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016;74:974-980.
1179. Workowski KA, Bolan GA. Sexually transmitted treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.
1180. Fife KH, Mugwanya K, Thomas KK, et al. Transient increase in herpes simplex virus type 2 (HSV- 2)-Associated genital ulcers following initiation of antiretroviral therapy in HIV/HSV-2-Coinfected individuals. J Infect Dis. 2016;213:1573-1578.
1181. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65:1405-1408.
1182. Soza GM, Patel M, Readinger A. Disseminated cutaneous histoplasmosis in newly diagnosed HIV. Proc (Bayl Univ Med Cent). 2016;29:50-51.
1183. Adizie T, Moots RJ, Hodkinson B, et al. Inflammatory arthritis in HIV positive patients: a practical guide. BMC Infect Dis. 2016;16:1-7.
1184. Walker-Bone K, Doherty E, Sanyal K, et al. Assessment and management of musculoskeletal disorders among patients living with HIV. Rheumatology. 2017;56:1648-1661.
1185. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24:2381-2390.
1186. Meintjes G, Stek C, Blumenthal L, et al. PredART Trial Team. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379:1915-1925.
1187. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697-706.
1188. Blanc FX, Sok T, Laureillard D, et al. CAMELIA (ANRS 1295–CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481.
1189. Havlir DV, Kendall MA, Ive P, et al. AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-1491.
1190. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta- analysis. Ann Intern Med. 2015;163:32-39.
1191. Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiret- roviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomized, placebo-controlled trial. Lancet Infect Dis. 2014;14:563-571.
1192. Eshun-Wilson I, Okwen MP, Richardson M, et al. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7:CD009012.
1193. Manzardo C, Guardo AC, Letang E, et al. Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a com- prehensive review. Expert Rev Anti Infect Ther. 2015;13:751-767.
1194. Church LWP, Chopra A, Judson MA. Paradoxical reactions and the immune reconstitution inflam- matory syndrome. Microbiol Spectr. 2017;5:1-5.
1195. Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. CurrOpin HIV AIDS. 2016;11:191-200.
1196. Walker NF, Stek C, Wasserman S, et al. The tuberculosis-associated immune reconstitution inflam- matory syndrome: recent advances in clinical and pathogenesis research. CurrOpin HIV AIDS. 2018;13:512-521.
1197. Nelson AM, Manabe YC, Lucas SB. Immune reconstitution inflammatory syndrome (IRIS): what pathologists should know. Semin Diagn Pathol. 2017;34:340-351.
1198. Elsegeiny W, Marr KA, Williamson PR. Immunology of cryptococcal infections: developing a rational approach to patient therapy. Front Immunol. 2018;9:1-9.
1199. Scriven JE, Rhein J, Hullsiek KH, et al. Early ART after cryptococcal meningitis is associated with cerebrospinal fluid pleocytosis and macrophage activation in a multisite randomized trial. J Infect Dis. 2015;212:769-778.
1200. Yoon HA, Nakouzi A, Chang CC, et al. Association between plasma antibody responses and risk for Cryptococcus-associated immune reconstitution inflammatory syndrome. J Infect Dis. 2019;219:420-428.
1201. Bowen L, Nath A, Smith B. CNS immune reconstitution inflammatory syndrome. Handb Clin Neurol. 2018;152:167-176.
1202. Benjamin LA, Allain TJ, Mzinganjira H, et al. The role of human immunodeficiency virus-associated vasculopathy in the etiology of stroke. J Infect Dis. 2017;216:545-553.
1203. Lai RP, Meintjes G, Wilkinson RJ. HIV-1 tuberculosis-associated immune reconstitution inflamma- tory syndrome. Semin Immunopathol. 2016;38:185-198.
1204. el Bcheraoui C, Mokdad AH, Dwyer-Lindgren L, et al. Trends and patterns of differences in infectious disease mortality among US counties, 1980-2014. JAMA. 2018;319:1248-1260.
1205. Polgreen PM, Polgreen EL. Infectious diseases, weather, and climate. Clin Infect Dis. 2018;66:815-817.
1206. Sen R, Nayak L, De RK. A review on host-pathogen interactions: classification and prediction. Eur J Clin Microbiol Infect Dis. 2016;35:1581-1599.
1207. Shah PS, Wojcechowskyj JA, Eckhardt M, et al. Comparative mapping of host-pathogen protein-protein interactions. Curr Opin Microbiol. 2015;27:62-68.
1208. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosiS. Lancet Infect Dis. 2018;18:318-327.
1209. Arcilla MS, van Hattem JM, Haverkate MR, et al. Import and spread of extended-spectrum ?-lactamase-producing Enterobacteriaceae by international travelers (COMBAT study): a prospective, multicenter cohort study. Lancet Infect Dis. 2017;17:78-85.
1210. Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623-628.
1211. Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358:1443-1448.
1212. Miller JM, Binnicker MJ, Campbell S, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society of Microbiology. Clin Infect Dis. 2018;67:e1-e94.
1213. Gwinn M, MacCannell D, Armstrong GL. Next-generation sequencing of infectious pathogens. JAMA. 2019;321:893-894.
1214. Hui W, Li T, Liu W, et al. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: an updated randomized controlled trial meta-analysis. PLoS ONE. 2019;14:1-14.
1215. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369-2379.
1216. Noecker C, McNally CP, Eng A, et al. High-resolution characterization of the human microbiome. Transl Res. 2017;179:10-23.
1217. Tamburini S, Shen N, Wu HC, et al. The microbiome in early life: implications for health outcomes. Nat Med. 2016;22:713-722.
1218. Young VB. The role of the microbiome in human health and disease: an introduction for clinicians. BMJ. 2017;356:1-14.
1219. Singer-Englar T, Barlow G, Mathur R. Obesity, diabetes, and the gut microbiome: an updated review. Expert Rev Gastroenterol Hepatol. 2019;13:3-15.
1220. Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019. [Epub ahead of print.]
1221. Libertucci J, Young VB. The role of the microbiota in infectious diseases. Nat Microbiol. 2019;4:35-45.
1222. Helmink BA, Khan MAW, Hermann A, et al. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25:377-388.
1223. Baxter NT, et al. DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model. Microbiome. 2016;4:1-6.
1224. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569-580.
1225. Nemeth J, Oesch G, Kuster SP. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. J Antimicrob Chemother. 2015;70:382-395.
1226. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonization with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:990-1001.
1227. Dubourg G, Lamy B, Ruimy R. Rapid phenotypic methods to improve the diagnosis of bacterial bloodstream infections: meeting the challenge to reduce the time to result. Clin Microbiol Infect. 2018;24:935-943.
1228. Arciola CR, Campoccia D, Montanaro L. Implant infections: adhesion, biofilm formation and immune evasion. Nat Rev Microbiol. 2018;16:397-409.
1229. FDA Pregnancy Categories. See: https://www.drugs.com/pregnancy-categories.html. Accessed April 22, 2019.
1230. Tacconelli E, Sifakis F, Harbarth S, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis. 2018;18:e99-e106.
1231. Cassini A, H?gberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19:56-66.
1232. Spellberg B, Srinivasan A, Chambers HF. New societal approaches to empowering antibiotic stewardship. JAMA. 2016;315:1229-1230.
1233. Ritchie ND, Irvine SC, Alieen H, et al. Restrictive antibiotic stewardship associated with reduced hospital mortality in gram-negative infection. QJM. 2017;110:155-161.
1234. Van Boeckel TP, Brower C, Gilbert M, et al Global trends in antimicrobial use in food animals. Proc Natl Acad Sci USA. 2015;112:5649-5654.
1235. Lemiengre MB, van Driel ML, Merenstein D, et al. Antibiotics for clinically diagnosed acute rhinosinusitis in adults. Cochrane Database Syst ReV. 2012;10:CD006089.
1236. Spurling GK, Del Mar CB, Dooley L, et al. Delayed antibiotic prescriptions for respiratory infections. Cochrane Database Syst ReV. 2017;9:CD004417.
1237. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312-1323
1238. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379:236-249.
1239. Andriolo BN, Andriolo RB, Salomao R, et al. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst ReV. 2017;1:CD010959.
1240. Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis. 2015;61:1071-1080.
1241. Jefferies S, Weatherall M, Young P, et al. The effect of antipyretic medications on mortality in critically ill patients with infection: a systematic review and meta-analysiS. Crit Care Resusc. 2011;13:125-131.
1242. Niven DJ, Gaudety JE, Laupland KV, et al. Accuracy of peripheral thermometers for estimating temperature: a systematic review and meta-analysis. Ann Intern Med. 2015;163:768-777.
1243. Tansey EA, Johnson CD. Recent advances in thermoregulation. Adv Physiol Ed. 2015;39:139-148.
1244. Ye F, Hatahet M, Youniss MA, et al. The clinical significance of relative bradycardia. WMJ. 2018;117:73-78.
1245. Thwaites GE, Day NPJ. Approach to fever in the returning traveler. N Engl J Med. 2017;376:548-560.
1246. McCreary EK, Heim ME, Schulz LT, et al. Top 10 myths regarding the diagnosis and treatment of cellulitis. J Emerg Med. 2017;53:485-492.
1247. MacMillan A, Rudinsky D, Han G, et al. Multidisciplinary approach to improve sepsis outcomes. J Healthc Qual. 2018. [Epub ahead of print.]
1248. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for the management of sepsis and septic shock: 2016. Crit Care Med. 2017;45:486-552.
1249. Park YK, Yi HJ, Choi KS, et al. Predictive factors of fever after aneurysmal subarachnoid hemorrhage and its impact on delayed cerebral ischemia and clinical outcomes. World Neurosurg. 2018;114:e524-e531.
1250. Wang Q, Li YM, Li Y, et al. (18)F-FDGPET/CT in fever of unknown origin and inflammation of unknown origin: a Chinese multi-center study. Eur J Nucl Med Mol Imaging. 2019;46:159-165.
1251. Schinau V, Vogel K, Englbrecht M, et al. The value of (18)F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. Ann Rheum Dis. 2018;77:70-77.
1252. Attard L, Tadolini M, De Rose DU, et al. Overview of fever of unknown origin in adult and paediatric patients. Clin Exp Rheumatol. 2018;36 (suppl. 110):10-24.
1253. Gafter-Gvili A, Raibman S, Grossman A, et al. [18F]FDG-PET/CT for the diagnosis of patients with fever of unknown origin. QJM. 2015;108:289-298.
1254. Kapsi AJ, Dittrich S, Gonzalez IJ, et al. Host biomarkers for distinguishing bacterial from non-bacterial causes of acute febrile illness: a comprehensive review. PLoS ONE. 2016;11:1-29.
1255. Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164:425-434.
1256. Vidal L, Ben Dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst ReV. 2013;10:CD003992.
1257. Beyar-Katz O, Dickstein Y, Borok S, et al. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst ReV. 2017;6: CD003914.
1258. Nakane T, Tamura K, Hino M, et al. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: a multicenter prospective randomized trial. J Infect Chemother. 2015;21:16-22.
1259. Horita N, Shibata Y, Watanabe H, et al. Comparison of antipseudomonal beta-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect. 2017;23:723-729.
1260. Stern A, Carrara E, Bitterman R, et al. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database Syst ReV. 2019;1:CD012184.
1261. DeWitt S, Chavez SA, Perkins J, et al. Evaluation of fever in the emergency department. Am J Emerg Med. 2017;35:1755-1758.
1262. Fishman JA. Infection in organ transplantation. Am J Transplant. 2017;17:856-879.
1263. White L, Ybarra M. Neutropenic fever. Hematol Oncol Clin North Am. 2017;31:981-993.
1264. Pizzo PA. Management of patients with fever and neutropenia through the arc of time: a narrative review. Ann Intern Med. 2019;170:389-397.
1265. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36:1443-1453.
1266. Moon H, Choi YJ, Sim SH. Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment? PLoS One. 2018;13:1-12.
1267. Schmidt-Hieber M, Teschner D, Maschmeyer G, et al. Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. Expert Rev Anti Infect Ther. 2019:1-13.
1268. Crawford J, Becker PS, Armitage J, et al. Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:1520-1541.
1269. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199-3212.
1270. Burke VE, Lopez FA. Approach to skin and soft tissue infections in non-HIV immunocompromised hosts. Curr Opin Infect Dis. 2017;30:354-363.
1271. Moura S, Cerqueira L, Almeida A. Invasive pulmonary aspergillosis: current diagnostic methodologies and a new molecular approach. Eur J Clin Microbiol Infect Dis. 2018;37:1393-1403.
1272. Bitterman R, Eliakim-Raz N, Vinograd I, et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst ReV. 2018;2:CD008983.
1273. Panarelli NC, Yantiss RK. Inflammatory and infectious manifestations of immunodeficiency in the gastrointestinal tract. Mod Pathol. 2018;31:844-861.
1274. Siddiqui ZA. An overview of parasitic infections of the gastro-intestinal tract in developed countries affecting immunocompromised individuals. J Parasit Dis. 2017;41:621-626.
1275. Levin SN, Lyons JL. Infections of the nervous system. Am J Med. 2018;131:25-32.
1276. Anderson DJ, Chen LF, Weber DJ, et al. Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomized, multicenter, crossover study. Lancet. 2017;389:805-814.
1277. Mimoz O, Lucet JC, Kerforne T, et al. Skin antisepsis with chlorhexidine-alcohol versus povidone iodine-alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial. Lancet. 2015;386:2069-2077.
1278. Tuuli MG, Liu J, Stout MJ, et al. A randomized trial comparing skin antiseptic agents at cesarean delivery. N Engl J Med. 2016;374:647-655.
1279. Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368:533-542.
1280. Milstone AM, Elward A, Song X, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet. 2013;381:1099-1106.
1281. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368:2255-2265.
1282. Noto MJ, Domenico HJ, Byrne DW, et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA. 2015;313:369-378.
1283. Swan JT, Ashton CM, Bui LN, et al. Effect of chlorhexidine bathing every other day on prevention of hospital-acquired infections in the surgical ICU: a single-center, randomized controlled trial. Crit Care Med. 2016;44:1822-1832.
1284. Oostdijk EA, Kesecioglu J, Schultz MJ, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA. 2014;312:1429-1437.
1285. Huang SS, Singh R, McKinnell JA, et al. Decolonization to reduce postdischarge infection risk among MRSA carriers. N Engl J Med. 2019;380:638-650.
1286. Huskins W, Huckabee C, O’Grady N, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med. 2011;364:1407-1418.
1287. Harris AD, Pineles L, Belton B, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA. 2013;310:1571-1580.
1288. Magill SS, Dumyati G, Ray SM, et al. Evaluating epidemiology and improving surveillance of infections associated with health care, United States. Emerg Infect Dis. 2015;21:1537-1542.
1289. Magill SS, O’Leary E, Janelle SJ, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379:1732-1744.
1290. Miller LM, Clark E, Dipchand C, et al. Hemodialysis tunneled catheter-related infections. Can J Kidney Health DiS. 2016;3:1-10.
1291. Cobrado L, Silva-Dias A, Azevedo MM, et al. High-touch surfaces: microbial neighbours at hand. Eur J Clin Microbiol Infect Dis. 2017;36:2053-2062.
1292. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016;37:1288-1301.
1293. Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management and treatment. Crit Care. 2017;21:211.
1294. Balsells E, Shi T, Leese C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob HealtH. 2019;9:1-20.
1295. Jullian-Desayes I, Landelle C, Mallaret MR, et al. Clostridium difficile contamination of health care workers’ hands and its potential contribution to the spread of infection: review of the literature. Am J Infect Control. 2017;45:51-58.
1296. Bell T, O’Grady NP. Prevention of central line-associated bloodstream infections. Infect Dis Clin North Am. 2017;31:551-559.
1297. Saint S, Greene MT, Krein SL, et al. A program to prevent catheter-associated urinary tract infection in acute care. N Engl J Med. 2016;374:2111-2119.
1298. Spalding MC, Cripps MW, Minshall CT. Ventilator-associated pneumonia: new definitions. Crit Care Clin. 2017;33:277-292.
1299. Goff DA, Kullar R, Bauer KA, et al. Eight habits of highly effective antimicrobial stewardship programs to meet the Joint Commission standards for hospitals. Clin Infect Dis. 2017;64:1134-1139.
1300. Rennert-May E, Chew DS, Conly J, et al. Clinical practice guidelines for creating an acute care hospital-based antimicrobial stewardship program: a systematic review Am J Infect Control. 2019. [Epub ahead of print.]
1301. Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment and prevention of acute diarrheal infections in adults Am J Gastroenterol. 2016;111:602-622.
1302. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and managment of infectious diarrhea. Clin Infect Dis. 2017;65:1963-1973.
1303. Einarsson E, Ma’ayeh S, Svard SG. An up-date on Giardia and giardiasis. Curr Opin Microbiol. 2016;34:47-52.
1304. Steffan R, Hill DR, DuPont HL. Traveler’s diarrhea: a clinical review. JAMA. 2015;313:71-80.
1305. Acree M, Davis AM. Acute diarrheal infections in adultS. JAMA. 2017;318:957-958.
1306. Libbert C. Antimicrobial therapy of acute diarrhea: a clinical review. Expert Rev Anti Infect Ther. 2016;14:193-206.
1307. Bonyai K, Estes MK, Martella V, et al. Viral gastroenteritis. Lancet. 2018;392:175-186.
1308. Jiang ZD, DuPont HL. Etiology of travellers’ diarrhea. J Travel Med. 2017;24:S13-S16.
1309. Byrne S, Robson JM. Advances in molecular diagnosis of parasitic enteropathogens. Pathology. 2015;47:234-242.
1310. Binnicker MJ. Multiplex molecular panels for the diagnosis of gastrointestinal infection: performance, result interpretation and cost-effectiveness. J Clin Microbiol. 2015;53:3723-3728.
1311. Eckbo EJ, Yansouni CP, Pernica JM, et al. New tools to test stool: managing travelers’ diarrhea in the era of molecular diagnostics. Infect Dis Clin North Am. 2019;33:197-212.
1312. Hirvonen JJ. Comparison of three multiplex real-time PCR assays for detection of enteric viruses in patients with diarrhea. Eur J Clin Microbiol Infect Dis. 2019;38:241-244.
1313. DuPont HL. Persistent diarrhea: a clinical review. JAMA. 2016;315:2712-2723.
1314. Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. JAMA. 2018;319:1781-1789.
1315. Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA. 2012;307:583-589.
1316. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012;380:484-490.
1317. Dinh A, Davido B, Etienne M, et al. Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial. Eur J Clin Microbiol Infect DiS. 2017;36:1443-1448.
1318. Fox MT, Melia MT, Same RG, et al. A seven-day course of TMP-SMX may be as effective as a seven-day course of ciprofloxacin for the treatment of pyelonephritis. Am J Med. 2017;130:842-845.
1319. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380:729-740.
1320. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788-799.
1321. Widmer M, Lopez I, Gulmezoglu AM, et al. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev. 2015;11:CD000491.
1322. van Nieuwkoop C, van der Starre WE, Stalenhoef JE, et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med. 2017;15:1-9.
1323. Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178:1509-1515.
1324. Price JR, Guran LA, Gregory WT, et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016;215:548-560.
1325. Juthani-Mehta M, Van Ness PH, Bianco L, et al. Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: a randomized clinical trial. JAMA. 2016;316:1879-1887.
1326. Beerepoot MA, Geerlings SE, van Haarst EP, et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013;190:1981-1989.
1327. Fisher H, Oluboyede Y, Chadwick T, et al. Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial. Lancet Infect DiS. 2018;18:957-968.
1328. Nakra NA, Madan RP, Buckley N, et al. Loss of innate host defense following unprotected vaginal sex. J Infect Dis. 2016;213:840-847.
1329. Zasloff M. Why are diabetics prone to kidney infections? J Clin Invest. 2018;128:5213-5215.
1330. Bollestad M, Vik I, Grude N, et al. Bacteriology in uncomplicated urinary tract infections in Norwegian general practice from 2001-2015. BJGP Open. 2018;1:1-20.
1331. Espinosa-Ortiz EJ, Eisner BH, Lange D, et al. Current insights into the mechanisms and management of infection stones. Nat Rev Urol. 2019;16:35-53.
1332. Alidjanov JF, Naber KG, Abdufattaev UA, et al. Reliability of symptom-based diagnosis of uncomplicated cystitis. Urol Int. 2018;1-13.
1333. Wagenlehner FM, Tandogdu Z, Bjerklund Johansen TE. An update on classification and management of urosepsis. Curr Opin Urol. 2017;27:133-137.
1334. Wise GJ, Schlegel PN. Sterile pyuria. N Engl J Med. 2015;372:1048-1054.
1335. O’Grady MC, Barry L, Corcoran GD, et al. Empirical treatment of urinary tract infections: how rational are our guidelines? J Antimicrob Chemother. 2019;74:214-217.
1336. Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol. 2018;219:40-51.
1337. Kazemier BM, Koningstein FN, Schneeberger C, et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis. 2015;15:1324-1333.
1338. Cai T, Nesi G, Mazzoli S, et al. Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. Clin Infect Dis. 2015;61:1655-1661.
1339. Daniel M, Keller S, Mozafarihashjin M, et al. An implementation guide to reducing overtreatment of asymptomatic bacteriuria. JAMA Intern Med. 2018;178:271-276.
1340. Schaeffer AJ, Nicolle LE. Clinical practice. Urinary tract infections in older men. N Engl J Med. 2016;374:562-571.
1341. Bonkat G, Cai T, Veeratterapillay R, et al. Management of urosepsis in 2018. Eur Urol Focus. 2019;5:5-9.
1342. Saint S, Greene MT, Krein SL, et al. A program to prevent catheter-associated urinary tract infection in acute care. N Engl J Med. 2016;374:2111-2119.
1343. Eshleman SH, Hudelson SE, Redd AD, et al. Treatment as prevention: characterization of partner infections in the HIV prevention trials network 052 trial. J Acquir Immune Defic Syndr. 2017; 74: 112-116.
1344. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64: 1-137.
1345. Kissinger P, Muzny CA, Mena LA, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis. 2018; 18: 1251-1259.
1346. Creighton S. Gonorrhoea. BMJ Clin Evid. 2014; 2: 1-12.
1347. Savaris RF, Fuhrich DG, Duarte RV, et al. Antibiotic therapy for pelvic inflammatory disease. Cochrane Database Syst Rev. 2017; 4: CD010285.
1348. Ross JD. Воспалительные заболевания органов малого таза. BMJ Clin Evid. 2013; 12: 1-28.
1349. Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS. 2012; 26: 609-615.
1350. Ferreira A, Young T, Mathews C, et al. Strategies for partner notification for sexually transmitted infections, including HIV. Cochrane Database Syst Rev. 2013; 4: CD002843.
1351. Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis. 2017; 17: e235-e279.
1352. Nwankwo TO, Aniebue UU, Umeh UA. Syndromic diagnosis in evaluation of women with symptoms of vaginitis. Curr Infect Dis Rep. 2017; 19: 1-9.
1353. Wagenlehner FM, Brockmeyer NH, Discher T, et al. The presentation, diagnosis, and treatment of sexually transmitted infections. Dtsch Arztebl Int. 2016; 113: 11-22.
1354. Lau A, Bradshaw CS, Lewis D, et al. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis Clin Infect Dis. 2015; 61: 1389-1399.
1355. Horner PJ, Blee K, Falk L, et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016; 27: 928-937.
1356. Bachmann LH, Manhart LE, Martin DH, et al. Достижения в понимании и лечении уретрита у мужчин. Clin Infect Dis. 2015; 61 (suppl 8): S763-S769.
1357. Feltner C, Grodensky C, Ebel C, et al. Serologic screening for genital herpes: an updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016; 316: 2531-2543.
1358. Levy SB, Gunta J, Edemekong P. Screening for sexually transmitted diseases. Prim Care. 2019; 46: 157-173.
1359. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for syphilis infection in nonpregnant adults and adolescents: US Preventive Services Task Force recommendation statement. JAMA. 2016; 315: 2321-2327.
1360. Wentzensen N, Arbyn M, Berkhof J, et al. Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer. 2017; 140: 2192-2200.
1361. Paavonen J, Brunham RC. Bacterial vaginosis and desquamative inflammatory vaginitis. N Engl J Med. 2018; 379: 2246-2254.
1362. Reiter S, Kellogg Spadt S. Bacterial vaginosis: a primer for clinicians. Postgrad Med. 2018; 1-11.
1363. Donders GG, Sobel JD. Candida vulvovaginitis: a store with a buttery and a show window. Mycoses. 2017; 60: 70-72.
1364. Bouchemal K, Bories C, Loiseau PM. Strategies for prevention and treatment of Trichomonas vaginalis infections. Clin Microbiol Rev. 2017; 30: 811-825.
1365. Price MJ, Ades AE, Welton NJ, et al. Proportion of pelvic inflammatory disease cases caused by Chlamydia trachomatis: consistent picture from different methods. J Infect Dis. 2016; 214: 617-624.
1366. Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med. 2015; 372: 2039-2048.
1367. Ross J, Guaschino S, Cusini M, et al. 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018; 29: 108-114.
1368. Gonthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA panel. JAMA. 2016; 316: 191-210.
1369. Hofmeyr GJ, Singata-Madliki M, Lawrie TA, et al. Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. J Fam Plann Reprod Health Care. 2017; 43: 175-180.
1370. Riddle MS, Connor P, Fraser J, et al. Trial evaluating ambulatory therapy of travelers’ diarrhea (TrEAT TD) study: a randomized controlled trial comparing 3 single-dose antibiotic regimens with loperamide. Clin Infect Dis. 2017;65:2008-2017.
1371. Ng QX, Ho CYX, Shin D, et al. A meta-analysis of the use of rifaximin to prevent travellers’ diarrhoea. J Travel Med. 2017;24:1-5.
1372. Clarke MJ, Broderick C, Hopewell S, et al. Compression stockings for preventing deep vein thrombosis in airline passengerS. Cochrane Database Syst Rev. 2016;9:CD004002.
1373. Tortorolo F, Farren F, Rada G. Is melatonin useful for jet lag? Medwave. 2015;15(suppl 3):1-9.
1374. Nieto Estrada VH, Molano Franco D, Medina RD, et al. Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs. Cochrane Database Syst Rev. 2017;6:CD009761.
1375. Low EV, Avery AJ, Gupta V, et al. Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis. BMJ. 2012;345: 1-14.
1376. Simancas-Racines D, Arevalo-Rodriguez I, Osorio D, et al. Interventions for treating acute high altitude illness. Cochrane Database Syst Rev. 2018;6:CD009567.
1377. Freedman DO, Chen LH, Kozarsky PE. Medical considerations before international travel. N Engl J Med. 2016;375:247-260.
1378. Angelo KM, Kozarsky PE, Ryan ET, et al. What proportion of international travellers acquire a travel-related illness? A review of the literature. J Travel Med. 2017;1-8.
1379. Steffen R, Behrens RH, Hill DR, et al. Vaccine-preventable travel health risks: what is the evidence—what are the gaps? J Travel Med. 2015;22:1-12.
1380. Centers for Disease Control and PreventioN. Recommended Immunization Schedules for Adults. Updated annuallY. http://www.cdc.gov/vaccines/schedules/hcp/adult.html. Accessed April 22, 2019.
1381. Travelers’ HealtH. DestinationS. Centers for Disease Control and Prevention http://wwwnc.cdc.gov/travel/destinations/list. Accessed April 22, 2019.
1382. Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2018;5:CD001261.
1383. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2018-19 influenza season. MMWR Recomm Rep. 2018;67:1-20.
1384. Barrett ADT. Yellow fever live attenuated vaccine: a very successful live attenuated vaccine but still we have problems controlling the disease. Vaccine. 2017;35:5951-5955.
1385. Caldwell JP, Chen LH, Hamer DH. Evolving epidemiology of Japanese encephalitis: implications for vaccination. Curr Infect Dis Rep. 2018;20:1-13.
1386. Cholera, 2017. Wkly Epidemiol Rec. 2018;93:489-500.
1387. Weaver SC, Charlier C, Vasilakis N, et al. Zika, Chikungunya, and other emerging vector-borne viral diseases. Annu Rev Med. 2018;69:395-408.
1388. Yactayo S, Staples JE, Millot V, et al. Epidemiology of Chikungunya in the Americas. J Infect Dis. 2016;214(suppl 5):S441-S445.
1389. Petridou C, Simpson A, Charlett A, et al. Zika virus infection in travellers returning to the United Kingdom during the period of the outbreak in the Americas (2016-17): a retrospective analysis. Travel Med Infect Dis. 2019. [Epub ahead of print.]
1390. Steffen R, Hill DR, DuPont HL. Traveler’s diarrhea: a clinical review. JAMA. 2015;313:71-80.
1391. Zaidi D, Wine E. An update on travelers’ diarrhea. Curr Opin Gastroenterol. 2015;31:7-13.
1392. Lalani T, Maguire JD, Grant EM, et al. Epidemiology and self-treatment of travelers’ diarrhea in a large, prospective cohort of Department of Defense beneficiaries. J Travel Med. 2015;22:152-160.
1393. Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report. J Travel Med. 2017;24 (suppl 1):S2-S19.
1394. Thwaites GE, Day NPJ. Approach to fever in the returning traveler. N Engl J Med. 2017;376:548-560.
1395. Scaggs Huang FA. Schlaudecker E. Fever in the returning traveler. Infect Dis Clin North Am. 2018;32:163-188.
1396. Eckbo EJ, Yansouni CP, Pernica JM, et al. New tools to test stool: managing travelers’ diarrhea in the era of molecular diagnostics. Infect Dis Clin North Am. 2019;33:197-212.
1397. Duplessis CA, Gutierrez RL, Porter CK. Review: chronic and persistent diarrhea with a focus in the returning traveler. Trop Dis Travel Med Vaccines. 2017;3:1-17.
1398. Nemeth J, Oesch G, Kuster SP. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. J Antimicrob Chemother. 2015;70:382-395.
1399. Cook PP, Gooch M. Long-term effects of an antimicrobial stewardship programme at a tertiary-care teaching hospital. Int J Antimicrob Agents. 2015;45:262-267.
1400. Emberger J, Tassone D, Stevens MP, et al. The current state of antimicrobial stewardship: challenges, successes, and future directions. Curr Infect Dis Rep. 2018;20:1-12.
1401. Frenk SM, Kit BK, Lukacs SL, et al. Trends in the use of prescription antibiotics: NHANES 1999-2012. J Antimicrob Chemother. 2016;71:251-256.
1402. King LM, Bartoces M, Fleming-Dutra KE, et al. Changes in US outpatient antibiotic prescriptions from 2011-2016. Clin Infect Dis. 2019. [Epub ahead of print.]
1403. Louie A, Boyne MT 2nd, Patel V, et al. Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States. Antimicrob Agents Chemother. 2015;59:622-632.
1404. Wald-Dickler N, Holtom P, Spellberg B. Busting the myth of “static vs cidal”: a systemic literature review. Clin Infect Dis. 2018;66:1470-1474.
1405. Chong Y, Shimoda S, Shimono N. Current epidemiology, genetic evolution and clinical impact of extended-spectrum ?-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Genet Evol. 2018;61:185-188.
1406. Gorelik E, Masarwa R, Perlman A, et al. Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides. Antimicrob Agents Chemother. 2018;62:1-9.
1407. Daum RS, Miller LG, Immergluck L, et al. A placebo-controlled trial of antibiotics for smaller skin abscesses. N Engl J Med. 2017;376:2545-2555.
1408. Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016;374:823-832.
1409. McDanel JS, Perencevich EN, Diekema DJ, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61:361-367.
1410. Bidell MR, Patel N, O’Donnell JN. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother. 2018;73:2643-2651.
1411. Wang Y, Zou Y, Xie J, et al. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing metaanalysis. Eur J Clin Pharmacol. 2015;71:107-115.
1412. Corey GR, Wilcox MH, Talbot GH, et al; CANVAS 1 investigatorS. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65 (suppl 4):iv41-iv51.
1413. Rubinstein E, Lalani T, Corey GR, et al; ATTAIN Study GrouP. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52:31-40.
1414. Thwaites GE, Scarborough M, Szubert M, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicenter, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:668-678.
1415. Huang SS, Septimus E, Kleinman K, et al; CDC Prevention Epicenters Program; AHRQ DECIDE Network and Healthcare-Associated Infections PrograM. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368:2255-2265.
1416. Huang SS, Singh R, McKinnell JA, et al. Decolonization to reduce postdischarge infection risk among MRSA carriers. N Engl J Med. 2019;380:638-650.
1417. Noto MJ, Domenico HJ, Byrne DW, et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA. 2015;313:369-378.
1418. Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010;362:9-17.
1419. Schwameis M, Roppenser B, Firbas C, et al. Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial. Lancet Infect Dis. 2016;16:1036-1044.
1420. Lin MY, Hayden MK, Lyles RD, et al. Regional epidemiology of methicillin-resistant Staphylococcus aureus among adult intensive care unit patients following state-mandated active surveillance. Clin Infect Dis. 2018;66:1535-1539.
1421. Lee AS, de Lencastre H, Garau J, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018;4:1-23.
1422. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019;17:203-218.
1423. Ricciardi BF, Muthukrishnan G, Masters E, et al. Staphylococcus aureus evasion of host immunity in the setting of prosthetic joint infection: biofilm and beyond. Curr Rev Musculoskelet Med. 2018;11:389-400.
1424. Chan LC, Chaili S, Filler SG, et al. Innate immune memory contributes to host defense against recurrent skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Infect Immun. 2017;85:1-19.
1425. Keely Boyle K, Rachala S, Nodzo SR. Centers for Disease Control and Prevention 2017 Guidelines for Prevention of Surgical Site Infections: review and relevant recommendations. Curr Rev Musculoskelet Med. 2018;11:357-369.
1426. Jung N, Rieg S. Essentials in the management of S. aureus bloodstream infection. Infection. 2018;46:441-442.
1427. Herfiot GS, Tong SYC, Cheng AC, Liew D. What risk of endocarditis is low enough to justify the omission of transesophageal echocardiography in Staphylococcus aureus bacteraemia? A narrative review. Clin Microbiol Infect. 2018;24:1251-1256.
1428. Oizumi H, Ichinokawa H, Hoshino H, et al. Pericardial window for methicillin-resistant Staphylococcus aureus pericarditis. Ann Thorac Surg. 2019;107:e27-e29.
1429. Kavanagh N, Ryan EJ, Widaa A, et al. Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions. Clin Microbiol Rev. 2018;31:1-25.
1430. Ross JJ. Septic arthritis of native joints. Infect Dis Clin North Am. 2017;31:203-218.
1431. Arciola CR, Campoccia D, Montanaro L. Implant infections: adhesion, biofilm formation and immune evasion. Nat Rev Microbiol. 2018;16:397-409.
1432. Fisher EL, Otto M, Cheung GYC. Basis of virulence in enterotoxin-mediated staphylococcal food poisoning. Front Microbiol. 2018;9:1-8.
1433. Pierson JD, Hansmann MA, Davis CC, et al. The effect of vaginal microbial communities on colonization by Staphylococcus aureus with the gene for toxic shock syndrome toxin 1 (TSST-1): a case-control study. Pathog Dis. 2018;76:1-8.
1434. McDanel JS, Roghmann MC, Perencevich EN, et al. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study. Clin Infect Dis. 2017;65:100-106.
1435. Troeman DPR, Van Hout D, Kluytmans J. Antimicrobial approaches in the prevention of Staphylococcus aureus infections; a review. J Antimicrob Chemother. 2019;74:281-294.
1436. Natsis NE, Cohen PR. Coagulasenegative Staphylococcus skin and soft tissue infections. Am J Clin Dermatol. 2018;19:671-677.
1437. Garin N, Genn? D, Carballo S, et al. ?-lactam monotherapy vs ?-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174:1894-1901.
1438. Nie W, Li B, Xiu Q. ?-Lactam/macrolide dual therapy versus ?-lactam monotherapy for the treat­ment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:1441-1496.
1439. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18:95-107.
1440. Pepper D, Sun J, Rhee C, et al. Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults: a systematic review and meta-analysis. Chest. 2019;155:1109-1118.
1441. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313:677-686.
1442. Briel M, Spoorenberg SMC, Snijders D, et al. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data meta-analysiS. Clin Infect Dis. 2018;66:346-354.
1443. Vadlamudi NK, Parhar K, Altre Malana KL, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: a systematic review and meta-analysiS. Vaccine. 2019;37:1021-1029.
1444. Marrie TJ, File TM Jr. Bacterial pneumonia in older adults. Clin Geriatr Med. 2016;32:459-477.
1445. Feldman C, Anderson R. The role of Streptococcus pneumoniae in community-acquired pneumonia. Semin Respir Crit Care Med. 2016;37:806-818.
1446. Engholm DH, Kilian M, Goodsell DS, et al. A visual review of the human pathogen Streptococcus pneumoniae. FEMS Microbiol Rev. 2017;41:854-879.
1447. Richter SS, Musher DM. The ongoing genetic adaptation of Streptococcus pneumoniae. J Clin Microbiol. 2017;55:681-685.
1448. Feldman C, Anderson R. Epidemiology, virulence factors and management of the pneumococcus. F1000ReS. 2016;5:1-11.
1449. Torres A, Cilloniz C, Blasi F, et al. Burden of pneumococcal community-acquired pneumonia in adults across Europe: a literature review. Respir Med. 2018;137:6-13.
1450. Weisler JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16:355-367.
1451. Okamoto S, Nagase S. Pathogenic mechanisms of invasive group A Streptococcus infections by influenza virus-group A Streptococcus superinfection. Microbiol Immunol. 2018;62:141-149.
1452. Young N, Thomas M. Meningitis in adults: diagnosis and management. Intern Med J. 2018;48:1294-1307.
1453. Marrie TJ, Tyrrell GJ, Majumdar SR, et al. Risk factors for pneumococcal endocarditis. Eur J Clin Microbiol Infect Dis. 2018;37:277-280.
1454. Wunderink RG, Self WH, Anderson EJ, et al. Pneumococcal community-acquired pneumonia detected by serotype-specific urinary antigen detection assays. Clin Infect Dis. 2018;66:1504-1510.
1455. Froes F, Pereira JG, Povoa P. Outpatient management of community-acquired pneumonia. Curr Opin Infect Dis. 2018;31:170-176.
1456. Seok H, Kang CI, Huh K, et al. Risk factors for community-onset pneumonia caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Microb Drug Resist. 2018;24:1412-1416.
1457. Wunderink RG, Yin Y. Antibiotic resistance in community-acquired pneumonia pathogens. Semin Respir Crit Care Med. 2016;37:829-838.
1458. Cheng AC, Jenney AWI. Macrolide resistance in pneumococci — is it relevant? Bio Med Central. 2016;8:1-3.
1459. Cilloniz C, Albert RK, Liapikou A, et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med. 2015;191:1265.
1460. Farrell DJ, Flamm RK, Sader HS, et al. Results from the solithromycin international surveillance program (2014). Antimicrob Agents Chemother. 2016;60:3662-3668.
1461. Bordon JM, Fernandez-Botran R, Wiemken TL. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response. Infection. 2015;43:729-738.
1462. Chalmers J. Corticosteroids for community-acquired pneumonia: a critical view of the evidence. Eur Respir J. 2016;48:984.
1463. van Driel ML, De Sutter AI, Habraken H, et al. Different antibiotic treatments for group A strepto­coccal pharyngitiS. Cochrane Database Syst Rev. 2016;9:CD004406.
1464. Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012;1:CD003261.
1465. Aboltins CA, Hutchinson AF, Sinnappu RN, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. J Antimicrob Chemother. 2015;70: 581-586.
1466. Pallin DJ, Binder WD, Allen MB, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis. 2013;56:1754-1762.
1467. Miller LG, Daum RS, Creech CB, et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med. 2015;372:1093-1103.
1468. Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016;374:823-832.
1469. Thomas KS, Crook AM, Nunn AJ, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013;368:1695-1703.
1470. Madhi SA, Cutland CL, Jose L, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016;16:923-934.
1471. Maness DL, Martin M, Mitchell G. Poststreptococcal illness: recognition and management. Am Fam Physician. 2018;97:517-522.
1472. Kachroo P, Eraso JM, Beres SB, et al. Integrated analysis of population genomics, transcriptomics and virulence provides novel insights into Streptococcus pyogenes pathogenesis. Nat Genet. 2019;51:548-559.
1473. Valderrama JA, Nizet V. Group A Streptococcus encounters with host macrophages. Future Microbiol. 2018;13:119-134.
1474. Harris AM, Hicks LA, Qaseem A, et al. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164:425-434.
1475. Rao A, Berg B, Quezada T, et al. Diagnosis and antibiotic treatment of group a streptococcal phar­yngitis in children in a primary care setting: impact of point-of-care polymerase chain reaction. BMC Pediatr. 2019;19:1-8.
1476. Lamagni T, Guy R, Chand M, et al. Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study. Lancet Infect Dis. 2018;18:180-187.
1477. Liu Y, Chan TC, Yap LW, et al. Resurgence of scarlet fever in China: a 13-year population-based surveillance study. Lancet Infect Dis. 2018;18:903-912.
1478. Walker MJ, Brouwer S, Forde BM, et al. Detection of epidemic scarlet fever group A Streptococcus in Australia. Clin Infect Dis. 2019. [Epub ahead of print.]
1479. Stevens DL, Bryant AE. Necrotizing soft-tissue infections. N Engl J Med. 2017;377:2253-2265.
1480. DeMuri GP, Sterkel AK, Kubica PA, et al. Macrolide and clindamycin resistance in group A Streptococci isolated from children with pharyngitis. Pediatr Infect Dis J. 2017;36:342-344.
1481. Gottlieb M, Long B, Koyfman A. The evaluation and management of toxic shock syndrome in the emergency department: a review of the literature. J Emerg Med. 2018;54:807-814.
1482. Andreoni F, Z?rcher C, Tarnutzer A, et al. Клиндамицин влияет на факторы вирулентности Streptococcus группы A и улучшает клинический исход. J Infect Dis. 2017;215:269-277.
1483. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 2017;377:713-722.
1484. Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet. 2018;392:161-174.
1485. Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131:1806-1818.
1486. Beaton A, Aliku T, Dewyer A, et al. Latent rheumatic heart disease: identifying the children at highest risk of unfavorable outcome. Circulation. 2017;136:2233-2244.
1487. Woldu B, Bloomfield GS. Rheumatic heart disease in the twenty-first century. Curr Cardiol Rep. 2016;18:1-11.
1488. Orlovska S, Vestergaard CH, Bech BH, et al. Association of streptococcal throat infection with mental disorders: testing key aspects of the PANDAS hypothesis in a nationwide study. JAMA Psychiatry. 2017;74:740-746.
1489. Francois Watkins LK, McGee L, Schrag SJ, et al. Epidemiology of invasive group B streptococcal infections among nonpregnant adults in the United States, 2008-2016. JAMA Intern Med. 2019;179:479-488.
1490. van Samkar A, Brouwer MC, Schultsz C, et al. Streptococcus suis meningitis: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2015;9:1-10.
1491. Corredoira J, Grau I, Garcia-Rodriguez JF, et al. Colorectal neoplasm in cases of Clostridium septicum and Streptococcus gallolyticus subsp. gallolyticus bacteraemia. Eur J Intern Med. 2017;41:68-73.
1492. Chuang YC, Wang JT, Lin HY, et al. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect DiS. 2014;14:1-10
1493. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415-424
1494. Climo MW, Yokoe DS, Warren DK, et al. Effect of daily bathing with chlorhexidine on hospital acquired infection. N Engl J Med. 2013;368:533-542
1495. Noto MJ, Domenico HJ, Byrne DW, et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA. 2015;313:369-378
1496. Lowe CF, Lloyd-Smith E, Sidhu B, et al. Reduction in hospital-associated methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enteroccus with daily chlorhexidine gluconate bathing for medical inpatients. Am J Infect Control. 2017;45:255-259
1497. Harris AD, Pineles L, Belton B, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA. 2013;310:1571-1580
1498. van Harten RM, Willems RJL, Martin NI, et al. Multidrug-resistant enterococcal infections: new compounds, novel antimicrobial therapies? Trends Microbiol. 2017;25:467-479
1499. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37:1-14
1500. Goh HMS, Yong MHA, Chong KKL, et al. Model systems for the study of Enterococcal colonization and infection. Virulence. 2017;19:1-38
1501. Pericas JM, Corredoira J, Moreno A, et al. Relationship between Enterococcus faecalis infective endocarditis and colorectal neoplasm: preliminary results from a cohort of 154 patients. Rev Esp Cardiol (Engl Ed). 2017;70:451-458
1502. Yim J, Smith JR, Rybak MJ. Role of combination antimicrobial therapy for vancomycin-resistant Enterococcus faecium infections: review of the current evidence. Pharmacatherapy. 2017;37:579-592
1503. Patel R, Gallagher JC. Vancomycin-resistant enterococcal bacteremia pharmacotherapy. Ann Pharmacother. 2015;49:69-85
1504. Zasowski EJ, Claeys KC, Lagnf AM, et al. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis. 2016;62:1242-1250
1505. Chuang YC, Lin HY, Chen PY, et al. Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia. Clin Infect Dis. 2017;64:1026-1034
1506. Beganovic M, Luther MK, Rice LB, et al. A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis. Clin Infect Dis. 2018;67:303-309
1507. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132:1435-1486
1508. Eiset AH, Wejse C. Review of infectious diseases in refugees and asylum seekers — current status and going forward. Public Health Rev. 2017;38:1-16.
1509. Scheifer C, Rolland-Debord C, Badell E, et aL. Re-emergence of Corynebacterium diphtheriae. Med Mal Infect. 2018. [Epub ahead of print.]
1510. Centers for Disease Control and PreventioN. Notifiable diseases and mortality tables. MMWR. 2017;66: https://www.cdc.gov/mmwr/volumes/66/wr/mm6611md.htm?s_cid=mm6611md_w. Accessed April 1, 2019.
1511. Both L, Collins S, de Zoysa A, et aL. Molecular and epidemiological review of toxigenic diphtheria infections in England between 2007 and 2013. J Clin MicrobioL. 2015;53:567-572.
1512. Swart EM, van Gageldonk PG, de Melker HE, et aL. Long-term protection against diphtheria in the Netherlands after 50 years of vaccination: results from a seroepidemiological study. PLoS ONE. 2016;11:1-15.
1513. Kantsone I, Lucenko I, Perevoscikovs J. More than 20 years after re-emerging in the 1990s, diphtheria remains a public health problem in Latvia. Euro SurveilL. 2016;21:30414.
1514. Santos LS, Sant’anna LO, Ramos JN, et aL. Diphtheria outbreak in Maranh?o, Brazil: microbiological, clinical and epidemiological aspects. Epidemiol Infect. 2015;143:791-798.
1515. Hughes GJ, Mikhail AF, Husada D, et aL. Seroprevalence and determinants of immunity to diphtheria for children living in two districts of contrasting incidence during an outbreak in East Java, Indonesia. Pediatr Infect Dis J. 2015;34:1152-1156.
1516. Sein C, Tiwari T, Macneil A, et aL. Diphtheria outbreak in Lao People’s Democratic Republic, 2012-2013 Vaccine. 2016;34:4321-4326.
1517. Pan American Health Organization/World Health OrganizatioN. Epidemiological Alert: Diphtheria 16 December 2016. Epidemiological Alert. December 16, 2016. http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=37504&lang=eN. Accessed April 1, 2019.
1518. Lodeiro-Colatosti A, Reisel U, Holzmann T, et aL. Diphtheria outbreak in Amerindian communities, Wonken, Venezuela, 2016–2017. Emerg Infect DiS. 2018;24:1340-1344.
1519. Blumberg LH, Prieto MA, Diaz JV, et aL. The preventable tragedy of diphtheria in the 21st century. J Infect Dis. 2018;71:122-123.
1520. Sangal V, Hoskisson PA. Evolution, epidemiology and diversity of Corynebacterium diphtheriae: new perspectives on an old foe. Infect Genet EvoL. 2016;43:364-370.
1521. Dash N, Verma S, Jayashree M, et aL. Clinico-epidemiological profile and predictors of outcome in children with diphtheria: a study from northern India. Trop Doct. 2019. [Epub ahead of print.]
1522. Berkowitz AL. Tetanus, botulism, and diphtheria. Continuum (Minneap Minn). 2018;24:1459-1488.
1523. Moore LS, Leslie A, Meltzer M, et aL. Corynebacterium ulcerans cutaneous diphtheria. Lancet Infect Dis. 2015;15:1100-1107.
1524. World Health OrganizatioN. Meeting of the Strategic Advisory Group of Experts on immunization, April 2017 — conclusions and recommendations. Wkly Epi Record. 2017;92:301-320.
1525. Broker M. Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates. Hum Vaccin Immunother. 2016;12:664-667.
1526. Poojary I, Kurian A, Jayalekshmi VA, et aL. Corynebacterium species causing breast abscesses among patients attending a tertiary care hospital in Chennai, South India. Infect Dis. 2017;49:528-531.
1527. Hong HL, Koh HI, Lee AJ. Native valve endocarditis due to Corynebacterium striatum confirmed by 16S ribosomal RNA sequencing: a case report and literature review. Infect Chemother. 2016;48:239-245.
1528. Radoshevich L, Cossart P. Listeria monocytogenes: towards a complete picture of its physiology and pathogenesis. Nat Rev Microbiol. 2018;16:32-46.
1529. Lomanco S, Nucera D, Filipellp V. The evolution and epidemiology of Listeria monocytogenes in Europe and the United States. Infect Genet Evol. 2015;35:172-183.
1530. Pouillot R, Klontz K, Chen Y, et aL. Infectious dose of Listeria monocytogenes in outbreak linked to ice cream, United States, 2015. Emerg Infect Dis. 2016;22:2113-2119.
1531. Churchill KJ, Sargeant JM, Farber JM, et aL. Prevalence of Listeria monocytogenes in select ready-to-eat foods—deli meat, soft cheese, and packaged salad: a systematic review and meta-analysis. J Food Prot. 2019;82:344-357.
1532. Salama PJ, Embarek PKB, Bagaria J, et aL. Learning from listeria: safer food for all. Lancet. 2018;391:2305-2306.
1533. Jensen AK, Simonsen J, Ethelberg S. Use of proton pump inhibitors and the risk of listeriosis: a nationwide registry-based case-control study. Clin Infect Dis. 2017;64:845-851.
1534. Jacob J, Lorber B. Listeriosis after transient infectious or mechanical disturbance of the gastrointestinal tract. Infect Dis Clin Pract. 2015;23:13-15.
1535. Fattouh R, Kwon H, Czuczman MA, et aL. The diaphanous-related formins promote protrusion formation and cell-to-cell spread of Listeria monocytogenes. J Infect Dis. 2015;211:1185-1195.
1536. Qiu Z, Khalirallah C, Sheridan BS. Listeria monocytogenes: a model pathogen continues to refine our knowledge of the CD8 T cell response. Pathogens. 2018;7:1-22.
1537. Angelo KM, Jackson KA, Wong KK, et aL. Assessment of the incubation period for invasive listeriosis. Clin Infect Dis. 2016;63:1487-1489.
1538. Best R, Bhagirath KM, Pearce S, et aL. Listeria monocytogenes and prosthetic valve endocarditis. Infect Dis Clin Pract. 2017;25:9-12.
1539. Charlier C, Perrodeau E, Leclercq A, et aL. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infect Dis. 2017;17:510-519.
1540. Bush LM, Alrifai A, Perez MT. Listeria monocytogenes prosthetic joint infections a review a propos a case report. Infect Dis Clin Pract. 2015;23:66-69.
1541. Garrido-Maestu A, Tom?s Forn?s D, Prado Rodr?guez M. The use of multiplex real-time PCR the simultaneous detection of foodborne bacterial pathogens. Methods Mol BioL. 2019;1918:35-45.
1542. Jackson BR, Tarr C, Strain E, et aL. Implementation of nationwide real-time whole genome sequencing to enhance listeriosis outbreak detection and investigation. Clin Infect Dis. 2016;63:380-386.
1543. Gray JA, Chandry PS, Kaur M, et aL. Novel biocontrol methods for Listeria monocytogenes biofilms in food production facilities. Front Microbiol. 2018;9:1-12.
1544. Arora G, Misra R, Sajid A. Model systems for pulmonary infectious diseases: paradigms of anthrax and tuberculosis. Curr Top Med Chem. 2017;17:2077-2099.
1545. Zasada AA. Injectional anthrax in human: a new face of the old disease. Adv Clin Exp Med. 2018;27:553-558.
1546. Jouvion G, Corre JP, Khun H, et aL. Physical sequestration of Bacillus anthracis in the pulmonary capillaries in terminal infection. J Infect Dis. 2016;214:281-287.
1547. Pilo P, Frey J. Pathogenicity, population genetics and dissemination of Bacillus anthracis. Infect Genet Evol. 2018;64:115-125.
1548. Katharios-Lanwermeyer S, Holty JE, Person M, et aL. Identifying meningitis during an anthrax mass casualty incident: systematic review of systemic anthrax since 1880. Clin Infect Dis. 2016;62:1537-1545.
1549. Hupert N, Person M, Hanfling D, et aL. Development and performance of a checklist for initial triage after an anthrax mass exposure event. Ann Intern Med. 2019. [Epub ahead of print.]
1550. Treatment: anthrax. CDC.
1551. Vietri NJ. Does anthrax antitoxin therapy have a role in the treatment of inhalation anthrax? Curr Opin Infect Dis. 2018;31:257-262.
1552. Migone TS, Bolmer S, Zhong J, et aL. Added benefit of raxibacumab to antibiotic treatment of inha­lational anthrax. Antimicrob Agents Chemother. 2015;59:1145-1151.
1553. Hou AW, Morrill AM. Obiltoxaximab: adding to the treatment arsenal for Bacillus anthracis infection. Ann Pharmacother. 2017;51:908-913.
1554. Boyer A, Gallegos-Candela M, Quinn C, et aL. High sensitivity MALDI-TOF MS quantitation of anthrax lethal toxin for diagnostics and evaluation of medical countermeasures. Anal Bioanal Chem. 2015;407:2847-2858.
1555. Rubinson L, Corey A, Hanfling D. Estimation of time period for effective human inhalational anthrax treatment including antitoxin therapy. PLoS Curr. 2017;9:1-26.
1556. Tan EM, Marcelin JR, Adeel N, et aL. Erysipelothrix rhusiopathiae bloodstream infection—a 22-year experience at Mayo Clinic, Minnesota. Zoonoses Public Health. 2017;64:e65-e72.
1557. Hofseth K, Dalen H, Kibsgaard L, et aL. Infectious tenosynovitis with bloodstream infection caused by Erysipelothrix rhusiopathiae, a case report on an occupational pathogen. BMC Infectious Diseases. Case Rep. 2017;17:12-16.
1558. Asimaka E, Nolte O, Overesch G, et aL. A dangerous hobby? Erysipelothrix rhusiopathiae bacteremia most probably acquired from freshwater aquarium fish handling. Infection. Case Rep. 2017;45:557-562.
1559. Vasagar B, Jain V, Germinario A, et aL. Approach to aquatic skin infections. Prim Care. 2018;45:555-566.
1560. Zhu W, Cai C, Huang J, et aL. Characterization of pathogenic roles of two Erysiplothrix rhusiopathiae surface proteins. Microb Pathog. 2018;114:166-168.
1561. Ogawa Y, Shiraiwa K, Nishikawa S, et aL. Identification of the chromosomal region essential for serovar-specific antigen and virulence of serovar 1 and 2 strains of Erysipolothrix rhusiopathiae. Infect Immun. 2018;86:1-11.
1562. Hua P, Liu J, Tao J, et aL. Erysipelothrix rhusiopathiae-induced aortic valve endocarditis: case report and literature review. Int J Clin Exp Med. 2015;8:730-736.
1563. Principe L, Bracco S, Mauri C, et aL. Erysipelothrix rhusiopathiae bacteremia without endocarditis: rapid identification from positive blood culture by MALDI-TOF mass spectrometry. A case report and literature review. Infect Dis Rep. 2016;8:1-4.
1564. Alawdah LS, Campbell JN, Pollock N, et aL. Erysipelothrix rhusiopathiae suppurative arthritis in a 12-year-old boy after an unusual fresh water exposure. Pediatr Infect Dis J. 2017;36:431-433.
1565. Groeschel M, Forde T, Turvey S, et aL. An unusual case of Erysipelothrix rhusiopathiae prosthetic joint infection from the Canadian Arctic: whole genome sequencing unable to identify a zoonotic source. BMC Infect Dis. 2019;19:1-7.
1566. Volard B, Mignot L, Piednoir E, et aL. Systemic Erysipelothrix rhusiopathiae infection not associated with endocarditis highlighting bacteriological diagnosis difficulties: case report and literature review. Ann Biol Clin (Paris). 2016;74:306-312.
1567. Micaelo M, Rasmy P, Amara M, et aL. Erysipelothrix rhusiopathiae bacteremia: a challenging diagnosis! Ann Biol Clin (Paris). 2016;74:613-615.
1568. Xu CW, Zhang AY, Yang CM, et aL. First report of macrolide resistance gene erm(T) harbored by a novel small plasmid from Erysipelothrix rhusiopathiae. Antimicrob Agent Chemother. 2015;59:2462-2465.
1569. Johnson S, Louie TJ, Gerding DN, et aL. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345-354.
1570. Cornely OA, Nathwani D, Ivanescu C, et aL. Clinical efficacy of fidaxomicin compared with vanco­mycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69:2892-2900.
1571. Wilcox MH, Gerding DN, Poxton IR, et aL. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376:305-317.
1572. van Nood E, Vrieze A, Nieuwdorp M, et aL. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415.
1573. Hui W, Li T, Liu W, et aL. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: an updated randomized controlled trial meta-analysis. PLoS ONE. 2019;14:1-14.
1574. Lee CH, Steiner T, Petrof EO, et aL. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315:142-149.
1575. Kelly CR, Khoruts A, Staley C, et aL. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized triaL. Ann Intern Med. 2016;165:609-616.
1576. Kao D, Roach B, Silva M, et aL. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318:1985-1993.
1577. Gerding DN, Meyer T, Lee C, et aL. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313:1719-1727.
1578. Curry SR. Clostridium difficile. Clin Lab Med. 2017;37:341-369.
1579. Lessa FC, Mu Y, Bamberg WM, et aL. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825-834.
1580. Donskey CJ. Clostridium difficile in older adults. Infect Dis Clin North Am. 2017;8:273-297.
1581. Jullian-Desayes I, Landelle C, Mallaret MR, et al. Clostridium difficile contamination of healthcare workers’ hands and its potential contribution to the spread of infection: review of the literature. Am J Infect ControL. 2017;45:51-58.
1582. Martinez-Melendez A, Camacho-Ortiz A, Morfin-Ofero R, et aL. Current knowledge on the labora­tory diagnosis of Clostridium difficile infection. World J Gastroenterol. 2017;23:1552-1567.
1583. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539-1548.
1584. Brown KA, Daneman N, Jones M, et aL. The drivers of acute and long-term care Clostridium difficile infection rates: a retrospective multilevel cohort study of 251 facilities. Clin Infect Dis. 2017;65:1282-1288.
1585. Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis. 2015;60:S122-S128.
1586. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection: 2017 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2018;66:987-994.
1587. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic. review. JAMA. 2015;313:398-408.
1588. Alonso CD, Mahoney MV. Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile. Infect Drug Resist. 2019;12:1-9.
1589. Chong E, Winikoff B, Charles D, et aL. Vaginal and rectal Clostridium sordellii and Clostridium per­fringens presence among women in the United Statee. Obstet GynecoL. 2016;127:360-368.
1590. Srivastava I, Aldape MJ, Bryant AE, et aL. Spontaneous C. septicum gas gangrene: a literature review. Anaerobe. 2017;48:165-171.
1591. Centers for Disease Control and Prevention (CDC). Notes from the field: botulism outbreak from drinking prison-made illicit alcohol in a federal correctional Facility — Mississippi, June 2016. MMWR Morb Mortal Wkly Rep. 2017;65:1491-1492.
1592. Qureshi IA, Qureshi MA, Rauf Afzal M, et aL. Black tar heroin skin popping as a cause of wound botulism. Neurocrit Care. 2017;27:415-419.
1593. Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus. Lancet. 2015;385:362-370.
1594. Burke M, Rowe T. Vaccination in older adults. Clin Geriatr Med. 2018;34:131-143.
1595. Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev. 2014;5:CD001181
1596. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI) Clin Infect Dis. 2015;60:1462-1471
1597. Vena A, Munoz P, Alcala L, et al. Are incidence and epidemiology of anaerobic bacteremia really changing? Eur J Clin Microbiol Infect Dis. 2015;34:1621-1629
1598. Kwong TNY, Wang X, Nakatsu G, et aL. Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer. Gastroenterology. 2018;155:383-390
1599. Brook I. Microbiology and treatment of brain abscess. J Clin Neurosci. 2017;38:8-12
1600. Lee AS, Ryu JH. Aspiration pneumonia and related syndromeS. Mayo Clin Proc. 2018;93:752-762
1601. Brook I. Spectrum and treatment of anaerobic infections. J Infect Chemother. 2016;22:1-13
1602. Byun JH, Kim M, Lee Y, et al. Antimicrobial susceptibility patterns of anaerobic bacterial clinical isolates from 2014 to 2016, including recently named or renamed species. Ann Lab Med. 2019;39:190-199
1603. Hastey CJ, Boyd H, Schuetz AN, et aL. Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology. Anaerobe. 2016;42:27-30
1604. Soki J, Hedberg M, Patrick S, et aL. Emergence and evolution of an international cluster of MDR Bacteroides fragilis isolates. J Antimicrob Chemother. 2016;71:2441-2448
1605. Brouwer MC, McIntyre P, Prasad K, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;9:CD004405.
1606. Coldiron ME, Assao B, Page AL, et al. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: a 3-arm, open-label, cluster-randomized trial. PLoS Med. 2018;15:1-19.
1607. Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377:2349-2362.
1608. Borrow R, Alarcon P, Carlos J, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313-328.
1609. Gianchecchi E, Torelli A, Piccini G, et al. Neisseria meningitidis infection: who, when and where? Expert Rev Anti Infect Ther. 2015;13:1249-1263.
1610. Peterson ME, Li Y, Bita A, et aL. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9:1-25.
1611. Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017;35:2034-2041.
1612. Mbaeyi SA, Blain A, Whaley MJ, et al. Epidemiology of meningococcal disease outbreaks in the United States, 2009-2013. Clin Infect Dis. 2019;68:580-585.
1613. Yezli S, Gautret P, Assiri AM, et al. Prevention of meningococcal disease at mass gatherings: lessons from the Hajj and Umrah. Vaccine. 2018;36:4603-4609.
1614. Parikh SR, Campbell H, Gray SJ, et al. Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010-2015. Vaccine. 2018;36:3876-3881.
1615. Cohen R, Raymond J, Hees L, et al. Bacterial meningitis antibiotic treatment. Arch Pediatr. 2017;24:S42-S45.
1616. McGill F, Heyderman RS, Michael BD, et al. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. J Infect. 2016;72:405-438.
1617. McNamara LA, MacNeil JR, Cohn AC, et al. Mass chemoprophylaxis for control of outbreaks of meningococcal disease. Lancet Infect Dis. 2018;18:e272-e281.
1618. CDC Meningococcal ACIP Vaccine Recommendations; 2017.
1619. McCarthy PC, Sharyan A, Sheikhi Moghaddam L. Meningococcal vaccines: current status and emerging strategies. Vaccines (Basel). 2018;6:1-13.
1620. Basta NE, Mahmoud AA, Wolfson J, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med. 2016;375:220-228.
1621. Feavers IM, Maiden MCJ. Recent progress in the prevention of serogroup B meningococcal disease. Clin Vaccine Immunol. 2017;24:1-13.
1622. Creighton S. Gonorrhoea. Clin Evid (Online). 2014;2:1-12.
1623. Kirkcaldy RD, Weinstock HS, Moore PC, et aL. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis. 2014;59:1083-1091.
1624. Taylor SN, Marrazzo J, Batteiger BE, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med. 2018;379:1835-1845.
1625. Ferreira A, Young T, Mathews C, et aL. Strategies for partner notification for sexually transmitted infections, including HIV. Cochrane Database Syst Rev. 2013;10:CD002843.
1626. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2017. Atlanta: U.S. Department of Health and Human Services; 2018. https://www.cdc.gov/nchhstp/newsroom/2018/2017-STD-surveillance-report.html Дата просмотра: 7 мая 2019 г.
1627. Quillin SJ, Seifert HS. Neisseria gonorrhoeae host adaptation and pathogenesis. Nat Rev Microbiol. 2018;16:226-240.
1628. Thomas JC, Seby S, Abrams AJ, et aL. Evidence of recent genomic evolution in gonococcal strains with decreased susceptibility to cephalosporins or azithromycin in the United States, 2014-2016. J Infect Dis. 2019. [Epub ahead of print.]
1629. Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nat Rev Urol. 2017;14:139-152.
1630. Fifer H, Cole M, Hughes G, et aL. Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoae in England: an observational study. Lancet Infect Dis. 2018;18:573-581.
1631. Belga S, Gratrix J, Smyczek P, et aL. Gonococcal conjunctivitis in adults: case report and retrospective review of cases in Alberta, Canada, 2000-2016. Sex Transm Dis. 2019;46:47-51.
1632. Ross J, Guaschino S, Cusini M, Jensen J. 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018;29:108-114.
1633. Reekie J, Donovan B, Guy R, et aL. Risk of ectopic pregnancy and tubal infertility following gonorrhoea and chlamydia infections. Clin Infect Dis. 2019. [Epub ahead of print.]
1634. Chan PA, Robinette A, Montgomery M, et aL. Extragenital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol. 2016;2016:1-17.
1635. Bamberger DM, Graham G, Dennis L, et aL. Extragenital gonorrhea and chlamydia among men and women according to type of sexual exposure. Sex Transm Dis. 2019. [Epub ahead of print.]
1636. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2016: Gonococcal Isolate Surveillance Project (GISP) Supplement and Profiles. February 2018. https://www.cdc.gov/std/stats16/gisp2016/docs/gisp_2016_supplement_final_2018.pdf. Дата просмотра: 7 мая 2019 г.
1637. Hilbert SM, Reno HEL. Management of patients with sexually transmitted infections in the emergency department. Emerg Med Clin North Am. 2018;36:767-776.
1638. Kidd S, Workowski KA. Management of gonorrhea in adolescents and adults in the United States. Clin Infect Dis. 2015;61(suppl 8):S785-S801.
1639. Buono SA, Watson TD, Borenstein LA, et aL. Stemming the tide of drug-resistant Neisseria gonorrhoeae: the need for an individualized approach to treatment. J Antimicrob Chemother. 2015;70:374-381.
1640. Hook EW, 3rd, Kirkcaldy RD. A brief history of evolving diagnostics and therapy for gonorrhea: lessons learned. Clin Infect Dis. 2018;67:1294-1299.
1641. Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med. 2015;372:2039-2048.
1642. Soeters HM, Blain A, Pondo T, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease – United States, 2009-2015. Clin Infect Dis. 2018;67:881-889.
1643. Tsang RS, Shuel M, Whyte K, et al. Antibiotic susceptibility and molecular analysis of invasive Haemophilus influenzae in Canada, 2007 to 2014. J Antimicrob Chemother. 2017;72:1314-1319.
1644. MacLennan CA, Richter A, Hodson J, et al. Brief report: immunization of HIV-infected adults in the UK with Haemophilus influenza b/meningococcal C glycoconjugate and pneumococcal polysac­charide vaccines. J Acquir Immune Defic Syndr. 2016;73:287-293.
1645. Whittaker R, Economopoulou A, Dias JG, et al. Epidemiology of invasive Haemophilus influenzae disease, Europe, 2007-2014. Emerg Infect Dis. 2017;23:396-404.
1646. Staples M, Graham RM, Jennison AV. Characterization of invasive clinical Haemophilus influenzae isolates in Queensland, Australia using whole-genome sequencing. Epidemiol Infect. 2017;145:1727-1736.
1647. Tuyama M, Corea-Antonio J, Schlackman J, et al. Invasive Haemophilus influenzae disease in the vaccine era in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz. 2017;112:196-202.
1648. Wang S, Tafalla M, Hanssens L, et al. A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Rev Vaccines. 2017;16:1095-1105.
1649. Duell BL, Su Y-C, Riesbeck K. Host-pathogen interactions of nontypeable Haemophilus influenza: from commensal to pathogen. FEBS Lett. 2016;590:3840-3853.
1650. Zhao L, Xia J, Li T, et al. Shp2 deficiency impairs the inflammatory response against Haemophilus influenzae by regulating macrophage polarization. J Infect Dis. 2016;214:625-633.
1651. Baird SM, Marsh PA, Padiglione A, et al. Review of epiglottitis in the post Haemophilus influenzae type-b vaccine era. ANZ J Surg. 2018;88:1135-1140.
1652. Deza G, Martin-Ezquerra G, Gomez J, et al. Isolation of Haemophilus influenzae and Haemophilus parainfluenzae in urethral exudates from men with acute urethritis: a descriptive study of 52 caseS. Sex Transm Infect. 2016;92:29-31.
1653. Tanaka E, Hara N, Wajima T, et al. Emergence of Haemophilus influenzae with low susceptibility to quinolones and persistence in tosufloxacin treatment. J Glob Antimicrob Resist. 2019. [Epub ahead of print.]
1654. Blakeway LV, Tan A, Peak IRA. Seib KL. Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development. Microbiology. 2017;163:1371-1384.
1655. Gonzolez-Beiras C, Kapa A, Vall-Mayans M, et al. Single-dose azithromycin for the treatment of Haemophilus ducreyi skin ulcers in Papua New Guinea. Clin Infect Dis. 2017;65:2085-2090.
1656. Gonzalez-Beiras C, Marks M, Chen CY, et al. Epidemiology of Haemophilus ducreyi infections. Emerg Infect Dis. 2016;22:1-8.
1657. Noguera-Julian M, Gonzalez-Beiras C, Parera M, et aL. Etiological characterization of the cutaneous ulcer syndrome in Papua New Guinea using shotgun metagenomics. Clin Infect Dis. 2019;68:482-489.
1658. Gangaiah D, Spinola SM. Haemophilus ducreyi cutaneous ulcer strains diverged from both Class I and Class II genital ulcer strains: implications for epidemiological studies. PLoS Negl Trop Dis. 2016;10:1-8.
1659. van Hattem JM, Langeveld TJC, Bruisten SM, et aL. Haemophilus ducreyi cutaneous ulcer contracted at Seram Island, Indonesia, presented in the Netherlands. PLoS Negl Trop Dis. 2018;12:1-9.
1660. Singer M, Li W, Morre SA, et al. Host polymorphisms in TLR9 and IL10 are associated with the outcomes of experimental Haemophilus ducreyi infection in human volunteers. J Infect Dis. 2016;214:489-495.
1661. Houinei W, Godornes C, Kapa A, et al. Haemophilus ducreyi DNA is detectable on the skin of asymptomatic children, flies and fomites in villages of Papua New Guinea. PLoS Negl Trop Dis. 2017;11:1-10.
1662. Centers for Disease Control and PreventioN. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.
1663. Lautenschlager S, Kemp M, Christensen JJ, et al. 2017 European guideline for the management of chancroid. Int J STD AIDS. 2017;28:324-329.
1664. Leibovici-Weissman Y, Neuberger A, Bitterman R, et al. Antimicrobial drugs for treating cholera. Cochrane Database Syst Rev. 2014;6:CD008625.
1665. Bhattacharya MK, Kanungo S, Ramamurthy T, et aL. Comparison between single dose azithromycin and six doses, 3 day norfloxacin for treatment of cholera in adult. Int J Biomed Sci. 2014;10:248-251.
1666. Lopez AL, Deen J, Azman AS, et al. Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review and metaanalysis. Clin Infect Dis. 2018;66:1960-1971.
1667. Desai SN, Akalu Z, Teshome S, et al. A randomized, placebo-controlled trial evaluating safety and immunogenicity of the killed, bivalent, whole-cell oral cholera vaccine in Ethiopia. Am J Trop Med Hyg. 2015;93:527-533.
1668. Bi Q, Ferreras E, Pezzoli L, et al. Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:1080-1088.
1669. Qadri F, Wierzba TF, Ali M, et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Ban­gladesh. N Engl J Med. 2016;374:1723-1732.
1670. Weill FX, Domman D, Njamkepo E, et al. Genomic history of the seventh pandemic of cholera in Africa. Science. 2017;358:785-789.
1671. Richterman A, Sainvilien DR, Eberly L, et al. Individual and household risk factors for symptomatic cholera infection: a systematic review and meta-analysis. J Infect Dis. 2018;218:S154-S164.
1672. Anyamba A, Chretien JP, Britch SC, et al. Global disease outbreaks associated with the 2015-2016 El Nino event. Sci Rep. 2019;9:1-14.
1673. Loharikar A, Newton AE, Stroika S, et al. Cholera in the United States, 2001-2011: a reflection of patterns of global epidemiology and travel. Epidemiol Infect. 2015;143:695-703.
1674. Federspiel F, Ali M. The cholera outbreak in Yemen: lessons learned and way forward. BMC Public Health. 2018;18:1-8.
1675. Cholera, 2016. Wkly Epidemiol Rec. 2017;92:521-530.
1676. Clemens JD, Nair GB, Ahmed T, et al. Cholera. Lancet. 2017;390:1539-1549.
1677. Azman AS, Parker LA, Rumunu J, et al. Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. Lancet Glob Health. 2016;4:e856-e863.
1678. Wong KK, Burdette E, Mahon BE, et al. Recommendations of the Advisory Committee on Immunization Practices for use of cholera vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:482-485.
1679. Luquero FJ, Rondy M, Boncy J, et al. Mortality rates during cholera epidemic, Haiti, 2010-2011. Emerg Infect Dis. 2016;22:410-416.
1680. Djouma FN, Ateudjieu J, Ram M, et al. Factors associated with fatal outcomes following cholera-like syndrome in far north region of Cameroon: a community-based survey. Am J Trop Med Hyg. 2016;95:1287-1291.
1681. Baker-Austin C, Oliver JD, Alam M, et al. Vibrio spP. infections. Nat Rev Dis Primers. 2018;4:1-19.
1682. Centers for Disease Control and PreventioN. Vibrio species causing vibriosis. Questions and answers. https://www.cdc.gov/vibrio/faq.htmL. Accessed April 23, 2019.
1683. Fitzgerald C. Campylobacter. Clin Lab Med. 2015;35:289-298.
1684. Platts-Mills JA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health. 2015;3:e564-e575.
1685. Marder EP, Cieslak PR, Cronquist AB, et al. Incidence and trends of infections with pathogens transmitted commonly through food and the effect of use of culture-independent diagnostic tests on surveillance — Foodborne Diseases Active Surveillance Network, 10 U.S. cities, 2013-2016. MMWR Morb Mortal Wkly Rep. 2017;66:397-403.
1686. Djennad A, Lo Iacono G, Sarran C, et al. Seasonality and the effects of weather on Campylobacter infections. BMC Infect Dis. 2019;19:1-10.
1687. Jiang ZD, DuPont HL. Etiology of travellers’ diarrhea. J Travel Med. 2017;24 (suppl_1):S13-S16.
1688. Moffatt CR, Glass K, Stafford R, et al. The campylobacteriosis conundrum — examining the incidence of infection with campylobacter spp. in Australia, 1998-2013. Epidemiol Infect. 2017;145:839-847.
1689. Awofisayo-Okuyelu A, Hall I, Adak G, et al. A systematic review and meta-analysis on the incubation period of Campylobacteriosis. Epidemiol Infect. 2017;145:2241-2253.
1690. Rodriguez Y, Rojas M, Pacheco Y, et al. Guillain-Barr? syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol. 2018;15:547-562.
1691. Ricke SC, Feye KM, Chaney WE, et al. Developments in rapid detection methods for the detection of foodborne Campylobacter in the United States. Front Microbiol. 2018;9:1-19.
1692. Shen Z, Wang Y, Zhang Q, et al. Antimicrobial resistance in Campylobacter spp. Microbiol Spectr. 2018;6:1-13.
1693. van Samkar A, Brouwer MC, van der Ende A, et al. Campylobacter fetus meningitis in adults: report of 2 cases and review of the literature. Medicine (Baltimore). 2016;95:1-5.
1694. Gregorio GV, Dans LF, Silvestre MA. Early versus delayed refeeding for children with acute diarrhoea. Cochrane Database Syst Rev. 2011;7:CD007296.
1695. Lazzerini M, Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2013;1:CD005436.
1696. Francavilla R, Lionetti E, Castellaneta S, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhea — a double-blind study. Aliment Pharmacol Ther. 2012;36:363-369.
1697. Hu Y, Ren J, Zhan M, et al. Efficacy of rifaximin in prevention of travelers’ diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Travel Med. 2012;19:352-356.
1698. Riddle MS, Connor P, Fraser J, et al. Trial evaluating ambulatory therapy of travelers’ diarrhea (TrEAT TD) study: a randomized controlled trial comparing 3 single-dose antibiotic regimens with loperamide. Clin Infect Dis. 2017;65:2008-2017.
1699. Alajbegovic S, Sanders JW, Atherly DE, et al. Effectiveness of rifaximin and fluoroquinolones in preventing travelers’ diarrhea (TD): a systematic review and meta-analysiS. Syst Rev. 2012;1:1-10.
1700. Ahmed T, Bhuiyan TR, Zaman K, et al. Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev. 2013;7:CD009029.
1701. Rojas ER, Billings G, Odermatt PD, et al. The outer membrane is an essential load-bearing element in Gram-negative bacteria. Nature. 2018;559:617-621.
1702. Bi Y, Mann E, Whitfield C, et al. Architecture of a channel-forming O-antigen polysaccharide ABC transporter. Nature. 2018;553:361-365.
1703. Palmela C, Chevarin C, Xu Z, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 2018;67:574-587.
1704. Zaidi D, Wine E. An update on travelers’ diarrhea. Curr Opin Gastroenterol. 2015;31:7-13.
1705. Santos AKS, de Medeiros P, Bona MD, et al. Virulence related genes and co-enteropathogens associated with clinical outcomes of enteropathogenic Escherichia coli infections in children from Brazilian semiarid region: a case-control study of diarrhea. J Clin MicrobioL. 2019. [Epub ahead of print.]
1706. Hu J, Torres AG. Enteropathogenic Escherichia coli: foe or innocent bystander? Clin Microbiol Infect. 2015;21:729-734
1707. Hazen TH, Donnenberg MS, Panchalingam S, et al. Genomic diversity of EPEC associated with clinical presentations of differing severity. Nat Microbiol. 2016;1:1-9.
1708. Kindle P, Nuesch-Inderbinen M, Cernela N, et al. Detection, isolation, and characterization of Shiga toxin-producing Escherichia coli in flour. J Food Prot. 2019;82:164-167.
1709. Yang SC, Lin CH, Aljuffali IA, et al. Current pathogenic Escherichia coli foodborne outbreak cases and therapy development. Arch MicrobioL. 2017;199:811-825.
1710. Crowe SJ, Bottichio L, Shade LN, et al. Shiga toxin-producing E. coli infections associated with flour. N Engl J Med. 2017;377:2036-2043.
1711. Newell DG, La Ragione RM. Enterohaemorrhagic and other Shiga toxin-producing Escherichia coli (STEC): where are we now regarding diagnostics and control strategies? Transbound Emerg DiS. 2018;65 (suppl 1):49-71.
1712. Fakhouri F, Zuber J, Fremeaux-Bacchi V, et al. Hemolytic uremic syndrome. Lancet. 2017;390:681-696.
1713. Rogawski ET, Guerrant RL, Havt A, et al; MAL-ED network investigatorS. Epidemiology of enteroaggregative Escherichia coli infections and associated outcomes in the MAL-ED birth cohort. Plos Negl Trop Dis. 2017;11:1-17.
1714. Jackson N, Wu TZ, Adams-Sapper S, et al. A multiplexed, indirect enzyme-linked immunoassay for the detection and differentiation of E. coli from other Enterobacteriaceae and P. aeruginosa from other glucose non-fermenters. J Microbiol Methods. 2019;158:52-58.
1715. Shane AL, Moody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65:e45-e80.
1716. Lalani T, Maguire JD, Grant EM, et al. Epidemiology and self-treatment of travelers’ diarrhea in a large, prospective cohort of Department of Defense beneficiariel. J Travel Med. 2015;22:152-160.
1717. Rojas-Lopez M, Monterio R, Pizza M, et al. Intestinal pathogenic Escherichia coli:insights for vaccine development. Front Microbiol. 2018;9:1-17.
1718. Cody EM, Dixon BP. Hemolytic uremic syndrome. Pediatr Clin North Am. 2019;66:235-246.
1719. Donnenberg MS, Hazen TH, Farag TH, et al. Bacterial factors associated with lethal outcome of enteropathogenic Escherichia coli infection: genomic case-control studies. PLoS Negl Trop Dis. 2015;9:1-11.
1720. Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320:984-994
1721. Centers for Disease Control and Prevention. Healthcare-associated infections. Containment strategy responding to emerging AR threats.
1722. Britt NS, Ritchie DJ, Kollef MH, et al. Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: shifting burden of disease? Am J Insect Control. 2018;46:1092-1096
1723. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8:460-469
1724. Castillo-Tokumori F, Irey-Salgado C, M?laga G. Worrisome high frequency of extended-spectrum bray-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case-control study. Int J Infect Dis. 2017;55:16-19
1725. Claeys KC, Blanco N, Morgan DJ, et aL. Advances and challenges in the diagnosis and treatment of urinary tract infections: the need for diagnostic stewardship. Curr Infect Dis Rep. 2019;21:1-9
1726. Adamus-Bialex W, Baraniak A, Wawszczak M, et al. The genetic background of antibiotic resistance among clinical uropathogenic Escherichia coli strains. Mol Biol Rep. 2018;45:1055-1065
1727. Lee CR, Lee JH, Park KS, et al. Antimicrobial resistance of hypervirulent Klebsiella pneumoniae: epidemiology, hypervirulence-associated determinants, and resistance mechanisms. Front Cell Infect Microbiol. 2017;21:1-13
1728. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016;37:1288-1301
1729. Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist. 2016;22:412-431
1730. Sader HS, Castanheira M, Duncan LR, et al. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016. Diagn Microbiol Infect Dis. 2018;92:69-74
1731. Schwartz KL, Morris SK. Travel and the spread of drug-resistant bacteria. Curr Infect Dis Rep. 2018;20:1-10
1732. Woodworth KR, Walters MS, Weiner LM, et aL. Vital signs: containment of novel multidrug-resistant organisms and resistance mechanisms—United States 2006-2017. MMWR Morb Mortal Wkly Rep. 2018;67:396-401
1733. Blair JMA, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13:42-49
1734. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161-168
1735. Iovleva A, Doi Y. Carbapenem-resistant Enterobacteriaceae. Clin Lab Med. 2017;37:303-315
1736. Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae Curr Opin Infect Dis. 2016;29:583-594
1737. Harris PN, Wei JY, Shen AW, et al. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother. 2016;71:296-306
1738. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI) Clin Infect Dis. 2015;60:1462-1471
1739. van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2018;66:163-171
1740. Guti?rrez-Guti?rrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17:726-734
1741. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318-327
1742. Avery LM, Nicolau DP. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opin Investig Drugs. 2018;27:325-338
1743. Smith S, Rowbotham NJ, Regan KH. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2018;3:CD001021.
1744. Chetchotisakd P, Chierakul W, Chaowagul W, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet. 2014;383:807-814.
1745. Moradali MF, Ghods S, Rehm BH. Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence. Front Cell Infect Microbiol. 2017;7:1-29.
1746. Wiener LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37:1288-1301.
1747. Corlouer C, Lamy B, Desroches M, et al. Stenotrophomonas maltophilia healthcare-associated infections: identification of two main pathogenic genetic backgrounds. J Hosp Infect. 2017;96:183-188.
1748. Perual Samy R, Stiles BG, Sethi G, et al. Melioidosis: clinical impact and public health threat in thetropics. PLoS Negl Trop Dis. 2017;11:1-28.
1749. Sylvester MJ, Sanghvi S, Patel VM, et al. Malignant otitis externa hospitalizations: analysis of patient characteristics. Laryngoscope. 2017;127:2328-2336.
1750. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:575-582.
1751. Crull MR, Somayaji R, Ramos KJ, et al. Changing rates of chronic Pseudomonas aeruginosa infections in cystic fibrosis: a population-based cohort study. Clin Infect Dis. 2018;67:1089-1095.
1752. Sujimoto S, Miyoshi K, Yamane M, et al. Lung transplantation for diffuse panbronchiolitis: 5 cases from a single centre. Interact Cardiovasc Thorac Surg. 2016;22:679-681.
1753. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132:1435-1486.
1754. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304-377.
1755. Pang Z, Raudonis R, Glick BR, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37:177-192.
1756. Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10-39.
1757. Falagas ME, Rafailidis PI. Fosfomycin: the current status of the drug. Clin Infect Dis. 2015;61:1144-1146.
1758. Wood GC, Swanson JM. An update on aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia in adults. Ann Pharmacother. 2017;51:1112-1121.
1759. Tunkel AR, Hasbun R, Bhimraj A. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64:e64-e65.
1760. Berbari EF, Kanj SS, Kowalski TJ, et aL. 2015 infectious diseases society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adultS. Clin Infect Dis. 2015;61:e26-e46.
1761. Hadano Y. Imported melioidosis in Japan: a review of cases. Infect Drug Resist. 2018;11:163-168.
1762. Pena C, Cabot G, Gomez-Zorrilla S, et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis. 2015;60:539-548.
1763. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57:349-358
1764. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391-400
1765. Wong D, Nielsen TB, Bonomo RA, et al. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30:409-447
1766. Oh DH, Kim YC, Kim EJ, et al. Multidrug-resistant Acinetobacter baumannii infection in lung transplant recipients: risk factors and prognosis. Infect Dis (Lond). 2019;51:493-501
1767. Garcia-Patiio MG, Garcea-Contreras R, Licona-Lim?n P. The immune response against Acinetobacter baumannii, an emerging pathogen in nosocomial infections. Front Immunol. 2017;8:1-10
1768. Huang H, Chen B, Liu G, et al. A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii. BMC Infect Dis. 2018;18:1-6
1769. Wood GC, Swanson JM. An update on aerosolized antibiotics for treating hospital-acquired pneumonia in adults. Ann Pharmacother. 2017;51:1112-1121
1770. Dexter C, Murray GL, Paulsen IT, et al. Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis. Expert Rev Anti Infect Ther. 2015;13:567-573
1771. Shin B, Park W. Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy. J Microbiol. 2017;55:837-849
1772. Lee CR, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment optionS. Front Cell Infect Microbiol. 2017;7:1-35
1773. Velkov T, Dai C, Ciccotosto GD, et al. Polymyxins for CNS infections: pharmacology and neurotoxicity. Pharmacol Ther. 2018;181:85-90
1774. Isler B, Doi Y, Bonomo RA, et al. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2019;63:1-17
1775. Espinal P, Pantel A, Rolo D, et al. Relationship between different resistance mechanisms and virulence in Acinetobacter baumannii. Microb Drug Resist. 2019;25:752-760
1776. Garnacho-Montero J, Timsit JF. Managing Acinetobacter baumannii infectionS. Curr Opin Infect Dis. 2019;32:69-76
1777. Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10-39
1778. Pogue JM, Ortwine JK, Kaye KS. Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing. Clin Microbiol Infect. 2017;23:229-233
1779. Pogue JM, Ortwine JK, Kaye KS. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins? Int J Antimicrob Agents. 2016;48:622-626
1780. Leso AC, Menezes PR, Oliveira MS, et aL. Acinetobacter spp. are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis. BMC Infect Dis. 2016;16:1-8
1781. Jones CL, Clancy M, Honnold C, et al. Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence. Clin Infect Dis. 2015;61:145-154
1782. Vazquez Guillamet C, Kollef MH. Acinetobacter pneumonia: improving outcomes with early identification and appropriate therapy. Clin Infect Dis. 2018;67:1455-1462
1783. Choi SH, Cho EB, Chung JW, et al. Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center. J Infect Chemother. 2019;25:6-11
1784. Adegoke AA, Stenstrom TA, Okoh AI. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy. Front Microbiol. 2017;8:1-18
1785. Chang YT, Lin CY, Chen YH, et al. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:1-20
1786. Berdah L, Taytard J, Leyronnas S, et al. Stenotrophomonas maltophilia: a marker of lung disease severity. Pediatr Pulmonol. 2018;53:426-430
1787. Wang Y, He T, Shen Z, et al. Antimicrobial resistance in Stenotrophomonas spp. Microbiol Spectr. 2018;6:1-14
1788. Mojica MF, Papp-Wallace KM, Taracila MA, et al. Avibactam restores the susceptibility of clinical isolates of Stenotrophomonas maltophilia to aztreonam. Antimicrob Agents Chemother. 2017;61:1-5
1789. Effa EE, Lassi ZS, Critchley JA, et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev. 2011;10:CD004530.
1790. Arjyal A, Basnyat B, Nhan HT, et al. Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial. Lancet Infect Dis. 2016;16:535-545.
1791. Thompson CN, Karkey A, Dongol S, et al. Treatment response in enteric fever in an era of increasing antimicrobial resistance: an individual patient data analysis of 2092 participants enrolled into 4 randomized, controlled trials in Nepal. Clin Infect Dis. 2017;64:1522-1531
1792. Voysey M, Pollard AJ. Seroefficacy of Vi polysaccharide-tetanus toxoid conjugate vaccine (TypbarTCV). Clin Infect Dis. 2018;67:18-24.
1793. Ricke SC, Kim SA, Shi Z, et al. Molecular-based identification and detection of Salmonella in food production systems: current perspectives. J Appl MicrobioL. 2018;125:313-327.
1794. Date KA, Newton AE, Medalla F, et al. Changing patterns in enteric fever incidence and increasing antibiotic resistance of enteric fever isolates in the United States, 2008-2012. Clin Infect Dis. 2016;63:322-329.
1795. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19:369-381.
1796. Bosch S, Tauxe RV, Behravesh CB. Turtle-associated salmonellosis, United States, 2006-2014. Emerg Infect Dis. 2016;22:1149-1155.
1797. Kirk MD, Pires SM, Black RE, et al. World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal, and viral diseases, 2010: a data synthesis. PLoS Med. 2015;12:1-21.
1798. Lofton H, Anwar N, Rhen M, et al. Fitness of Salmonella mutants resistant to antimicrobial peptides. J Antimicrob Chemother. 2015;70:432-440.
1799. Angelo KM, Reynolds J, Karp BE, et al. Antimicrobial resistance among nontyphoidal Salmonella isolated from blood in the United States, 2003-2013. J Infect Dis. 2016;214:1565-1570.
1800. Reddy SP, Wang H, Adams JK, et al. Prevalence and characteristics of salmonella serotypes isolated from fresh produce marketed in the United States. J Food Prot. 2016;79:6-16.
1801. Dos Santos AMP, Ferrari RG, Conte-Junior CA. Virulence factors in Salmonella Typhimurium: the sagacity of a bacterium. Curr MicrobioL. 2018. [Epub ahead of print.]
1802. Katiyo S, Muller-Pebody B, Minaji M, et al. Epidemiology and outcomes of nontyphoidal salmonella bacteremias from England, 2004 to 2015. J Clin Microbiol. 2019;57:1-10.
1803. Katz D, Ben-Chetrit E, Sherer SS, et al. Correlates of non-typhoidal salmonella bacteraemia: a case-control study. Int J Infect Dis. 2019;81:170-175.
1804. Wain J, Hendriksen RS, Mikoleit ML, et al. Typhoid fever. Lancet. 2015;385:1136-1145.
1805. GlobalSurg CollaborativE. Management and outcomes following surgery for gastrointestinal typhoid: an international, prospective. multicentre cohort study. World J Surg. 2018;42:3179-3188.
1806. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdF. Accessed April 30, 2019.
1807. World Health Organization. Typhoid vaccines: WHO position paper, March 2018 — recommendations. Vaccine. 2019;37:214-216.
1808. World Health Organization. Typhoid vaccines: WHO position paper — March 2018. Bull World Health Organ. 2018;93:153-172.
1809. Marzel A, Desai PT, Goren A, et al. Persistent infections by nontyphoidal Salmonella in humans: epidemiology and genetics. Clin Infect Dis. 2016;62:879-886.
1810. Christopher PR, David KV, John SM, et al. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev. 2010;8:CD006784.
1811. Kotloff KL, Riddle MS, Platts-Mills JA, et al. Shigellosis. Lancet. 2018;391:801-812.
1812. Anderson M, Sansonetti PJ, Marteyn BS. Shigella diversity and changing landscape: insights for the twenty-first century. Front Cell Infect Microbiol. 2016;6:1-9.
1813. Thompson CN, Duy PT, Baker S. The rising dominance of Shigella sonnei: an intercontinental shift in the etiology of bacillary dysentery. PLoS Negl Trop Dis. 2015;9:1-13.
1814. Muthuirulandi Sethuvel DP, Devanga Ragupathi NK, Anandan S, et al. Update on: Shigella new serogroups/serotypes and their antimicrobial resistance. Lett Appl Microbiol. 2017;64:8-18
1815. Wikswo ME, Kambhampati A, Shioda K, et al. Outbreaks of acute gastroenteritis transmitted by person-to-person contact, environmental contamination, and unknown modes of transmission–United States, 2009-2013. MMWR Surveill Summ. 2015;64:1-16.
1816. Baker KS, Dallman TJ, Ashton PM, et al. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. Lancet Infect Dis. 2015;15:913-921.
1817. Hines JZ, Pinsent T, Rees K, et al. Notes from the field: shigellosis outbreak among men who have sex with men and homeless persons — Oregon, 2015–2016. MMWR Morb Mortal Wkly Rep. 2016;65:812-813.
1818. Marder EP, Cieslak PR, Cronquist AB, et al. Incidence and trends of infections with pathogens transmitted commonly through food and the effect of increasing use of culture-independent diagnostic tests on surveillance — Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2013-2016. MMWR Morb Mortal Wkly Rep. 2017;66:397-403.
1819. George CM, Ahmed S, Talukder KA, et al. Shigella infections in household contacts of pediatric shigellosis patients in rural Bangladesh. Emerg Infect Dis. 2015;21:2006-2013.
1820. Pires SM, Fischer-Walker CL, Lanata CF, et al. Aetiology-specific estimates of the global and regional incidence and mortality of diarrhoeal diseases commonly transmitted through food. PLoS One. 2015;10:1-17.
1821. GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17:909-948.
1822. Lederer I, Taus K, Allerberger F, et al. Shigellosis in refugees, Austria, July to November 2015. Euro Surveill. 2015;20:1-4.
1823. McCrickard LS, Crim SM, Bowen A. Disparities in severe shigellosis among adults — Foodborne Diseases Active Surveillance Network, 2002–2014. BMC Public Health. 2018;18:1-8.
1824. Mattock E, Blocker AJ. How do the virulence factors of Shigella work together to cause disease? Front Cell Infect Microbiol. 2017;7:1-24.
1825. Bonnet M, Tran Van Nhieu G. How Shigella utilizes Ca(2+) jagged edge signals during invasion of epithelial cells. Front Cell Infect Microbiol. 2016;6:1-8.
1826. Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet. 2016;388:1291-1301.
1827. Pavlinac PB, Denno DM, John-Stewart GC, et al. Failure of syndrome-based diarrhea management guidelines to detect Shigella infections in Kenyan children. J Pediatric Infect Dis Soc. 2016;5:366-374.
1828. Puzari M, Sharma M, Chetia P. Emergence of antibiotic resistant Shigella species: a matter of concern. J Infect Public Health. 2018;11:451-454.
1829. CDC recommendations for diagnosing and managing Shigella strains with possible reduced susceptibility to ciprofloxacin. CDC Health Alert Network; 2017.
1830. The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medi­cines for Children). Geneva: World Health Organization; 2017 (WHO technical report series; no. 1006). https://www.who.int/medicines/publications/essentialmedicines/EML_2017_EC21_Unedited_Full_Report.pdf. Accessed April 30, 2019.
1831. Walker RI. An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children. Vaccine. 2015;33:954-965.
1832. Raqib R, Sarker P, Zaman K, et al. A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children. Hum Vaccin Immunother. 2019;1-12.
1833. Hashemi SH, Gachkar L, Keramat F, et al. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. Int J Infect Dis. 2012;16:e247-e251.
1834. Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, et aL. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012;10:CD007179.
1835. Franc KA, Krecek RC, H?sler BN, et al. Brucellosis remains a neglected disease in the developing world: a call for interdisciplinary action. BMC Public Health. 2018;18:1-9.
1836. Georgi E, Walter MC, Pfalzgraf MT, et al. Whole genome sequencing of Brucella melitensis isolated from 57 patients in Germany reveals high diversity in strains from Middle East. PLoS One. 2017;12:1-15.
1837. Franco-Paredes C, Chastain D, Taylor P, et al. Boar hunting and brucellosis caused by Brucella suiS. Travel Med Infect Dis. 2017;16:18-22.
1838. Dadar M, Shahali Y, Whatmore AM. Human brucellosis caused by raw dairy products: a review on the occurrence, major risk factors and preventioN. Int J Food Microbiol. 2019;292:39-47.
1839. Tuon FF, Gondolfo RB, Cerchiari N. Human-to-human transmission of Brucella — a systematic review. Trop Med Int Health. 2017;22:539-546.
1840. Ghanem-Zoubi N, Eljay SP, Anis E, et al. Association between human brucellosis and adverse pregnancy outcome: a cross-sectional population-based study. Eur J Clin Microbiol Infect Dis. 2018;37:883-888.
1841. Mirnejad R, Jazi FM, Mostafaei S, et al. Molecular investigation of virulence factors of Brucella melitensis and Brucella abortus strains isolated from clinical and non-clinical samples. Microb Pathog. 2017;109:8-14.
1842. Giambartolomei GH, Arriola Benitez PC, Delpino MV. Brucella and osteoarticular cell activation: partners in crime. Front MicrobioL. 2017;8:1-9.
1843. Lewis JM, Folb J, Kalra S, et al. Brucella melitensis prosthetic joint infection in a traveller returning to the UK from Thailand: case report and review of the literature. Travel Med Infect Dis. 2016;14:444-450.
1844. de Glanville WA, Conde-?lvarez R, Moriy?n I, et al. Poor performance of the rapid test for human brucellosis in health facilities in Kenya. PLoS Negl Trop Dis. 2017;11:1-15.
1845. James J, Kaul DR, Goldberger ZD, et al. Clinical problem-solving: back to nature. N Engl J Med. 2015;373:2271-2276.
1846. Maurin M, Gyuranecz M. Tularaemia: clinical aspects in Europe. Lancet Infect Dis. 2016;16:113-124.
1847. Faber M, Heuner K, Jacob D, et al. Tularemia in Germany a re-emerging zoonosis. Front Cell Infect Microbiol. 2018;8:1-10.
1848. Zargar A, Maurin M, Mostafavi E. Tularemia, a re-emerging infectious disease in Iran and neighboring countries. Epidemiol Health. 2015;37:1-6.
1849. Pedati C, House J, Hancock-Allen J, et al. Notes from the field: increase in human cases of Tularemia-Colorado, Nebraska, South Dakota, Wyoming, January-September 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1317-1318.
1850. Mani RJ, Morton RJ, Clinkenbeard KD. Ecology of tularemia in central US endemic region. Curr Trop Med Rep. 2016;3:75-79.
1851. Maurin M. Francisella tularensis as a potential agent of bioterrorism? Expert Rev Anti Infect Ther. 2015;13:141-144.
1852. Clemens DL, Lee BY, Horwitz MA. The Francisella type VI secretion system. Front Cell Infect Microbiol. 2018;8:1-20.
1853. Frischknecht M, Meier A, Mani B, et al. Tularemia: an experience of 13 cases including a rare myocarditis in a referral center in Eastern Switzerland (Central Europe) and a review of the literature. Infection. 2019. [Epub ahead of print.]
1854. Polat M, Karapinar T, Sirmatel F. Dermatological aspects of tularaemia: a study of 168 cases. Clin Exp Dermatol. 2018;43:770-774.
1855. Fachinger P, Tini GM, Grobholz R, et al. Pulmonary tularaemia: all that looks like cancer is not cancer-case report of four consecutive cases. BMC Pulm Med. 2015;15:1-6.
1856. Frischknecht M, Meier A, Mani B, et al. Tularemia: an experience of 13 cases including a rare myocarditis in a referral center in Eastern Switzerland (Central Europe) and a review of the literature. Infection. 2019. [Epub ahead of print.]
1857. Rastawicki W, Rokosz-Chudziak N, Chrost A, et al. Development and evaluation of a latex agglutination test for the rapid serodiagnosis of tularemia. J Microbiol Methods. 2015;112:1-2.
1858. Becker S, Lochau P, Jacob D, et al. Successful re-evaluation of broth medium T for growth of Fran­cisella tularensis ssp. and other highly pathogenic bacteria. J Microbiol Methods. 2016;121:5-7.
1859. Caspar Y, Maurin M. Francisella tularensis susceptibility to antibiotics: a comprehensive review of the data obtained in vitro and in animal models. Front Cell Infect Microbiol. 2017;7:1-18.
1860. Roberts LM, Powell DA, Frelinger JA. Adaptive immunity to Francisella tularensis and considerations for vaccine development. Front Cell Infect Microbiol. 2018;8:1-11.
1861. Andrianaivoarimanana V, Piola P, Wagner DM, et al. Trends of human plague, Madagascar, 1998–2016. Emerg Infect Dis. 2019;25:220-228.
1862. Majumder MS, Cohn EL, Santillana M, et al. Estimation of pneumonic plague transmission in Madagascar, August–November 2017. PLoS Curr. 2018;10:1-6.
1863. Markman DW, Antolin MF, Bowen RA, et al. Yersinia pestis survival and replication in potential ameba reservoir. Emerg Infect Dis. 2018;24:294-302.
1864. Kwit N, Nelson C, Kugeler K, et al. Human plague — United States 2015. MMWR Morb Mortal Wkly Rep. 2015;64:918-919.
1865. Mead PS. Plague in Madagascar — a tragic opportunity for improving public health. N Eng J Med. 2018;378:106-108.
1866. Kugeler KJ, Staples JE, Hinckley AF, et al. Epidemiology of human plague in the United States, 1900-2012. Emerg Infect Dis. 2015;21:16-22.
1867. Andersson JA, Sha J, Erova TE, et al. Identification of new virulence factors and vaccine candidates for Yersinia pestis. Front Cell Infect Microbiol. 2017;7:1-16.
1868. Yang R. Plague: recognition, treatment, and prevention. J Clin Microbiol. 2017;56:1-6.
1869. Galen JE, Wang JY, Carrasco JA, et al. A bivalent typhoid live vector vaccine expressing both chromosome- and plasmid-encoded Yersinia pestis antigens fully protects against murine lethal pulmonary plague infection. Infect Immun. 2015;83:161-172.
1870. Bancerz-Kisiel A, Szweda W. Yersiniosis — a zoonotic foodborne disease of relevance to public health. Ann Agric Environ Med. 2015;22:397-402.
1871. Centers for Disease Control and Prevention. Foodborne Disease Active Surveillance Network (FoodNet): FoodNet 2015 surveillance report (final data).
1872. Hering NA, Fromm A, Kikhney J, et al. Yersinia enterocolitica affects intestinal barrier function in the colon. J Infect Dis. 2016;213:1157-1162.
1873. Marder EP, Cieslak PR, Cronquist AB, et al. Incidence and trends of infections with pathogens transmitted commonly through food and the effect of increasing use of culture-independent diagnostic tests on surveillance — Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2013-2016. MMWR Morb Mortal Wkly Rep. 2017;66:397-403.
1874. Soumana IH, Linz B, Harvill ET. Environmental origin of the genus Bordetella. Front Microbiol. 2017;8:1-10.
1875. Kilgore PE, Salim AM, Zervos MJ, Schmitt H-J. Pertussis: microbiology, disease, treatment and prevention. J Clin Microbiol. 2016;29:449-486.
1876. Weigand MR, Williams MM, Peng Y, et al. Genomic survey of Bordetella pertussis diversity, United States, 2000-2013. Emerg Infect Dis. 2019;25:780-783.
1877. Srigley JA, Goldfarb DM, Pernica JM. Bordetella species other than Bordetella pertussis. Clin Microbiol Newsletter. 2015;37:61-65.
1878. Forsyth KD, Tan T, von Konig CW, et al. Recommendations to control pertussis prioritized relative to economies: a Global Pertussis Initiative update. Vaccine. 2018;36:7270-7275.
1879. Aronsson B, von Segebaden K, Kallberg H, et al. Pertussis surveillance in Sweden: seventeen year report: the Public Health Agency of Sweden; 2015.
1880. Dorji D, Mooi F, Yantorno O, et al. Bordetella pertussis virulence factors in the continuing evolu­tion of whooping cough vaccines for improved performance. Med Microbiol Immunol. 2018;207:3-26.
1881. Solans L, Locht C. The role of mucosal immunity in pertussis. Front Immunol. 2018;9:1-10.
1882. Weigand MR, Pawloski LC, Peng Y, et al. Screening and genomic characterization of filamentous hemagglutinin-deficient Bordetella pertussis. Infect Immunol. 2018;86:1-13.
1883. Carbonetti NH. Pertussis leukocytosis: mechanisms, clinical relevance and treatment. Pathog Dis. 2016;74:1-8.
1884. Carbonetti NH. Contribution of pertussis toxin to the pathogenesis of pertussis disease. Pathog Dis. 2015;73:1-8.
1885. Nee P, Weir E, Vardhan M, et al. Could this be whooping cough? Emerg Med J. 2018;35:639-642.
1886. Moore A, Harnden A, Grant CC, et al. Clinically diagnosing pertussis-associated cough in adults and children: CHEST guideline and expert panel report. Chest. 2019;155:147-154.
1887. Zycinska K, Cieplak M, Chmielewska M, et al. Whooping cough in adults: a series of severe cases. Adv Exp Med Biol. 2017;955:47-50.
1888. Martini H, Detemmerman L, Soetens O, et al. Improving specificity of Bordetella pertussis detection using a four target real-time PCR. PLoS One. 2017;12:1-11.
1889. Healy CM, Rench MA, Wootton SH, et al. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis J. 2015;34:22-26.
1890. Martin SW, Pawloski L, Williams M, et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis. 2015;60:223-227.
1891. Gill C, Rohani P, Thea DM. The relationship between mucosal immunity, nasopharyngeal carriage, asymptomatic transmission and the resurgence of Bordetella pertussis. F1000Res.2017;6:1-15.
1892. McNamara LA, Skoff T, Faulkner A, et al. Reduced severity of pertussis in persons with age-appropriate pertussis vaccination — United States, 2010–2012. Clin Infect Dis. 2017;65:811-818.
1893. Locht C, Papin JF, Lecher S, et al. Live attenuated pertussis vaccine BPZE1 protects baboons against pertussis disease and infection. J Infect Dis. 2017;216:117-124.
1894. Massis LM, Assis-Marques MA, Castanheira FVS, et al. Legionella longbeachae is immunologically silent and highly virulent in vivo. J Infect Dis. 2017;215:440-451.
1895. Cameron RL, Pollock KG, Lindsay DS, et al. Comparison of Legionella longbeachae and Legionella pneumophila cases in Scotland. Implications for diagnosis, treatment and public health response. J Med Microbiol. 2016;65:142-146.
1896. Garrison LE, Kunz JM, Cooley LA, et al. Vital signs: deficiencies in environmental control identified in outbreaks of legionnaires’ disease — North America, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;65:576-584.
1897. Rucinski SL, Murphy MP, Kies KD, et al. Eight years of clinical Legionella PCR testing illustrate seasonal pattern. J Infect Dis. 2018;218;669-670.
1898. Orkis LT, Harrison LH, Mertz KJ, et al. Environmental sources of community-acquired legionnaires’ disease: a review. Int J Hyg Environ Health. 2018;221:764-774.
1899. Burillo A, Pedro-Botet ML, Bouza E. Microbiology and epidemiology of Legionnaire’s disease. Infect Dis Clin North Am. 2017;31:7-27.
1900. Hlavsa MC, Cikesh BL, Roberts VA, et al. Outbreaks associated with treated recreational water — United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2018;67:547-551.
1901. Dooling KL, Toews KA, Hicks LA, et al. Active bacterial core surveillance for legionellosis, United States, 2011–2013. MMWR. 2015;64:1190-1192.
1902. Hamilton KA, Prussin AJ 2nd, Ahmed W, et al. Outbreaks of Legionnaire’s disease and Pontiac Fever 2006–2017. Curr Environ Health Rep. 2018;5:263-271.
1903. Lanternier F, Ader F, Pilmis B, et al. Legionnaire’s disease in compromised hosts. Infect Dis Clin North Am. 2017;31:125-135.
1904. Oliva G, Sahr T, Buchrieser C. The life cycle of L. pneumophila: cellular differentiation is linked to virulence and metabolism. Front Cell Infect Microbiol. 2018;8:1-120.
1905. Casey JD, Engelert JA, Katz JT, et al. An unexpected expectoration. N Engl J Med. 2018;378:853-858.
1906. Cunha BA, Burillo A, Bouza E. Legionnaires’ disease. Lancet. 2016;387:376-385.
1907. Cilliniz C, Miguel-Escuder L, Pedro-Bonet ML, et al. Community-acquired Legionella pneumonia in HIV-infected adult patients: a matched case-control study. Clin Infect Dis. 2018;67:958-961.
1908. Cunha BA, Cunha CB. Legionnaire’s disease: a clinical diagnostic approach. Infect Dis Clin North Am. 2017;31:81-93.
1909. Viasus D, Calatayud L, McBrown MV, et al. Urinary antigen testing in community-acquired pneu­monia in adults: an update. Expert Rev Anti Infect Ther. 2019;17:107-115.
1910. Cristovam E, Almeida D, Caldeira D, et al. Accuracy of diagnostic tests for Legionnaires’ disease: a systematic review. J Med Microbiol. 2017;66:485-489.
1911. Garcia Vidal C, Sanchez-Rodriguez I, Simonetti AF, et al. Levofloxacin vs azithromycin for treating legionella pneumonia a propensity score analysis. Clin Microbiol Infect. 2017;23:653-658.
1912. Herwaldt LA, Marra AR. Legionella: a reemerging pathogen. Curr Opin Infect Dis. 2018;31:325-333.
1913. Ruiz J. Bartonella quintana, past, present, and future of the scourge of World War I. APMIS. 2018;126:831-837.
1914. Nelson CA, Moore AR, Perea AE, et al. Cat scratch disease: U.S. clinicians’ experience and knowledge. Zoonoses Public Health. 2018;65:67-73.
1915. Gomes C, Ruiz J. Carrion’s disease: the sound of silence. Clin Microbiol Rev. 2017;31:1-51.
1916. Barros S, De Andrade GC, Cavalcanti C, Nascimento H. Cat scratch disease: not a benign condition. Ocul Immunol Inflamm. 2018;26:1115-1122.
1917. Okaru U, Addisu A, Casanas B, et al. Bartonella species, an emerging cause of blood-culture-negative endocarditis. Clin Microbiol Rev. 2017;30:709-746.
1918. Nakasu A, Ishimine T, Yasumoto H, et al. Infective endocarditis associated with Bartonella henselae: a case series. IDCases. 2018;12:127-129.
1919. Canneti B, Cabo-L?pez I, Puy-N??ez A, et al. Neurological presentations of Bartonella henselae infection. Neurol Sci. 2019;40:261-268.
1920. Mabra D, Yeh S, Shantha JG. Ocular manifestations of bartonellosis. Curr Opin Ophthalmol. 2018;29:582-587.
1921. Amer R, Tugal-Tutkun I. Ophthalmic manifestations of bartonella infection. Curr Opin Ophthalmol. 2017;28:607-612.
1922. Pachirat O, Prathanee S, Watt G. Echocardiographic features in Bartonella endocarditis: a case series. Cardiol Res. 2018;9:116-119.
1923. Urbanowicz M, Kutzner H, Riveiro-Falkenbach E, et al. Infectious angiogenesis — different pathways, the same goal. Am J DermatopathoL. 2016;38:793-801.
1924. Allizond V, Costa C, Sidoti F, et al. Serological and molecular detection of Bartonella henselae in specimens from patients with suspected cat scratch disease in Italy: a comparative study. PLoS One. 2019;14:1-11.
1925. Hobson C, Le Brun C, Beaurelle C, et al. Detection of Bartonella in cat scratch disease using a single-step PCR assay kit. J Med Microbiol. 2017;66:1596-1601.
1926. Yanagihara M, Tsuneoka H, Tanimoto A, et al. Bartonella henselae DNA in seronegative patients with cat-scratch disease. Emerg Infect Dis. 2018;24:924-925.
1927. Edouard S, Nabet C, Lepidi H, et al. Bartonella, a common cause of endocarditis: a report on 106 cases and review. J Clin MicrobioL. 2015;53:824-829.
1928. Okaro U, Addisu A, Casanas B, et al. Bartonella species, an emerging cause of blood-culture-negative endocarditis. Clin Microbiol Rev. 2017;30:709-746.
1929. Arora AK, Kumaran MS, Narang T, et al. Donovanosis and squamous cell carcinoma: the relationship conundrum! Int J STD AIDS. 2017; 28: 411-414.
1930. Pfennig CL. Sexually transmitted diseases in the emergency department. Emerg Med Clin North Am. 2019; 37: 165-192.
1931. O’Farrell N, Hoosen A, Kingston M. 2018 UK national guidelines for the management of donovanosis. Int J STD AIDS. 2018; 29: 946-948.
1932. O’Farrell N, Moi H. 2016 European guideline on donovanosis. Int J STD AIDS. 2016; 27: 605-607.
1933. Copeland NK, Decker CF. Other sexually transmitted diseases chancroid and donovanosis. Dis Mon. 2016; 62: 306-311.
1934. Mulholland S, Gavranich JB, Gillies MB, et al. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2012;9:CD004875.
1935. Huang L, Gao X, Chen M. Early treatment with corticosteroids in patients with Mycoplasma pneumoniae pneumonia: a randomized clinical trial. J Trop Pediatr. 2014;60:338-342.
1936. Bajantri B, Venkatram S, Diaz-Fuentes G. Mycoplasma pneumoniae: a potentially severe infection. J Clin Med Res. 2018;10:535-544.
1937. Maselli DJ, Medina JL, Brooks EG, et al. The immunopathologic effects of Mycoplasma pneumoniae and community-acquired respiratory distress syndrome toxin. A primate model. Am J Respir Cell Mol Biol. 2018;58:253-260.
1938. Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30:747-809.
1939. Clemmons NS, Jordan NN, Brown AD, et al. Outbreak of Chlamydia pneumoniae infections and X-ray-confirmed pneumonia in army trainees at Fort Leonard Wood, Missouri, 2014. Mil Med. 2019. [Epub ahead of print.]
1940. Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae-associated mucositis — case report and systematic review of literature. J Eur Acad Dermatol Venereol. 2015;29:595-598.
1941. Canavan TN, Mathes EF, Frieden I, et al. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens–Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72:239-245.
1942. Kammer J, Ziesing S, Davila LA, et al. Neurological manifestations of Mycoplasma pneumoniae infection in hospitalized children and their long-term follow-up. Neuropediatrics. 2016;47:308-317.
1943. Huang C, Huang PT, Yao JY, et al. Pooled analysis of nuclear acid sequence-based amplification for rapid diagnosis of Mycoplasma pneumoniae infection. J Clin Lab Anal. 2019. [Epub ahead of print.]
1944. Tashiro M, Fushimi K, Kawano K, et al. Comparison of efficacy of antimicrobial agents among hospitalized patients with Mycoplasma pneumoniae pneumonia in Japan during large epidemics of macrolide-resistant M. pneumoniae infections: a nationwide observational study. Clin Infect Dis. 2017;65:1837-1842.
1945. Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol. 2015;53:124-130.
1946. Miyashita N, Kawai Y, Inamura N, et al. Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother. 2015;21:153-160.
1947. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis. 2015;61:418-426.
1948. Jensen JS. Mycoplasma genitalium: yet another challenging STI. Lancet. 2017;17:795-796.
1949. Bissessor M, Tabrizi SN, Twin J, et al. Macrolide resistance and азитромицин failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60:1228-1236.
1950. Evans JR, Solomon AW. Antibiotics for trachoma. Cochrane Database Syst Rev. 2011;3:CD001860.
1951. Poez-Canro C, Alzate JP, Gonzalez LM, et al. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev. 2019;1:CD010871.
1952. Geisler WM, Uniyal A, Lee JY, et al. Azithromycin versus doxycycline for urogenital Chlamydia trachomatis infection. N Engl J Med. 2015;373:2512-2521.
1953. Pettengill MA, Abdul-Sater A, Coutinho-Silva R, et al. Danger signals, inflammasomes, and the intricate intracellular lives of chlamydiae. Biomed J. 2016;39:306-315.
1954. Lansingh VC. Trachoma. BMJ Clin Evid. 2016;2016:1-14.
1955. Habtamu E, Wondie T, Aweke S, et al. Predictors of trachomatous trichiasis surgery outcome. Ophthalmology. 2017;124:1143-1155.
1956. Centers for Disease Control and PreventioN. Sexually transmitted disease surveillance 2017. https://www.cdc.gov/std/stats17/2017-STD-Surveillance-Report_CDC-clearance-9.10.18.pdf. Дата просмотра: 1 мая 2019 г.
1957. Ronn MM, Tuite AR, Menzies NA, et al. The impact of screening and partner notification on chla­mydia prevalence and numbers of infections averted in the United States, 2000-2015: evaluation of epidemiologic trends using a pair-formation transmission model. Am J Epidemiol. 2019;188:545-554.
1958. Moi H, Blee K, Horner PJ. Management of non-gonococcal urethritis. BMC Infect Dis. 2015;15:1-7.
1959. Taylor SN. Epididymitis. Clin Infect Dis. 2015;61(suppl 8):S770-S773.
1960. Hoenderboom BM, van Benthem BHB, van Bergen J, et al. Relation between Chlamydia trachomatis infection and pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in a Dutch cohort of women previously tested for chlamydia in a chlamydia screening trial. Sex Transm Infect. 2019. [Epub ahead of print.]
1961. Price MJ, Ades AE, Welton NJ, et al. Proportion of pelvic inflammatory disease cases caused by Chlamydia trachomatis: consistent picture from different methods. J Infect Dis. 2016;214:617-624.
1962. Olson-Chen C, Balaram K, Hackney DN. Chlamydia trachomatis and adverse pregnancy outcomes: meta-analysis of patients with and without infection. Matern Child Health J. 2018;22:812-821.
1963. Stoner BP, Cohen SE. Lymphogranuloma venereum 2015: clinical presentation, diagnosis, and treatment. Clin Infect Dis. 2015;61(suppl 8):S865-S873.
1964. Wiesenfeld HC. Screening for Chlamydia trachomatis infection in women. N Engl J Med. 2017;376:765-773.
1965. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.
1966. Kong FY, Tabrizi SN, Fairley CK, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70:1290-1297.
1967. de Vries HJ, Zingoni A, Kreuter A, et al. 2013 European guideline on the management of lympho­granuloma venereum. J Eur Acad Dermatol Venereol. 2015;29:1-6.
1968. Clemmons NS, Jordan NN, Brown AD, et al. Outbreak of Chlamydia pneumoniae infections and X-ray-confirmed pneumonia in army trainees at Fort Leonard Wood, Missouri, 2014. Mil Med. 2019. [Epub ahead of print.]
1969. de Gier B, Hogerwerf L, Dijkstra F, et al. Disease burden of psittacosis in the Netherlands. Epidemiol Infect. 2018;146:303-305.
1970. Cunha BA, Cunha CB. Legionnaire’s disease and its mimics: a clinical perspective. Infect Dis Clin North Am. 2017;31:95-109.
1971. Hogerwerf L, DE Gier B, Baan B, et al. Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis. Epidemiol Infect. 2017;145:3096-3105.
1972. Cao Y, Su X, Wang Q, et al. A multicenter study evaluating ceftriaxone and benzathine penicillin G as treatment agents for early syphilis in Jiangsu, China. Clin Infect Dis. 2017; 65: 1683-1688.
1973. Hook EW III. Syphilis. Lancet. 2017; 389: 1550-1557.
1974. Radolf JD, Deka RK, Anand A, et al. Treponema pallidum, the syphilis spirochete: making a living as a stealth pathogen. Nat Rev Microbiol. 2016; 14: 744-759.
1975. Centers for Disease Control and Prevention. 2017 STD surveillance report.
1976. Hobbs E, Vera JH, Marks M, et al. Neurosyphilis in patients with HIV. Pract Neuroд. 2018; 18: 211-218.
1977. Marra CM. Neurosyphilis. Continuum (Minneap Minn). 2015; 21: 1714-1728.
1978. Woolston SL, Dhanireddy S, Marrazzo J. Ocular syphilis: a clinical review. Curr Infect Dis Rep. 2016; 18: 1-6.
1979. Peeling RW, Mabey D, Kamb ML, et al. Syphilis. Nat Rev Dis Primers. 2017; 3: 1-21.
1980. Cooper JM, Sanchez PJ. Congenital syphiliS. Semin Perinatol. 2018; 42: 176-184.
1981. Korenromp EL, Rowley J, Alonso M, et al. Global burden of maternal and congenital syphilis and associated adverse birth outcomes-Estimates for 2016 and progress since 2012. PLoS One. 2019; 14: 1-17.
1982. Lin JS, Eder ML, Bean SI. Screening for syphilis infection in pregnant women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018; 320: 918-925.
1983. Curry SJ, Krist AH, Owens DK, et al. Screening for syphilis infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2018; 320: 911-917.
1984. Causer LM, Kaldor JM, Conway DP, et al. An evaluation of a novel dual treponemal/nontreponemal point-of-care test for syphilis as a tool to distinguish active from past treated infection. Clin Infect Dis. 2015; 61: 184-191.
1985. Ghanem KG. Management of adult syphilis: key questions to inform the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelineS. Clin Infect Dis. 2015; 61: S818-S836.
1986. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64: 1-137.
1987. Tanizaki R, Nishijima T, Aoki T, et al. High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. Clin Infect Dis. 2015; 61: 177-183.
1988. Chow EPF, Callander D, Fairley CK, et al. Increased syphilis testing of men who have sex with men: greater detection of asymptomatic early syphilis and relative reduction in secondary syphilis. Clin Infect Dis. 2017; 65: 389-395.
1989. US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, Grossman DC, et al. Screening for syphilis infection in nonpregnant adults and adolescents: US Preventive Services Task Force recommendation statement. JAMA. 2016; 315: 2321-2327.
1990. Taylor M, Giddon H, Nurse-Findlay S, et al. Revisiting strategies to eliminate mother-to-child transmission of syphilis. Lancet Glob Health. 2018; 6: e26-e28.

Труды отечественных авторов при подготовке статей по терапии для пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.

- Вернуться в оглавление раздела "Терапия"

Редактор: Искандер Милевски. Дата обновления публикации: 7.5.2025